Model Prediction	Tags	Tokens
O	O	Clustering
O	O	of
O	O	missense
O	O	mutations
O	O	in
O	O	the
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	gene
O	O	in
O	O	a
B	B	sporadic
B	I	T
I	I	-
I	I	cell
I	I	leukaemia
O	O	.
B	B	Ataxia
I	I	-
I	I	telangiectasia
O	O	(
B	B	A
I	I	-
I	I	T
O	O	)
O	O	is
O	O	a
B	B	recessive
I	I	multi
I	I	-
I	I	system
I	I	disorder
O	O	caused
O	O	by
O	O	mutations
O	O	in
O	O	the
O	O	ATM
O	O	gene
O	O	at
O	O	11q22
O	O	-
O	O	q23
O	O	(
O	O	ref
O	O	.
O	O	3
O	O	)
O	O	.
O	O	The
O	O	risk
O	O	of
B	B	cancer
O	O	,
O	O	especially
B	B	lymphoid
I	I	neoplasias
O	O	,
O	O	is
O	O	substantially
O	O	elevated
O	O	in
B	B	A
I	I	-
I	I	T
O	O	patients
O	O	and
O	O	has
O	O	long
O	O	been
O	O	associated
O	O	with
O	O	chromosomal
O	O	instability
O	O	.
O	O	By
O	O	analysing
B	B	tumour
O	O	DNA
O	O	from
O	O	patients
O	O	with
O	B	sporadic
B	I	T
I	I	-
I	I	cell
I	I	prolymphocytic
I	I	leukaemia
O	O	(
B	B	T
I	I	-
I	I	PLL
O	O	)
O	O	,
O	O	a
O	O	rare
O	B	clonal
I	I	malignancy
O	O	with
O	O	similarities
O	O	to
O	O	a
O	B	mature
B	I	T
I	I	-
I	I	cell
I	I	leukaemia
O	O	seen
O	O	in
B	B	A
I	I	-
I	I	T
O	O	,
O	O	we
O	O	demonstrate
O	O	a
O	O	high
O	O	frequency
O	O	of
O	O	ATM
O	O	mutations
O	O	in
B	B	T
O	I	-
O	I	PLL
O	O	.
O	O	In
O	O	marked
O	O	contrast
O	O	to
O	O	the
O	O	ATM
O	O	mutation
O	O	pattern
O	O	in
B	B	A
I	I	-
I	I	T
O	O	,
O	O	the
O	O	most
O	O	frequent
O	O	nucleotide
O	O	changes
O	O	in
O	O	this
B	B	leukaemia
O	O	were
O	O	missense
O	O	mutations
O	O	.
O	O	These
O	O	clustered
O	O	in
O	O	the
O	O	region
O	O	corresponding
O	O	to
O	O	the
O	O	kinase
O	O	domain
O	O	,
O	O	which
O	O	is
O	O	highly
O	O	conserved
O	O	in
O	O	ATM
O	O	-
O	O	related
O	O	proteins
O	O	in
O	O	mouse
O	O	,
O	O	yeast
O	O	and
O	O	Drosophila
O	O	.
O	O	The
O	O	resulting
O	O	amino
O	O	-
O	O	acid
O	O	substitutions
O	O	are
O	O	predicted
O	O	to
O	O	interfere
O	O	with
O	O	ATP
O	O	binding
O	O	or
O	O	substrate
O	O	recognition
O	O	.
O	O	Two
O	O	of
O	O	seventeen
O	O	mutated
O	B	T
O	I	-
O	I	PLL
O	O	samples
O	O	had
O	O	a
O	O	previously
O	O	reported
B	B	A
O	I	-
O	I	T
O	O	allele
O	O	.
O	O	In
O	O	contrast
O	O	,
O	O	no
O	O	mutations
O	O	were
O	O	detected
O	O	in
O	O	the
O	O	p53
O	O	gene
O	O	,
O	O	suggesting
O	O	that
O	O	this
B	B	tumour
O	O	suppressor
O	O	is
O	O	not
O	O	frequently
O	O	altered
O	O	in
O	O	this
B	B	leukaemia
O	O	.
O	O	Occasional
O	O	missense
O	O	mutations
O	O	in
O	O	ATM
O	O	were
O	O	also
O	O	found
O	O	in
B	B	tumour
O	O	DNA
O	O	from
O	O	patients
O	O	with
B	B	B
I	I	-
O	I	cell
I	I	non
I	I	-
I	I	Hodgkins
I	I	lymphomas
O	O	(
B	B	B
I	I	-
B	I	NHL
O	O	)
O	O	and
O	O	a
B	B	B
O	I	-
O	I	NHL
O	O	cell
O	O	line
O	O	.
O	O	The
O	O	evidence
O	O	of
O	O	a
O	O	significant
O	O	proportion
O	O	of
O	O	loss
O	O	-
O	O	of
O	O	-
O	O	function
O	O	mutations
O	O	and
O	O	a
O	O	complete
O	O	absence
O	O	of
O	O	the
O	O	normal
O	O	copy
O	O	of
O	O	ATM
O	O	in
O	O	the
O	O	majority
O	O	of
O	O	mutated
B	B	tumours
O	O	establishes
O	O	somatic
O	O	inactivation
O	O	of
O	O	this
O	O	gene
O	O	in
O	O	the
O	O	pathogenesis
O	O	of
O	B	sporadic
B	I	T
I	I	-
I	I	PLL
O	O	and
O	O	suggests
O	O	that
O	O	ATM
O	O	acts
O	O	as
O	O	a
B	B	tumour
O	O	suppressor
O	O	.
O	O	As
O	O	constitutional
O	O	DNA
O	O	was
O	O	not
O	O	available
O	O	,
O	O	a
O	O	putative
O	O	hereditary
O	O	predisposition
O	O	to
B	B	T
I	I	-
I	I	PLL
O	O	will
O	O	require
O	O	further
O	O	investigation
O	O	.
O	O	.
B	B	Myotonic
I	I	dystrophy
O	O	protein
O	O	kinase
O	O	is
O	O	involved
O	O	in
O	O	the
O	O	modulation
O	O	of
O	O	the
O	O	Ca2
O	O	+
O	O	homeostasis
O	O	in
B	O	skeletal
O	O	muscle
O	O	cells
O	O	.
B	B	Myotonic
I	I	dystrophy
O	O	(
B	B	DM
O	O	)
O	O	,
O	O	the
O	O	most
O	O	prevalent
B	B	muscular
I	I	disorder
O	O	in
O	O	adults
O	O	,
O	O	is
O	O	caused
O	O	by
O	O	(
O	O	CTG
O	O	)
O	O	n
O	O	-
O	O	repeat
O	O	expansion
O	O	in
O	O	a
O	O	gene
O	O	encoding
O	O	a
O	O	protein
O	O	kinase
O	O	(
B	B	DM
O	O	protein
O	O	kinase
O	O	;
O	O	DMPK
O	O	)
O	O	and
O	O	involves
O	O	changes
O	O	in
O	O	cytoarchitecture
O	O	and
O	O	ion
O	O	homeostasis
O	O	.
O	O	To
O	O	obtain
O	O	clues
O	O	to
O	O	the
O	O	normal
O	O	biological
O	O	role
O	O	of
O	O	DMPK
O	O	in
O	O	cellular
O	O	ion
O	O	homeostasis
O	O	,
O	O	we
O	O	have
O	O	compared
O	O	the
O	O	resting
O	O	[
O	O	Ca2
O	O	+
O	O	]
O	O	i
O	O	,
O	O	the
O	O	amplitude
O	O	and
O	O	shape
O	O	of
O	O	depolarization
O	O	-
O	O	induced
O	O	Ca2
O	O	+
O	O	transients
O	O	,
O	O	and
O	O	the
O	O	content
O	O	of
O	O	ATP
O	O	-
O	O	driven
O	O	ion
O	O	pumps
O	O	in
O	O	cultured
O	O	skeletal
O	O	muscle
O	O	cells
O	O	of
O	O	wild
O	O	-
O	O	type
O	O	and
O	O	DMPK
O	O	[
O	O	-
O	O	/
O	O	-
O	O	]
O	O	knockout
O	O	mice
O	O	.
O	O	In
O	O	vitro
O	O	-
O	O	differentiated
O	O	DMPK
O	O	[
O	O	-
O	O	/
O	O	-
O	O	]
O	O	myotubes
O	O	exhibit
O	O	a
O	O	higher
O	O	resting
O	O	[
O	O	Ca2
O	O	+
O	O	]
O	O	i
O	O	than
O	O	do
O	O	wild
O	O	-
O	O	type
O	O	myotubes
O	O	because
O	O	of
O	O	an
O	O	altered
O	O	open
O	O	probability
O	O	of
O	O	voltage
O	O	-
O	O	dependent
O	O	l
O	O	-
O	O	type
O	O	Ca2
O	O	+
O	O	and
O	O	Na
O	O	+
O	O	channels
O	O	.
O	O	The
O	O	mutant
O	O	myotubes
O	O	exhibit
O	O	smaller
O	O	and
O	O	slower
O	O	Ca2
O	O	+
O	O	responses
O	O	upon
O	O	triggering
O	O	by
O	O	acetylcholine
O	O	or
O	O	high
O	O	external
O	O	K
O	O	+
O	O	.
O	O	In
O	O	addition
O	O	,
O	O	we
O	O	observed
O	O	that
O	O	these
O	O	Ca2
O	O	+
O	O	transients
O	O	partially
O	O	result
O	O	from
O	O	an
O	O	influx
O	O	of
O	O	extracellular
O	O	Ca2
O	O	+
O	O	through
O	O	the
O	O	l
O	O	-
O	O	type
O	O	Ca2
O	O	+
O	O	channel
O	O	.
O	O	Neither
O	O	the
O	O	content
O	O	nor
O	O	the
O	O	activity
O	O	of
O	O	Na
O	O	+
O	O	/
O	O	K
O	O	+
O	O	ATPase
O	O	and
O	O	sarcoplasmic
O	O	reticulum
O	O	Ca2
O	O	+
O	O	-
O	O	ATPase
O	O	are
O	O	affected
O	O	by
B	O	DMPK
O	O	absence
O	O	.
O	O	In
O	O	conclusion
O	O	,
O	O	our
O	O	data
O	O	suggest
O	O	that
O	O	DMPK
O	O	is
O	O	involved
O	O	in
O	O	modulating
O	O	the
O	O	initial
O	O	events
O	O	of
O	O	excitation
O	O	-
O	O	contraction
O	O	coupling
O	O	in
O	O	skeletal
O	O	muscle
O	O	.
O	O	.
O	O	Constitutional
O	O	RB1
O	O	-
O	O	gene
O	O	mutations
O	O	in
O	O	patients
O	O	with
B	O	isolated
B	B	unilateral
I	I	retinoblastoma
O	O	.
O	O	In
O	O	most
O	O	patients
O	O	with
B	O	isolated
B	B	unilateral
I	I	retinoblastoma
O	O	,
O	B	tumor
O	O	development
O	O	is
O	O	initiated
O	O	by
O	O	somatic
O	O	inactivation
O	O	of
O	O	both
O	O	alleles
O	O	of
O	O	the
O	O	RB1
O	O	gene
O	O	.
O	O	However
O	O	,
O	O	some
O	O	of
O	O	these
O	O	patients
O	O	can
O	O	transmit
B	B	retinoblastoma
O	O	predisposition
O	O	to
O	O	their
O	O	offspring
O	O	.
O	O	To
O	O	determine
O	O	the
O	O	frequency
O	O	and
O	O	nature
O	O	of
O	O	constitutional
O	O	RB1
O	O	-
O	O	gene
O	O	mutations
O	O	in
O	O	patients
O	O	with
B	O	isolated
B	B	unilateral
I	I	retinoblastoma
O	O	,
O	O	we
O	O	analyzed
O	O	DNA
O	O	from
O	O	peripheral
O	O	blood
O	O	and
O	O	from
B	B	tumor
O	O	tissue
O	O	.
O	O	The
O	O	analysis
O	O	of
B	B	tumors
O	O	from
O	O	54
O	O	(
O	O	71
O	O	%
O	O	)
O	O	of
O	O	76
O	O	informative
O	O	patients
O	O	showed
O	O	loss
O	O	of
O	O	constitutional
O	O	heterozygosity
O	O	(
O	O	LOH
O	O	)
O	O	at
O	O	intragenic
O	O	loci
O	O	.
O	O	Three
O	O	of
O	O	13
O	O	uninformative
O	O	patients
O	O	had
O	O	constitutional
O	O	deletions
O	O	.
O	O	For
O	O	39
O	O	randomly
O	O	selected
O	B	tumors
O	O	,
O	O	SSCP
O	O	,
O	O	hetero
O	O	-
O	O	duplex
O	O	analysis
O	O	,
O	O	sequencing
O	O	,
O	O	and
O	O	Southern
O	O	blot
O	O	analysis
O	O	were
O	O	used
O	O	to
O	O	identify
O	O	mutations
O	O	.
O	O	Mutations
O	O	were
O	O	detected
O	O	in
O	O	21
O	O	(
O	O	91
O	O	%
O	O	)
O	O	of
O	O	23
O	B	tumors
O	O	with
B	O	LOH
O	O	.
O	O	In
O	O	6
O	O	(
O	O	38
O	O	%
O	O	)
O	O	of
O	O	16
B	B	tumors
O	O	without
O	O	LOH
O	O	,
O	O	one
O	O	mutation
O	O	was
O	O	detected
O	O	,
O	O	and
O	O	in
O	O	9
O	O	(
O	O	56
O	O	%
O	O	)
O	O	of
O	O	the
O	B	tumors
O	O	without
O	O	LOH
O	O	,
O	O	both
O	O	mutations
O	O	were
O	O	found
O	O	.
O	O	Thus
O	O	,
O	O	a
O	O	total
O	O	of
O	O	45
O	O	mutations
O	O	were
O	O	identified
O	O	in
B	B	tumors
O	O	of
O	O	36
O	O	patients
O	O	.
O	O	Thirty
O	O	-
O	O	nine
O	O	of
O	O	the
O	O	mutations
O	O	-
O	O	including
O	O	34
O	O	small
O	O	mutations
O	O	,
O	O	2
O	O	large
O	O	structural
O	O	alterations
O	O	,
O	O	and
O	O	hypermethylation
O	O	in
O	O	3
B	O	tumors
O	O	-
O	O	were
O	O	not
O	O	detected
O	O	in
O	O	the
O	O	corresponding
O	O	peripheral
O	O	blood
O	O	DNA
O	O	.
O	O	In
O	O	6
O	O	(
O	O	17
O	O	%
O	O	)
O	O	of
O	O	the
O	O	36
O	O	patients
O	O	,
O	O	a
O	O	mutation
O	O	was
O	O	detected
O	O	in
O	O	constitutional
O	O	DNA
O	O	,
O	O	and
O	O	1
O	O	of
O	O	these
O	O	mutations
O	O	is
O	O	known
O	O	to
O	O	be
O	O	associated
O	O	with
O	O	reduced
O	O	expressivity
O	O	.
O	O	The
O	O	presence
O	O	of
O	O	a
O	O	constitutional
O	O	mutation
O	O	was
O	O	not
O	O	associated
O	O	with
O	O	an
O	O	early
O	O	age
O	O	at
O	O	treatment
O	O	.
O	O	In
O	O	1
O	O	patient
O	O	,
O	O	somatic
O	O	mosaicism
O	O	was
O	O	demonstrated
O	O	by
O	O	molecular
O	O	analysis
O	O	of
O	O	DNA
O	O	and
O	O	RNA
O	O	from
O	O	peripheral
O	O	blood
O	O	.
O	O	In
O	O	2
O	O	patients
O	O	without
O	O	a
O	O	detectable
O	O	mutation
O	O	in
O	O	peripheral
O	O	blood
O	O	,
O	O	mosaicism
O	O	was
O	O	suggested
O	O	because
O	O	1
O	O	of
O	O	the
O	O	patients
O	O	showed
B	O	multifocal
I	B	tumors
O	O	and
O	O	the
O	O	other
O	O	later
O	O	developed
B	B	bilateral
I	I	retinoblastoma
O	O	.
O	O	In
O	O	conclusion
O	O	,
O	O	our
O	O	results
O	O	emphasize
O	O	that
O	O	the
O	O	manifestation
O	O	and
O	O	transmissibility
O	O	of
B	B	retinoblastoma
O	O	depend
O	O	on
O	O	the
O	O	nature
O	O	of
O	O	the
O	O	first
O	O	mutation
O	O	,
O	O	its
O	O	time
O	O	in
O	O	development
O	O	,
O	O	and
O	O	the
O	O	number
O	O	and
O	O	types
O	O	of
O	O	cells
O	O	that
O	O	are
O	O	affected
O	O	.
O	O	.
O	B	Hereditary
I	I	deficiency
I	I	of
I	I	the
I	I	fifth
I	I	component
I	I	of
I	I	complement
O	O	in
O	O	man
O	O	.
O	O	I
O	O	.
O	O	Clinical
O	O	,
O	O	immunochemical
O	O	,
O	O	and
O	O	family
O	O	studies
O	O	.
O	O	The
O	O	first
O	O	recognized
O	O	human
O	O	kindred
O	O	with
B	B	hereditary
I	I	deficiency
I	I	of
I	I	the
I	I	fifth
I	I	component
I	I	of
I	I	complement
O	O	(
B	O	C5
O	O	)
O	O	is
O	O	described
O	O	.
O	O	The
O	O	proband
O	O	,
O	O	a
O	O	20
O	O	-
O	O	year
O	O	-
O	O	old
O	O	black
O	O	female
O	O	with
B	B	systemic
I	I	lupus
I	I	erythematosus
O	O	since
O	O	age
O	O	11
O	O	,
O	O	lacked
O	O	serum
O	O	hemolytic
O	O	complement
O	O	activity
O	O	,
O	O	even
O	O	during
O	O	remission
O	O	.
O	O	C5
O	O	was
O	O	undetectable
O	O	in
O	O	her
O	O	serum
O	O	by
O	O	both
O	O	immunodiffusion
O	O	and
O	O	hemolytic
O	O	assays
O	O	.
O	O	Other
O	O	complement
O	O	components
O	O	were
O	O	normal
O	O	during
B	O	remission
I	O	of
B	O	lupus
O	O	,
O	O	but
O	O	C1
O	O	,
O	O	C4
O	O	,
O	O	C2
O	O	,
O	O	and
O	O	C3
O	O	levels
O	O	fell
O	O	during
O	O	exacerbations
O	O	.
O	O	A
O	O	younger
O	O	half
O	O	-
O	O	sister
O	O	,
O	O	who
O	O	had
O	O	no
O	O	underlying
O	O	disease
O	O	,
O	O	was
O	O	also
O	O	found
O	O	to
O	O	lack
O	O	immunochemically
O	O	detectable
O	O	C5
O	O	.
O	O	By
O	O	hemolytic
O	O	assay
O	O	,
O	O	she
O	O	exhibited
O	O	1
O	O	-
O	O	2
O	O	%
O	O	of
O	O	the
O	O	normal
O	O	serum
O	O	C5
O	O	level
O	O	and
O	O	normal
O	O	concentrations
O	O	of
O	O	other
O	O	complement
O	O	components
O	O	.
O	O	C5
O	O	levels
O	O	of
O	O	other
O	O	family
O	O	members
O	O	were
O	O	either
O	O	normal
O	O	or
O	O	approximately
O	O	half
O	O	-
O	O	normal
O	O	,
O	O	consistent
O	O	with
O	O	autosomal
O	O	codominant
O	O	inheritance
O	O	of
O	O	the
O	O	gene
O	O	determining
B	B	C5
I	I	deficiency
O	O	.
O	O	Normal
B	O	hemolytic
I	O	titers
O	O	were
O	O	restored
O	O	to
O	O	both
O	O	homozygous
B	B	C5
I	I	-
I	I	deficient
O	O	(
B	B	C5D
O	O	)
O	O	sera
O	O	by
O	O	addition
O	O	of
O	O	highly
O	O	purified
O	O	human
O	O	C5
O	O	.
O	O	In
O	O	specific
O	O	C5
O	O	titrations
O	O	,
O	O	however
O	O	,
O	O	it
O	O	was
O	O	noted
O	O	that
O	O	when
O	O	limited
O	O	amounts
O	O	of
O	O	C5
O	O	were
O	O	assayed
O	O	in
O	O	the
O	O	presence
O	O	of
O	O	low
O	O	dilutions
O	O	of
O	O	either
O	B	C5D
O	O	serum
O	O	,
O	O	curving
O	O	rather
O	O	than
O	O	linear
O	O	dose
O	O	-
O	O	response
O	O	plots
O	O	were
O	O	consistently
O	O	obtained
O	O	,
O	O	suggesting
O	O	some
O	O	inhibitory
O	O	effect
O	O	.
O	O	Further
O	O	studies
O	O	suggested
O	O	that
O	O	low
O	O	dilutions
O	O	of
B	B	C5D
O	O	serum
O	O	contain
O	O	a
O	O	factor
O	O	(
O	O	or
O	O	factors
O	O	)
O	O	interfering
O	O	at
O	O	some
O	O	step
O	O	in
O	O	the
O	O	hemolytic
O	O	assay
O	O	of
O	O	C5
O	O	,
O	O	rather
O	O	than
O	O	a
O	O	true
O	O	C5
O	O	inhibitor
O	O	or
O	O	inactivator
O	O	.
O	O	Of
O	O	clinical
O	O	interest
O	O	are
O	O	(
O	O	a
O	O	)
O	O	the
O	O	documentation
O	O	of
B	O	membranous
I	B	glomerulonephritis
O	O	,
B	B	vasculitis
O	O	,
O	O	and
B	B	arthritis
O	O	in
O	O	an
O	O	individual
O	O	lacking
O	O	C5
O	O	(
O	O	and
O	O	its
O	O	biologic
O	O	functions
O	O	)
O	O	,
O	O	and
O	O	(
O	O	b
O	O	)
O	O	a
O	O	remarkable
O	O	propensity
O	O	to
B	B	bacterial
O	I	infections
O	O	in
O	O	the
O	O	proband
O	O	,
O	O	even
O	O	during
O	O	periods
O	O	of
O	O	low
O	O	-
O	O	dose
O	O	or
O	O	alternate
O	O	-
O	O	day
O	O	corticosteroid
O	O	therapy
O	O	.
O	O	Other
O	O	observations
O	O	indicate
O	O	that
O	O	the
O	B	C5D
O	O	state
O	O	is
O	O	compatible
O	O	with
O	O	normal
O	O	coagulation
O	O	function
O	O	and
O	O	the
O	O	capacity
O	O	to
O	O	mount
O	O	a
B	O	neutrophilic
I	O	leukocytosis
O	O	during
B	B	pyogenic
O	I	infection
O	O	.
O	O	.
O	O	Susceptibility
O	O	to
B	B	ankylosing
I	I	spondylitis
O	O	in
O	O	twins
O	O	:
O	O	the
O	O	role
O	O	of
O	O	genes
O	O	,
O	O	HLA
O	O	,
O	O	and
O	O	the
O	O	environment
O	O	.
O	O	OBJECTIVE
O	O	To
O	O	determine
O	O	the
O	O	relative
O	O	effects
O	O	of
O	O	genetic
O	O	and
O	O	environmental
O	O	factors
O	O	in
O	O	susceptibility
O	O	to
B	B	ankylosing
I	I	spondylitis
O	O	(
B	B	AS
O	O	)
O	O	.
O	O	METHODS
O	O	Twins
O	O	with
B	B	AS
O	O	were
O	O	identified
O	O	from
O	O	the
O	O	Royal
B	O	National
O	O	Hospital
O	O	for
I	B	Rheumatic
I	I	Diseases
O	O	database
O	O	.
O	O	Clinical
O	O	and
O	O	radiographic
O	O	examinations
O	O	were
O	O	performed
O	O	to
O	O	establish
O	O	diagnoses
O	O	,
O	O	and
O	O	disease
O	O	severity
O	O	was
O	O	assessed
O	O	using
O	O	a
O	O	combination
O	O	of
O	O	validated
O	O	scoring
O	O	systems
O	O	.
O	O	HLA
O	O	typing
O	O	for
O	O	HLA
O	O	-
O	O	B27
O	O	,
O	O	HLA
O	O	-
O	O	B60
O	O	,
O	O	and
O	O	HLA
O	O	-
O	O	DR1
O	O	was
O	O	performed
O	O	by
O	O	polymerase
O	O	chain
O	O	reaction
O	O	with
O	O	sequence
O	O	-
O	O	specific
O	O	primers
O	O	,
O	O	and
O	O	zygosity
O	O	was
O	O	assessed
O	O	using
O	O	microsatellite
O	O	markers
O	O	.
O	O	Genetic
O	O	and
O	O	environmental
O	O	variance
O	O	components
O	O	were
O	O	assessed
O	O	with
O	O	the
O	O	program
B	O	Mx
O	O	,
O	O	using
O	O	data
O	O	from
O	O	this
O	O	and
O	O	previous
O	O	studies
O	O	of
O	O	twins
O	O	with
B	B	AS
O	O	.
O	O	RESULTS
O	O	Six
O	O	of
O	O	8
O	O	monozygotic
O	O	(
O	O	MZ
O	O	)
O	O	twin
O	O	pairs
O	O	were
O	O	disease
O	O	concordant
O	O	,
O	O	compared
O	O	with
O	O	4
O	O	of
O	O	15
O	O	B27
O	O	-
O	O	positive
O	O	dizygotic
O	O	(
O	O	DZ
O	O	)
O	O	twin
O	O	pairs
O	O	(
O	O	27
O	O	%
O	O	)
O	O	and
O	O	4
O	O	of
O	O	32
B	O	DZ
O	O	twin
O	O	pairs
O	O	overall
O	O	(
O	O	12
O	O	.
O	O	5
O	O	%
O	O	)
O	O	.
O	O	Nonsignificant
O	O	increases
O	O	in
O	O	similarity
O	O	with
O	O	regard
O	O	to
O	O	age
O	O	at
O	O	disease
O	O	onset
O	O	and
O	O	all
O	O	of
O	O	the
O	O	disease
O	O	severity
O	O	scores
O	O	assessed
O	O	were
O	O	noted
O	O	in
O	O	disease
O	O	-
O	O	concordant
B	O	MZ
O	O	twins
O	O	compared
O	O	with
O	O	concordant
B	O	DZ
O	O	twins
O	O	.
O	O	HLA
O	O	-
O	O	B27
O	O	and
O	O	B60
O	O	were
O	O	associated
O	O	with
O	O	the
O	O	disease
O	O	in
O	O	probands
O	O	,
O	O	and
O	O	the
O	O	rate
O	O	of
O	O	disease
O	O	concordance
O	O	was
O	O	significantly
O	O	increased
O	O	among
B	O	DZ
O	O	twin
O	O	pairs
O	O	in
O	O	which
O	O	the
O	O	co
O	O	-
O	O	twin
O	O	was
O	O	positive
O	O	for
O	O	both
O	O	B27
O	O	and
O	O	DR1
O	O	.
O	O	Additive
O	O	genetic
O	O	effects
O	O	were
O	O	estimated
O	O	to
O	O	contribute
O	O	97
O	O	%
O	O	of
O	O	the
O	O	population
O	O	variance
O	O	.
O	O	CONCLUSION
O	O	Susceptibility
O	O	to
B	B	AS
O	O	is
O	O	largely
O	O	genetically
O	O	determined
O	O	,
O	O	and
O	O	the
O	O	environmental
O	O	trigger
O	O	for
O	O	the
O	O	disease
O	O	is
O	O	probably
O	O	ubiquitous
O	O	.
O	O	HLA
O	O	-
O	O	B27
O	O	accounts
O	O	for
O	O	a
O	O	minority
O	O	of
O	O	the
O	O	overall
O	O	genetic
O	O	susceptibility
O	O	to
B	B	AS
O	O	.
O	O	Cell
O	O	cycle
O	O	-
O	O	dependent
O	O	colocalization
O	O	of
O	O	BARD1
O	O	and
O	O	BRCA1
O	O	proteins
O	O	in
O	O	discrete
O	O	nuclear
O	O	domains
O	O	.
O	O	Germ
O	O	-
O	O	line
O	O	mutations
O	O	of
O	O	the
O	O	BRCA1
O	O	gene
O	O	predispose
O	O	women
O	O	to
O	O	early
O	O	-
O	O	onset
B	B	breast
I	I	and
I	I	ovarian
I	I	cancer
O	O	by
O	O	compromising
O	O	the
O	O	genes
O	O	presumptive
O	O	function
O	O	as
O	O	a
B	B	tumor
O	O	suppressor
O	O	.
O	O	Although
O	O	the
O	O	biochemical
O	O	properties
O	O	of
O	O	BRCA1
O	O	polypeptides
O	O	are
O	O	not
O	O	understood
O	O	,
O	O	their
O	O	expression
O	O	pattern
O	O	and
O	O	subcellular
O	O	localization
O	O	suggest
O	O	a
O	O	role
O	O	in
O	O	cell
O	O	-
O	O	cycle
O	O	regulation
O	O	.
O	O	When
O	O	resting
O	O	cells
O	O	are
O	O	induced
O	O	to
O	O	proliferate
O	O	,
O	O	the
O	O	steady
O	O	-
O	O	state
O	O	levels
O	O	of
O	O	BRCA1
O	O	increase
O	O	in
O	O	late
O	O	G1
O	O	and
O	O	reach
O	O	a
O	O	maximum
O	O	during
O	O	S
O	O	phase
O	O	.
O	O	Moreover
O	O	,
O	O	in
O	O	S
O	O	phase
O	O	cells
O	O	,
O	O	BRCA1
O	O	polypeptides
O	O	are
O	O	hyperphosphorylated
O	O	and
O	O	accumulate
O	O	into
O	O	discrete
O	O	subnuclear
O	O	foci
O	O	termed
O	O	""""
O	O	BRCA1
O	O	nuclear
O	O	dots
O	O	.
O	O	""""
O	O	BRCA1
O	O	associates
O	O	in
O	O	vivo
O	O	with
O	O	a
O	O	structurally
O	O	related
O	O	protein
O	O	termed
O	O	BARD1
O	O	.
O	O	Here
O	O	we
O	O	show
O	O	that
O	O	the
O	O	steady
O	O	-
O	O	state
O	O	levels
O	O	of
O	O	BARD1
O	O	,
O	O	unlike
O	O	those
O	O	of
O	O	BRCA1
O	O	,
O	O	remain
O	O	relatively
O	O	constant
O	O	during
O	O	cell
O	O	cycle
O	O	progression
O	O	.
O	O	However
O	O	,
O	O	immunostaining
O	O	revealed
O	O	that
O	O	BARD1
O	O	resides
O	O	within
O	O	BRCA1
O	O	nuclear
O	O	dots
O	O	during
O	O	S
O	O	phase
O	O	of
O	O	the
O	O	cell
O	O	cycle
O	O	,
O	O	but
O	O	not
O	O	during
O	O	the
O	O	G1
O	O	phase
O	O	.
O	O	Nevertheless
O	O	,
O	O	BARD1
O	O	polypeptides
O	O	are
O	O	found
O	O	exclusively
O	O	in
O	O	the
O	O	nuclear
O	O	fractions
O	O	of
O	O	both
O	O	G1
O	O	-
O	O	and
O	O	S
O	O	-
O	O	phase
O	O	cells
O	O	.
O	O	Therefore
O	O	,
O	O	progression
O	O	to
O	O	S
O	O	phase
O	O	is
O	O	accompanied
O	O	by
O	O	the
O	O	aggregation
O	O	of
O	O	nuclear
O	O	BARD1
O	O	polypeptides
O	O	into
O	O	BRCA1
O	O	nuclear
O	O	dots
O	O	.
O	O	This
O	O	cell
O	O	cycle
O	O	-
O	O	dependent
O	O	colocalization
O	O	of
O	O	BARD1
O	O	and
O	O	BRCA1
O	O	indicates
O	O	a
O	O	role
O	O	for
O	O	BARD1
O	O	in
O	O	BRCA1
O	O	-
O	O	mediated
B	B	tumor
O	O	suppression
O	O	.
O	O	Ethnic
O	O	differences
O	O	in
O	O	the
O	O	HFE
O	O	codon
O	O	282
O	O	(
O	O	Cys
O	O	/
O	O	Tyr
O	O	)
O	O	polymorphism
O	O	.
O	O	Recent
O	O	studies
O	O	have
O	O	shown
O	O	that
B	B	hereditary
I	I	hemochromatosis
O	O	(
B	B	HH
O	O	)
O	O	is
O	O	likely
O	O	to
O	O	be
O	O	caused
O	O	by
O	O	homozygosity
O	O	for
O	O	a
O	O	Cys282Tyr
O	O	mutation
O	O	in
O	O	the
O	O	HFE
O	O	gene
O	O	located
O	O	4
O	O	.
O	O	5
O	O	Mb
O	O	telomeric
O	O	to
O	O	HLA
O	O	-
O	O	A
O	O	.
O	O	Population
O	O	studies
O	O	of
O	O	this
O	O	polymorphism
O	O	are
O	O	facilitated
O	O	by
O	O	the
O	O	fact
O	O	that
O	O	the
O	O	Cys282Tyr
O	O	mutation
O	O	creates
O	O	a
O	O	Rsal
O	O	restriction
O	O	site
O	O	.
O	O	We
O	O	have
O	O	studied
O	O	the
O	O	codon
O	O	282
O	O	(
O	O	Cys
O	O	/
O	O	Tyr
O	O	)
O	O	polymorphism
O	O	in
O	O	different
O	O	ethnic
O	O	groups
O	O	.
O	O	In
O	O	agreement
O	O	with
O	O	previous
O	O	observations
O	O	the
O	O	Tyr
O	O	allele
O	O	appeared
O	O	to
O	O	be
O	O	rare
O	O	or
O	O	absent
O	O	in
O	O	Asiatic
O	O	(
O	O	Indian
O	O	,
O	O	Chinese
O	O	)
O	O	populations
O	O	.
O	O	The
O	O	highest
O	O	allele
O	O	frequency
O	O	(
O	O	7
O	O	.
O	O	5
O	O	%
O	O	)
O	O	was
O	O	found
O	O	in
O	O	Swedes
O	O	.
O	O	Saamis
O	O	(
O	O	2
O	O	%
O	O	)
O	O	and
O	O	Mordvinians
O	O	(
O	O	1
O	O	.
O	O	8
O	O	%
O	O	)
O	O	had
O	O	significantly
O	O	lower
O	O	frequencies
O	O	of
O	O	the
O	O	Tyr
O	O	allele
O	O	.
O	O	Comparisons
O	O	with
O	O	allele
O	O	frequencies
O	O	based
O	O	on
O	O	prevalence
O	O	estimates
O	O	of
B	B	HH
O	O	showed
O	O	some
O	O	disagreements
O	O	with
O	O	the
O	O	RFLP
O	O	data
O	O	,
O	O	particularly
O	O	in
O	O	Finns
O	O	.
O	O	The
O	O	newly
O	O	described
O	O	HFE
O	O	marker
O	O	provides
O	O	a
O	O	new
O	O	approach
O	O	to
O	O	the
O	O	screening
O	O	of
B	B	HH
O	O	as
O	O	well
O	O	as
O	O	studies
O	O	of
O	O	the
O	O	relationship
O	O	between
O	O	the
O	O	HFE
O	O	Tyr
O	O	allele
O	O	and
O	O	different
O	O	disorders
O	O	including
B	B	cancer
B	B	Autosomal
O	I	dominant
B	I	neurohypophyseal
I	I	diabetes
I	I	insipidus
O	O	associated
O	O	with
O	O	a
O	O	missense
O	O	mutation
O	O	encoding
O	O	Gly23
O	O	-
O	O	-
O	O	>
O	O	Val
O	O	in
B	O	neurophysin
O	O	II
O	O	.
B	B	Autosomal
I	I	dominant
I	I	neurohypophyseal
I	I	diabetes
I	I	insipidus
O	O	(
B	B	ADNDI
O	O	)
O	O	is
O	O	an
B	B	inherited
I	I	disease
O	O	caused
O	O	by
O	O	progressive
B	O	degeneration
I	O	of
I	O	the
I	O	magnocellular
I	O	neurons
O	O	of
I	O	the
I	O	hypothalamus
O	O	leading
O	O	to
O	O	decreased
O	O	ability
O	O	to
O	O	produce
O	O	the
O	O	hormone
O	O	arginine
O	O	vasopressin
O	O	(
O	O	AVP
O	O	)
O	O	.
O	O	Affected
O	O	individuals
O	O	are
O	O	not
O	O	symptomatic
O	O	at
O	O	birth
O	O	,
O	O	but
O	O	usually
O	O	develop
B	B	diabetes
I	I	insipidus
O	O	at
O	O	1
O	O	-
O	O	6
O	O	yr
O	O	of
O	O	age
O	O	.
O	O	The
O	O	genetic
O	O	locus
O	O	of
O	O	the
O	O	disease
O	O	is
O	O	the
O	O	AVP
O	O	-
O	O	neurophysin
O	O	II
O	O	(
O	O	NPII
O	O	)
O	O	gene
O	O	,
O	O	and
O	O	mutations
O	O	that
O	O	cause
B	B	ADNDI
O	O	have
O	O	been
O	O	found
O	O	in
O	O	both
O	O	the
O	O	signal
O	O	peptide
O	O	of
O	O	the
O	O	prepro
O	O	-
O	O	AVP
O	O	-
O	O	NPII
O	O	precursor
O	O	and
O	O	within
O	O	NPII
O	O	itself
O	O	.
O	O	An
O	O	affected
O	O	girl
O	O	who
O	O	presented
O	O	at
O	O	9
O	O	months
O	O	of
O	O	age
O	O	and
O	O	her
O	O	similarly
O	O	affected
O	O	younger
O	O	brother
O	O	and
O	O	father
O	O	were
O	O	all
O	O	found
O	O	to
O	O	have
O	O	a
O	O	novel
O	O	missense
O	O	mutation
O	O	(
O	O	G1758
O	O	-
O	O	-
O	O	>
O	O	T
O	O	)
O	O	encoding
O	O	the
O	O	amino
O	O	acid
O	O	substitution
O	O	Gly23
O	O	-
O	O	-
O	O	>
O	O	Val
O	O	within
O	O	NPII
O	O	.
O	O	The
O	O	mutation
O	O	was
O	O	confirmed
O	O	by
O	O	restriction
O	O	endonuclease
O	O	analysis
O	O	.
O	O	A
O	O	T1
O	O	-
O	O	weighted
O	O	magnetic
O	O	resonance
O	O	imaging
O	O	of
O	O	the
O	O	fathers
I	O	pituitary
O	O	gland
O	O	demonstrates
O	O	an
O	O	attenuated
O	O	posterior
I	O	pituitary
O	O	bright
O	O	spot
O	O	.
O	O	This
O	O	mutation
O	O	may
O	O	be
O	O	valuable
O	O	for
O	O	developing
O	O	models
O	O	of
O	B	dominantly
O	I	inherited
B	I	neurodegeneration
O	O	,
O	O	as
O	O	the
O	O	early
O	O	age
O	O	of
O	O	onset
O	O	of
O	O	symptoms
O	O	suggests
O	O	that
O	O	this
O	O	mutation
O	O	may
O	O	be
O	O	particularly
O	O	deleterious
O	O	to
O	O	the
O	O	magnocellular
O	O	neuron
O	O	.
O	O	.
O	O	Frequent
O	O	inactivation
O	O	of
O	O	PTEN
O	O	/
O	O	MMAC1
O	O	in
B	O	primary
I	B	prostate
I	I	cancer
O	O	.
B	B	Sporadic
B	I	prostate
I	I	carcinoma
O	O	is
O	O	the
O	O	most
O	O	common
B	B	male
I	I	cancer
O	O	in
O	O	the
O	O	Western
O	O	world
O	O	,
O	O	yet
O	O	many
O	O	of
O	O	the
O	O	major
O	O	genetic
O	O	events
O	O	involved
O	O	in
O	O	the
O	O	progression
O	O	of
O	O	this
O	O	often
O	O	fatal
I	B	cancer
O	O	remain
O	O	to
O	O	be
O	O	elucidated
O	O	.
O	O	Numerous
O	O	cytogenetic
O	O	and
O	O	allelotype
O	O	studies
O	O	have
O	O	reported
O	O	frequent
O	O	loss
O	O	of
O	O	heterozygosity
O	O	on
O	O	chromosomal
O	O	arm
O	O	10q
O	O	in
B	B	sporadic
B	I	prostate
I	I	cancer
O	O	.
O	O	Deletion
O	O	mapping
O	O	studies
O	O	have
O	O	unambiguously
O	O	identified
O	O	a
O	O	region
O	O	of
O	O	chromosome
O	O	10q23
O	O	to
O	O	be
O	O	the
O	O	minimal
O	O	area
O	O	of
O	O	loss
O	O	.
O	O	A
O	O	new
B	B	tumor
O	O	suppressor
O	O	gene
O	O	,
O	O	PTEN
O	O	/
O	O	MMAC1
O	O	,
O	O	was
O	O	isolated
O	O	recently
O	O	at
O	O	this
O	O	region
O	O	of
O	O	chromosome
O	O	10q23
O	O	and
O	O	found
O	O	to
O	O	be
O	O	inactivated
O	O	by
O	O	mutation
O	O	in
O	O	three
B	B	prostate
I	I	cancer
O	O	cell
O	O	lines
O	O	.
O	O	We
O	O	screened
O	O	80
B	B	prostate
I	I	tumors
O	O	by
O	O	microsatellite
O	O	analysis
O	O	and
O	O	found
O	O	chromosome
O	O	10q23
O	O	to
O	O	be
O	O	deleted
O	O	in
O	O	23
O	O	cases
O	O	.
O	O	We
O	O	then
O	O	proceeded
O	O	with
O	O	sequence
O	O	analysis
O	O	of
O	O	the
O	O	entire
O	O	PTEN
O	O	/
O	O	MMAC1
O	O	coding
O	O	region
O	O	and
O	O	tested
O	O	for
O	O	homozygous
O	O	deletion
O	O	with
O	O	new
O	O	intragenic
O	O	markers
O	O	in
O	O	these
O	O	23
O	O	cases
O	O	with
O	O	10q23
O	O	loss
O	O	of
O	O	heterozygosity
O	O	.
O	O	The
O	O	identification
O	O	of
O	O	the
O	O	second
O	O	mutational
O	O	event
O	O	in
O	O	10
O	O	(
O	O	43
O	O	%
O	O	)
B	B	tumors
O	O	establishes
O	O	PTEN
O	O	/
O	O	MMAC1
O	O	as
O	O	a
O	O	main
O	O	inactivation
O	O	target
O	O	of
O	O	10q
O	O	loss
O	O	in
B	B	sporadic
B	I	prostate
I	I	cancer
O	O	.
O	O	.
O	O	Risk
O	O	reversals
O	O	in
O	O	predictive
O	O	testing
O	O	for
B	B	Huntington
I	I	disease
O	O	.
O	O	The
O	O	first
O	O	predictive
O	O	testing
O	O	for
B	B	Huntington
I	I	disease
O	O	(
B	B	HD
O	O	)
O	O	was
O	O	based
O	O	on
O	O	analysis
O	O	of
O	O	linked
O	O	polymorphic
O	O	DNA
O	O	markers
O	O	to
O	O	estimate
O	O	the
O	O	likelihood
O	O	of
O	O	inheriting
O	O	the
O	O	mutation
O	O	for
B	B	HD
O	O	.
O	O	Limits
O	O	to
O	O	accuracy
O	O	included
O	O	recombination
O	O	between
O	O	the
O	O	DNA
O	O	markers
O	O	and
O	O	the
O	O	mutation
O	O	,
O	O	pedigree
O	O	structure
O	O	,
O	O	and
O	O	whether
O	O	DNA
O	O	samples
O	O	were
O	O	available
O	O	from
O	O	family
O	O	members
O	O	.
O	O	With
O	O	direct
O	O	tests
O	O	for
O	O	the
B	B	HD
O	O	mutation
O	O	,
O	O	we
O	O	have
O	O	assessed
O	O	the
O	O	accuracy
O	O	of
O	O	results
O	O	obtained
O	O	by
O	O	linkage
O	O	approaches
O	O	when
O	O	requested
O	O	to
O	O	do
O	O	so
O	O	by
O	O	the
O	O	test
O	O	individuals
O	O	.
O	O	For
O	O	six
O	O	such
O	O	individuals
O	O	,
O	O	there
O	O	was
O	O	significant
O	O	disparity
O	O	between
O	O	the
O	O	tests
O	O	.
O	O	Three
O	O	went
O	O	from
O	O	a
O	O	decreased
O	O	risk
O	O	to
O	O	an
O	O	increased
O	O	risk
O	O	,
O	O	while
O	O	in
O	O	another
O	O	three
O	O	the
O	O	risk
O	O	was
O	O	decreased
O	O	.
O	O	Knowledge
O	O	of
O	O	the
O	O	potential
O	O	reasons
O	O	for
O	O	these
O	O	changes
O	O	in
O	O	results
O	O	and
O	O	impact
O	O	of
O	O	these
O	O	risk
O	O	reversals
O	O	on
O	O	both
O	O	patients
O	O	and
O	O	the
O	O	counseling
O	O	team
O	O	can
O	O	assist
O	O	in
O	O	the
O	O	development
O	O	of
O	O	strategies
O	O	for
O	O	the
O	O	prevention
O	O	and
O	O	,
O	O	where
O	O	necessary
O	O	,
O	O	management
O	O	of
O	O	a
O	O	risk
O	O	reversal
O	O	in
O	O	any
O	O	predictive
O	O	testing
O	O	program
O	O	.
O	O	.
O	O	A
O	O	novel
O	O	common
O	O	missense
O	O	mutation
O	O	G301C
O	O	in
O	O	the
O	O	N
O	O	-
O	O	acetylgalactosamine
O	O	-
O	O	6
O	O	-
O	O	sulfate
O	O	sulfatase
O	O	gene
O	O	in
B	B	mucopolysaccharidosis
I	I	IVA
O	O	.
B	B	Mucopolysaccharidosis
I	I	IVA
O	O	(
B	B	MPS
I	I	IVA
O	O	)
O	O	is
O	O	an
B	B	autosomal
I	I	recessive
I	I	lysosomal
I	I	storage
I	I	disorder
O	O	caused
O	O	by
O	O	a
B	B	genetic
O	I	defect
O	O	in
B	O	N
I	O	-
O	O	acetylgalactosamine
O	O	-
O	O	6
O	O	-
O	O	sulfate
O	O	sulfatase
O	O	(
B	O	GALNS
O	O	)
O	O	.
O	O	In
O	O	previous
O	O	studies
O	O	,
O	O	we
O	O	have
O	O	found
O	O	two
O	O	common
O	O	mutations
O	O	in
O	O	Caucasians
O	O	and
O	O	Japanese
O	O	,
O	O	respectively
O	O	.
O	O	To
O	O	characterize
O	O	the
O	O	mutational
O	O	spectrum
O	O	in
O	O	various
O	O	ethnic
O	O	groups
O	O	,
O	O	mutations
O	O	in
O	O	the
O	O	GALNS
O	O	gene
O	O	in
O	O	Colombian
B	B	MPS
I	I	IVA
O	O	patients
O	O	were
O	O	investigated
O	O	,
O	O	and
O	O	genetic
O	O	backgrounds
O	O	were
O	O	extensively
O	O	analyzed
O	O	to
O	O	identify
O	O	racial
O	O	origin
O	O	,
O	O	based
O	O	on
O	O	mitochondrial
O	O	DNA
O	O	(
O	O	mtDNA
O	O	)
O	O	lineages
O	O	.
O	O	Three
O	O	novel
O	O	missense
O	O	mutations
O	O	never
O	O	identified
O	O	previously
O	O	in
O	O	other
O	O	populations
O	O	and
O	O	found
O	O	in
O	O	16
O	O	out
O	O	of
O	O	19
O	O	Colombian
B	B	MPS
B	I	IVA
O	O	unrelated
O	O	alleles
O	O	account
O	O	for
O	O	84
O	O	.
O	O	2
O	O	%
O	O	of
O	O	the
O	O	alleles
O	O	in
O	O	this
O	O	study
O	O	.
O	O	The
O	O	G301C
O	O	and
O	O	S162F
O	O	mutations
O	O	account
O	O	for
O	O	68
O	O	.
O	O	4
O	O	%
O	O	and
O	O	10
O	O	.
O	O	5
O	O	%
O	O	of
O	O	mutations
O	O	,
O	O	respectively
O	O	,
O	O	whereas
O	O	the
O	O	remaining
O	O	F69V
O	O	is
O	O	limited
O	O	to
O	O	a
O	O	single
O	O	allele
O	O	.
O	O	The
O	O	skewed
O	O	prevalence
O	O	of
O	O	G301C
O	O	in
O	O	only
O	O	Colombian
O	O	patients
O	O	and
O	O	haplotype
O	O	analysis
O	O	by
O	O	restriction
O	O	fragment
O	O	length
O	O	polymorphisms
O	O	in
O	O	the
O	O	GALNS
O	O	gene
O	O	suggest
O	O	that
O	O	G301C
O	O	originated
O	O	from
O	O	a
O	O	common
O	O	ancestor
O	O	.
O	O	Investigation
O	O	of
O	O	the
O	O	genetic
O	O	background
O	O	by
O	O	means
O	O	of
O	O	mtDNA
O	O	lineages
O	O	indicate
O	O	that
O	O	all
O	O	our
O	O	patients
O	O	are
O	O	probably
O	O	of
O	O	native
O	O	American
O	O	descent
O	O	Low
O	O	frequency
O	O	of
O	O	BRCA1
O	O	germline
O	O	mutations
O	O	in
O	O	45
O	O	German
B	B	breast
I	I	/
I	I	ovarian
I	I	cancer
O	O	families
O	O	.
O	O	In
O	O	this
O	O	study
O	O	we
O	O	investigated
O	O	45
O	O	German
B	B	breast
I	I	/
I	I	ovarian
I	I	cancer
O	O	families
O	O	for
O	O	germline
O	O	mutations
O	O	in
O	O	the
O	O	BRCA1
O	O	gene
O	O	.
O	O	We
O	O	identified
O	O	four
O	O	germline
O	O	mutations
O	O	in
O	O	three
B	B	breast
I	I	cancer
O	O	families
O	O	and
O	O	in
O	O	one
B	B	breast
I	I	-
I	I	ovarian
I	I	cancer
O	O	family
O	O	.
O	O	among
O	O	these
O	O	were
O	O	one
O	O	frameshift
O	O	mutation
O	O	,
O	O	one
O	O	nonsense
O	O	mutation
O	O	,
O	O	one
O	O	novel
O	O	splice
O	O	site
O	O	mutation
O	O	,
O	O	and
O	O	one
O	O	missense
O	O	mutation
O	O	.
O	O	The
O	O	missense
O	O	mutation
O	O	was
O	O	also
O	O	found
O	O	in
O	O	2
O	O	.
O	O	8
O	O	%
O	O	of
O	O	the
O	O	general
O	O	population
O	O	,
O	O	suggesting
O	O	that
O	O	it
O	O	is
O	O	not
O	O	disease
O	O	associated
O	O	.
O	O	The
O	O	average
O	O	age
O	O	of
O	O	disease
O	O	onset
O	O	in
O	O	those
O	O	families
O	O	harbouring
O	O	causative
O	O	mutations
O	O	was
O	O	between
O	O	32
O	O	.
O	O	3
O	O	and
O	O	37
O	O	.
O	O	4
O	O	years
O	O	,
O	O	whereas
O	O	the
O	O	family
O	O	harbouring
O	O	the
O	O	missense
O	O	mutation
O	O	had
O	O	an
O	O	average
O	O	age
O	O	of
O	O	onset
O	O	of
O	O	51
O	O	.
O	O	2
O	O	years
O	O	.
O	O	These
O	O	findings
O	O	show
O	O	that
O	O	BRCA1
O	O	is
O	O	implicated
O	O	in
O	O	a
O	O	small
O	O	fraction
O	O	of
B	B	breast
I	I	/
I	I	ovarian
I	I	cancer
O	O	families
O	O	suggesting
O	O	the
O	O	involvement
O	O	of
O	O	another
O	O	susceptibility
O	O	gene
O	O	(
O	O	s
O	O	)
O	O	Paternal
O	O	transmission
O	O	of
B	B	congenital
I	I	myotonic
I	I	dystrophy
O	O	.
O	O	We
O	O	report
O	O	a
O	O	rare
O	O	case
O	O	of
O	O	paternally
O	O	transmitted
B	B	congenital
I	I	myotonic
I	I	dystrophy
O	O	(
B	B	DM
O	O	)
O	O	.
O	O	The
O	O	proband
O	O	is
O	O	a
O	O	23
O	O	year
O	O	old
O	O	,
B	B	mentally
I	I	retarded
O	O	male
O	O	who
O	O	suffers
O	O	severe
B	B	muscular
I	I	weakness
O	O	.
O	O	He
O	O	presented
O	O	with
B	O	respiratory
O	O	and
O	O	feeding
O	O	difficulties
O	O	at
O	O	birth
O	O	.
O	O	His
O	O	two
O	O	sibs
O	O	suffer
O	O	from
O	O	childhood
O	O	onset
B	B	DM
O	O	.
O	O	Their
O	O	late
O	O	father
O	O	had
O	O	the
O	O	adult
O	O	type
O	O	of
B	B	DM
O	O	,
O	O	with
O	O	onset
O	O	around
O	O	30
O	O	years
O	O	.
O	O	Only
O	O	six
O	O	other
O	O	cases
O	O	of
O	O	paternal
O	O	transmission
O	O	of
B	B	congenital
I	I	DM
O	O	have
O	O	been
O	O	reported
O	O	recently
O	O	.
O	O	We
O	O	review
O	O	the
O	O	sex
O	O	related
O	O	effects
O	O	on
O	O	transmission
O	O	of
B	B	congenital
I	I	DM
O	O	.
O	O	Decreased
O	O	fertility
O	O	of
O	O	males
O	O	with
O	O	adult
O	O	onset
B	B	DM
O	O	and
O	O	contraction
O	O	of
O	O	the
O	O	repeat
O	O	upon
O	O	male
O	O	transmission
O	O	contribute
O	O	to
O	O	the
O	O	almost
O	O	absent
O	O	occurrence
O	O	of
O	O	paternal
O	O	transmission
O	O	of
B	B	congenital
B	I	DM
O	O	.
O	O	Also
O	O	the
O	O	fathers
O	O	of
O	O	the
O	O	reported
B	O	congenitally
O	O	affected
O	O	children
O	O	showed
O	O	,
O	O	on
O	O	average
O	O	,
O	O	shorter
O	O	CTG
O	O	repeat
O	O	lengths
O	O	and
O	O	hence
O	O	less
O	O	severe
O	O	clinical
O	O	symptoms
O	O	than
O	O	the
O	O	mothers
O	O	of
O	O	children
O	O	with
B	B	congenital
B	I	DM
O	O	.
O	O	We
O	O	conclude
O	O	that
O	O	paternal
O	O	transmission
O	O	of
B	B	congenital
B	I	DM
O	O	is
O	O	rare
O	O	and
O	O	preferentially
O	O	occurs
O	O	with
O	O	onset
O	O	of
B	B	DM
O	O	past
O	O	30
O	O	years
O	O	in
O	O	the
O	O	father
O	O	.
O	O	.
O	O	The
O	O	RB1
O	O	gene
O	O	mutation
O	O	in
O	O	a
O	O	child
O	O	with
B	B	ectopic
I	I	intracranial
I	I	retinoblastoma
O	O	.
O	O	The
O	O	RB1
O	O	gene
O	O	mutation
O	O	was
O	O	investigated
O	O	in
O	O	a
O	O	child
O	O	with
B	B	ectopic
I	I	intracranial
I	I	retinoblastoma
O	O	using
O	O	DNA
O	O	obtained
O	O	from
O	O	both
O	O	the
B	B	pineal
I	I	and
I	I	retinal
I	I	tumours
O	O	of
O	O	the
O	O	patient
O	O	.
O	O	A
O	O	nonsense
O	O	mutation
O	O	in
O	O	exon
O	O	17
O	O	(
O	O	codon
O	O	556
O	O	)
O	O	of
O	O	the
O	O	RB1
O	O	gene
O	O	was
O	O	found
O	O	to
O	O	be
O	O	present
O	O	homozygously
O	O	in
O	O	both
O	O	the
O	B	retinal
O	I	and
O	I	the
B	I	pineal
I	I	tumours
O	O	.
O	O	The
O	O	same
O	O	mutation
O	O	was
O	O	present
O	O	heterozygously
O	O	in
O	O	the
O	O	DNA
O	O	from
O	O	the
O	O	constitutional
O	O	cells
O	O	of
O	O	the
O	O	patient
O	O	,
O	O	proving
O	O	it
O	O	to
O	O	be
O	O	of
O	O	germline
O	O	origin
O	O	.
O	O	The
O	O	initial
O	O	mutation
O	O	was
O	O	shown
O	O	to
O	O	have
O	O	occurred
O	O	in
O	O	the
O	O	paternally
O	O	derived
O	O	RB1
O	O	allele
O	O	.
O	O	The
O	O	mutation
O	O	is
O	O	in
O	O	an
O	O	area
O	O	of
O	O	the
O	O	gene
O	O	that
O	O	encodes
O	O	the
O	O	protein
O	O	-
O	O	binding
O	O	region
O	O	known
O	O	as
O	O	the
O	O	pocket
O	O	region
O	O	and
O	O	has
O	O	been
O	O	detected
O	O	in
O	O	other
O	O	cases
O	O	of
B	B	retinoblastoma
O	O	.
O	O	.
O	O	Low
O	O	levels
O	O	of
O	O	beta
O	O	hexosaminidase
O	O	A
O	O	in
O	O	healthy
O	O	individuals
O	O	with
O	O	apparent
B	O	deficiency
O	O	of
O	O	this
O	O	enzyme
O	O	.
O	O	Appreciable
O	O	beta
O	O	hexosaminidase
O	O	A
O	O	(
O	O	hex
O	O	A
O	O	)
O	O	activity
O	O	has
O	O	been
O	O	detected
O	O	in
O	O	cultured
O	O	skin
O	O	fibroblasts
O	O	and
B	B	melanoma
O	O	tissue
O	O	from
O	O	healthy
O	O	individuals
O	O	previously
O	O	reported
O	O	as
O	O	having
B	B	deficiency
I	I	of
I	I	hex
I	I	A
O	O	activity
O	O	indistinguishable
O	O	from
O	O	that
O	O	of
O	O	patients
O	O	with
B	B	Tay
I	I	-
I	I	Sachs
I	I	disease
O	O	(
B	B	TSD
O	O	)
O	O	.
O	O	Identification
O	O	and
O	O	quantitation
O	O	of
O	O	hex
O	O	A
O	O	,
O	O	amounting
O	O	to
O	O	3
O	O	.
O	O	5
O	O	%
O	O	-
O	O	6
O	O	.
O	O	9
O	O	%
O	O	of
O	O	total
O	O	beta
O	O	hexosaminidase
O	O	activity
O	O	,
O	O	has
O	O	been
O	O	obtained
O	O	by
O	O	cellulose
O	O	acetate
O	O	gel
O	O	electrophoresis
O	O	,
O	O	DEAE
O	O	-
O	O	cellulose
O	O	ion
O	O	-
O	O	exchange
O	O	chromatography
O	O	,
O	O	radial
O	O	immunodiffusion
O	O	,
O	O	and
O	O	radioimmunoassay
O	O	.
O	O	Previous
O	O	family
O	O	studies
O	O	suggested
O	O	that
O	O	these
O	O	individuals
O	O	may
O	O	be
O	O	compound
O	O	heterozygotes
O	O	for
O	O	the
O	O	common
O	O	mutant
B	B	TSD
O	O	gene
O	O	and
O	O	a
O	O	rare
O	O	(
O	O	allelic
O	O	)
O	O	mutant
O	O	gene
O	O	.
O	O	Thus
O	O	,
O	O	the
O	O	postulated
O	O	rate
O	O	mutant
O	O	gene
O	O	appears
O	O	to
O	O	code
O	O	for
O	O	the
O	O	expression
O	O	of
O	O	low
O	O	amounts
O	O	of
O	O	hex
O	O	A
O	O	.
O	O	Heterozygotes
O	O	for
O	O	the
O	O	rare
O	O	mutant
O	O	may
O	O	be
O	O	indistinguishable
O	O	from
O	O	heterozygotes
O	O	for
O	O	the
O	O	common
B	B	TSD
O	O	mutant
O	O	.
O	O	However
O	O	,
O	O	direct
O	O	visualization
O	O	and
O	O	quantitation
O	O	of
O	O	hex
O	O	A
O	O	by
O	O	the
O	O	methods
O	O	described
O	O	may
O	O	prevent
O	O	false
O	O	-
O	O	positive
O	O	prenatal
O	O	diagnosis
O	O	of
B	B	TSD
O	O	in
O	O	fetuses
O	O	having
O	O	the
O	O	incomplete
B	B	hex
I	I	A
I	I	deficiency
I	O	of
O	O	the
O	O	type
O	O	described
O	O	in
O	O	the
O	O	four
O	O	healthy
O	O	individuals
O	O	The
B	B	tumor
O	O	suppressor
O	O	gene
O	O	Smad4
O	O	/
O	O	Dpc4
O	O	is
O	O	required
O	O	for
O	O	gastrulation
O	O	and
O	O	later
O	O	for
O	O	anterior
O	O	development
O	O	of
O	O	the
O	O	mouse
O	O	embryo
O	O	.
O	O	Mutations
O	O	in
O	O	the
O	O	SMAD4
O	O	/
O	O	DPC4
O	B	tumor
O	O	suppressor
O	O	gene
O	O	,
O	O	a
O	O	key
O	O	signal
O	O	transducer
O	O	in
O	O	most
O	O	TGFbeta
O	O	-
O	O	related
O	O	pathways
O	O	,
O	O	are
O	O	involved
O	O	in
O	O	50
O	O	%
O	O	of
B	B	pancreatic
I	I	cancers
O	O	.
O	O	Homozygous
O	O	Smad4
O	O	mutant
O	O	mice
O	O	die
O	O	before
O	O	day
O	O	7
O	O	.
O	O	5
O	O	of
O	O	embryogenesis
O	O	.
O	O	Mutant
O	O	embryos
O	O	have
O	O	reduced
O	O	size
O	O	,
O	O	fail
O	O	to
O	O	gastrulate
O	O	or
O	O	express
O	O	a
O	O	mesodermal
O	O	marker
O	O	,
O	O	and
O	O	show
O	O	abnormal
O	O	visceral
O	O	endoderm
O	O	development
O	O	.
B	B	Growth
I	I	retardation
O	O	of
O	O	the
B	O	Smad4
I	O	-
I	O	deficient
O	O	embryos
O	O	results
O	O	from
O	O	reduced
O	O	cell
O	O	proliferation
O	O	rather
O	O	than
O	O	increased
O	O	apoptosis
O	O	.
O	O	Aggregation
O	O	of
O	O	mutant
O	O	Smad4
O	O	ES
O	O	cells
O	O	with
O	O	wild
O	O	-
O	O	type
O	O	tetraploid
O	O	morulae
O	O	rescues
O	O	the
O	B	gastrulation
O	I	defect
O	O	.
O	O	These
O	O	results
O	O	indicate
O	O	that
O	O	Smad4
O	O	is
O	O	initially
O	O	required
O	O	for
O	O	the
O	O	differentiation
O	O	of
O	O	the
O	O	visceral
O	O	endoderm
O	O	and
O	O	that
O	O	the
O	B	gastrulation
O	I	defect
O	O	in
O	O	the
O	O	epiblast
O	O	is
O	O	secondary
O	O	and
O	O	non
O	O	-
O	O	cell
O	O	autonomous
O	O	.
O	O	Rescued
O	O	embryos
O	O	show
O	O	severe
O	O	anterior
O	O	truncations
O	O	,
O	O	indicating
O	O	a
O	O	second
O	O	important
O	O	role
O	O	for
O	O	Smad4
O	O	in
O	O	anterior
O	O	patterning
O	O	during
O	O	embryogenesis
O	O	.
O	O	Prevalence
O	O	of
O	O	p16
O	O	and
O	O	CDK4
O	O	germline
O	O	mutations
O	O	in
O	O	48
B	B	melanoma
O	O	-
O	O	prone
O	O	families
O	O	in
O	O	France
O	O	.
O	O	The
O	O	French
B	B	Familial
I	I	Melanoma
O	O	Study
O	O	Group
O	O	.
O	O	Germline
O	O	mutations
O	O	in
O	O	the
O	O	p16
O	O	and
O	O	CDK4
O	O	genes
O	O	have
O	O	been
O	O	reported
O	O	in
O	O	a
O	O	subset
O	O	of
B	B	melanoma
O	O	pedigrees
O	O	,
O	O	but
O	O	their
O	O	prevalence
O	O	is
O	O	not
O	O	well
O	O	known
O	O	.
O	O	We
O	O	searched
O	O	for
O	O	such
O	O	germline
O	O	mutations
O	O	in
O	O	48
O	O	French
B	B	melanoma
I	O	-
O	O	prone
O	O	families
O	O	selected
O	O	according
O	O	to
O	O	two
O	O	major
O	O	criteria
O	O	families
O	O	with
O	O	at
O	O	least
O	O	three
O	O	affected
O	O	members
O	O	(
O	O	n
O	O	=
O	O	20
O	O	)
O	O	or
O	O	families
O	O	with
O	O	two
O	O	affected
O	O	members
O	O	,
O	O	one
O	O	of
O	O	them
O	O	affected
O	O	before
O	O	the
O	O	age
O	O	of
O	O	50
O	O	(
O	O	n
O	O	=
O	O	28
O	O	)
O	O	,
O	O	and
O	O	one
O	O	additional
O	O	minor
O	O	criterion
O	O	.
O	O	Sixteen
O	O	different
O	O	p16
O	O	germline
O	O	mutations
O	O	were
O	O	found
O	O	in
O	O	21
O	O	families
O	O	,
O	O	while
O	O	one
O	O	germline
O	O	mutation
O	O	,
O	O	Arg24His
O	O	,
O	O	was
O	O	detected
O	O	in
O	O	the
O	O	CDK4
O	O	gene
O	O	.
O	O	The
O	O	frequency
O	O	of
O	O	p16
O	O	gene
O	O	mutation
O	O	in
O	O	our
O	O	sample
O	O	(
O	O	44
O	O	%
O	O	)
O	O	is
O	O	among
O	O	the
O	O	highest
O	O	rates
O	O	yet
O	O	reported
O	O	and
O	O	the
O	O	CDK4
O	O	mutation
O	O	is
O	O	the
O	O	second
O	O	mutation
O	O	detected
O	O	in
O	O	this
O	O	gene
O	O	worldwide
O	O	.
O	O	In
O	O	summary
O	O	,
O	O	our
O	O	results
O	O	show
O	O	frequent
O	O	involvement
O	O	of
O	O	the
O	O	p16
O	O	gene
O	O	in
B	B	familial
I	I	melanoma
O	O	and
O	O	confirm
O	O	the
O	O	role
O	O	of
O	O	the
O	O	CDK4
O	O	gene
O	O	as
O	O	a
B	B	melanoma
O	O	-
O	O	predisposing
O	O	gene
O	O	.
O	O	.
O	O	Progression
O	O	of
O	O	somatic
O	O	CTG
O	O	repeat
O	O	length
O	O	heterogeneity
O	O	in
O	O	the
O	O	blood
O	O	cells
O	O	of
B	B	myotonic
I	I	dystrophy
O	O	patients
O	O	.
O	O	The
O	O	genetic
O	O	basis
O	O	of
B	B	myotonic
I	I	dystrophy
O	O	(
B	B	DM
O	O	)
O	O	is
O	O	the
O	O	expansion
O	O	of
O	O	an
O	O	unstable
O	O	CTG
O	O	repeat
O	O	in
O	O	the
O	O	34
O	O	UTR
O	O	of
O	O	the
B	B	DM
O	O	protein
O	O	kinase
O	O	gene
O	O	on
O	O	chromosome
O	O	19
O	O	.
O	O	One
O	O	of
O	O	the
O	O	principal
O	O	features
O	O	of
O	O	the
B	B	DM
O	O	mutation
O	O	is
O	O	an
O	O	extraordinarily
O	O	high
O	O	level
O	O	of
O	O	somatic
O	O	mosaicism
O	O	,
O	O	due
O	O	to
O	O	an
O	O	extremely
O	O	high
O	O	degree
O	O	of
O	O	somatic
O	O	instability
O	O	both
O	O	within
O	O	and
O	O	between
O	O	different
O	O	tissues
O	O	.
O	O	This
O	O	instability
O	O	appears
O	O	to
O	O	be
O	O	biased
O	O	towards
O	O	further
O	O	expansion
O	O	and
O	O	continuous
O	O	throughout
O	O	the
O	O	life
O	O	of
O	O	an
O	O	individual
O	O	,
O	O	features
O	O	that
O	O	could
O	O	be
O	O	associated
O	O	with
O	O	the
O	O	progressive
O	O	nature
O	O	of
O	O	the
O	O	disease
O	O	.
O	O	Although
O	O	increasing
O	O	measured
O	O	allele
O	O	size
O	O	between
O	O	patients
O	O	clearly
O	O	correlates
O	O	with
O	O	an
O	O	increased
O	O	severity
O	O	of
O	O	symptoms
O	O	and
O	O	an
O	O	earlier
O	O	age
O	O	of
O	O	onset
O	O	,
O	O	this
O	O	correlation
O	O	is
O	O	not
O	O	precise
O	O	and
O	O	measured
O	O	allele
O	O	length
O	O	cannot
O	O	be
O	O	used
O	O	as
O	O	an
O	O	accurate
O	O	predictor
O	O	of
O	O	age
O	O	of
O	O	onset
O	O	.
O	O	In
O	O	order
O	O	to
O	O	further
O	O	characterize
O	O	the
O	O	dynamics
O	O	of
B	B	DM
O	O	CTG
O	O	repeat
O	O	somatic
O	O	instability
O	O	,
O	O	we
O	O	have
O	O	studied
O	O	repeat
O	O	length
O	O	changes
O	O	over
O	O	time
O	O	in
O	O	111
B	B	myotonic
I	I	dystrophy
O	O	patients
O	O	with
O	O	varying
O	O	clinical
O	O	severity
O	O	and
O	O	CTG
O	O	repeat
O	O	size
O	O	over
O	O	time
O	O	intervals
O	O	of
O	O	1
O	O	-
O	O	7
O	O	years
O	O	.
O	O	We
O	O	have
O	O	found
O	O	a
O	O	direct
O	O	progression
O	O	of
O	O	the
O	O	size
O	O	heterogeneity
O	O	over
O	O	time
O	O	related
O	O	to
O	O	initial
O	O	CTG
O	O	repeat
O	O	size
O	O	and
O	O	the
O	O	time
O	O	interval
O	O	and
O	O	always
O	O	biased
O	O	towards
O	O	further
O	O	expansion
O	O	.
O	O	Attempts
O	O	to
O	O	mathematically
O	O	model
O	O	the
O	O	dynamics
O	O	have
O	O	proved
O	O	only
O	O	partially
O	O	successful
O	O	suggesting
O	O	that
O	O	individual
O	O	specific
O	O	genetic
O	O	and
O	O	/
O	O	or
O	O	environmental
O	O	factors
O	O	also
O	O	play
O	O	a
O	O	role
O	O	in
O	O	somatic
O	O	mosaicism
O	O	.
O	O	.
B	B	Aspartylglucosaminuria
O	O	among
O	O	Palestinian
O	O	Arabs
O	O	.
B	B	Aspartylglucosaminuria
O	O	(
B	B	AGU
O	O	)
O	O	is
O	O	a
O	O	rare
I	B	disorder
I	I	of
O	I	glycoprotein
O	I	metabolism
O	O	caused
O	O	by
O	O	the
B	B	deficiency
I	I	of
I	I	the
I	I	lysosomal
I	I	enzyme
O	I	aspartylglucosaminidase
O	O	(
B	O	AGA
O	O	)
O	O	.
B	B	AGU
O	O	is
O	O	inherited
O	O	as
O	O	an
O	O	autosomal
O	O	recessive
O	O	trait
O	O	and
O	O	occurs
O	O	with
O	O	a
O	O	high
O	O	frequency
O	O	in
O	O	Finland
O	O	because
O	O	of
O	O	a
O	O	founder
O	O	effect
O	O	.
O	O	While
O	O	very
O	O	few
O	O	patients
O	O	with
B	B	AGU
O	O	have
O	O	been
O	O	reported
O	O	from
O	O	non
O	O	-
O	O	Finnish
O	O	origin
O	O	,
O	O	we
O	O	diagnosed
O	O	the
O	O	disorder
O	O	in
O	O	8
O	O	patients
O	O	originating
O	O	from
O	O	3
O	O	unrelated
O	O	families
O	O	,
O	O	all
O	O	Palestinian
O	O	Arabs
O	O	from
O	O	the
O	O	region
O	O	of
O	O	Jerusalem
O	O	.
O	O	The
O	O	clinical
O	O	diagnosis
O	O	of
B	B	AGU
O	O	is
O	O	often
O	O	difficult
O	O	,
O	O	in
O	O	particular
O	O	early
O	O	in
O	O	the
O	O	course
O	O	of
O	O	the
O	O	disease
O	O	,
O	O	and
O	O	most
O	O	of
O	O	the
O	O	patients
O	O	are
O	O	diagnosed
O	O	after
O	O	the
O	O	age
O	O	of
O	O	5
O	O	years
O	O	.
O	O	However
O	O	,
O	O	since
O	O	these
O	O	patients
O	O	excrete
O	O	early
O	O	large
O	O	amounts
O	O	of
O	O	aspartylglucosamine
O	O	in
O	O	urine
O	O	,
O	O	biochemical
O	O	screening
O	O	is
O	O	easy
O	O	by
O	O	urine
O	O	chromatography
O	O	.
O	O	.
O	O	Detection
O	O	of
O	O	heterozygous
O	O	carriers
O	O	of
O	O	the
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	(
O	O	ATM
O	O	)
O	O	gene
O	O	by
O	O	G2
O	O	phase
O	O	chromosomal
O	O	radiosensitivity
O	O	of
O	O	peripheral
O	O	blood
O	O	lymphocytes
O	O	.
O	O	In
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	(
B	B	A
I	I	-
I	I	T
O	O	)
O	O	patients
O	O	,
O	O	mutations
O	O	in
O	O	a
O	O	single
O	O	gene
O	O	,
O	O	ATM
O	O	,
O	O	result
O	O	in
O	O	an
B	B	autosomal
I	I	recessive
I	I	syndrome
O	O	that
O	O	embraces
O	O	a
O	O	variety
O	O	of
O	O	clinical
O	O	features
O	O	and
O	O	manifests
O	O	extreme
O	O	radiosensitivity
O	O	and
O	O	a
O	O	strong
O	O	pre
O	O	-
O	O	disposition
O	O	to
B	B	malignancy
O	O	.
O	O	Heterozygotes
O	O	for
O	O	the
O	O	ATM
O	O	gene
O	O	have
O	O	no
O	O	clinical
O	O	expression
O	O	of
B	B	A
I	I	-
I	I	T
O	O	but
O	O	may
O	O	be
B	B	cancer
O	O	prone
O	O	with
O	O	a
O	O	moderate
O	O	increase
O	O	in
O	O	in
O	O	vitro
O	O	radiosensitivity
O	O	.
O	O	We
O	O	performed
O	O	a
O	O	blind
O	O	chromosomal
O	O	analysis
O	O	on
O	O	G2
O	O	-
O	O	phase
O	O	lymphocytes
O	O	from
O	O	7
O	O	unrelated
B	B	A
I	I	-
I	I	T
O	O	patients
O	O	,
O	O	13
O	O	obligate
B	B	A
I	I	-
I	I	T
O	O	heterozygotes
O	O	(
O	O	parents
O	O	of
O	O	the
O	O	patients
O	O	)
O	O	,
O	O	and
O	O	14
O	O	normal
O	O	controls
O	O	following
O	O	X
O	O	-
O	O	irradiation
O	O	with
O	O	1
O	O	Gy
O	O	in
O	O	order
O	O	to
O	O	evaluate
O	O	this
O	O	cytogenetic
O	O	method
O	O	as
O	O	a
O	O	tool
O	O	for
O	O	detection
O	O	of
O	O	ATM
O	O	carriers
O	O	.
O	O	Both
B	B	A
I	I	-
I	I	T
O	O	homozygotes
O	O	and
O	O	heterozygotes
O	O	showed
O	O	significantly
O	O	increased
O	O	levels
O	O	of
O	O	radiation
O	O	-
O	O	induced
O	O	chromatid
O	O	damage
O	O	relative
O	O	to
O	O	that
O	O	of
O	O	normal
O	O	controls
O	O	.
O	O	These
O	O	results
O	O	show
O	O	that
O	O	the
O	O	G2
O	O	-
O	O	phase
O	O	chromosomal
O	O	radiosensitivity
O	O	assay
O	O	can
O	O	be
O	O	used
O	O	for
O	O	the
O	O	detection
O	O	of
B	B	A
I	I	-
I	I	T
O	O	heterozygotes
O	O	.
O	O	In
O	O	combination
O	O	with
O	O	molecular
O	O	genetic
O	O	analyses
O	O	,
O	O	this
O	O	test
O	O	may
O	O	be
O	O	of
O	O	value
O	O	in
O	O	studies
O	O	of
B	B	familial
I	I	and
I	I	sporadic
I	I	cancers
O	O	aimed
O	O	at
O	O	determination
O	O	of
O	O	the
O	O	potential
O	O	involvement
O	O	of
O	O	ATM
O	O	mutations
O	O	in
B	B	tumor
O	O	risk
O	O	or
O	O	development
O	O	.
O	O	.
B	B	Ataxia
I	I	-
I	I	telangiectasia
O	O	:
O	O	identification
O	O	and
O	O	detection
O	O	of
O	O	founder
O	O	-
O	O	effect
O	O	mutations
O	O	in
O	O	the
O	O	ATM
O	O	gene
O	O	in
O	O	ethnic
O	O	populations
O	O	.
O	O	To
O	O	facilitate
O	O	the
O	O	evaluation
O	O	of
O	O	ATM
O	O	heterozygotes
O	O	for
O	O	susceptibility
O	O	to
O	O	other
O	O	diseases
O	O	,
O	O	such
O	O	as
B	B	breast
I	I	cancer
O	O	,
O	O	we
O	O	have
O	O	attempted
O	O	to
O	O	define
O	O	the
O	O	most
O	O	common
O	O	mutations
O	O	and
O	O	their
O	O	frequencies
O	O	in
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	(
B	B	A
I	I	-
I	I	T
O	O	)
O	O	homozygotes
O	O	from
O	O	10
O	O	ethnic
O	O	populations
O	O	.
O	O	Both
O	O	genomic
O	O	mutations
O	O	and
O	O	their
O	O	effects
O	O	on
O	O	cDNA
O	O	were
O	O	characterized
O	O	.
O	O	Protein
O	O	-
O	O	truncation
O	O	testing
O	O	of
O	O	the
O	O	entire
O	O	ATM
O	O	cDNA
O	O	detected
O	O	92
O	O	(
O	O	66
O	O	%
O	O	)
O	O	truncating
O	O	mutations
O	O	in
O	O	140
O	O	mutant
O	O	alleles
O	O	screened
O	O	.
O	O	The
O	O	haplotyping
O	O	of
O	O	patients
O	O	with
O	O	identical
O	O	mutations
O	O	indicates
O	O	that
O	O	almost
O	O	all
O	O	of
O	O	these
O	O	represent
O	O	common
O	O	ancestry
O	O	and
O	O	that
O	O	very
O	O	few
O	O	spontaneously
O	O	recurring
O	O	ATM
O	O	mutations
O	O	exist
O	O	.
O	O	Assays
O	O	requiring
O	O	minimal
O	O	amounts
O	O	of
O	O	genomic
O	O	DNA
O	O	were
O	O	designed
O	O	to
O	O	allow
O	O	rapid
O	O	screening
O	O	for
O	O	common
O	O	ethnic
O	O	mutations
O	O	.
O	O	These
O	O	rapid
O	O	assays
O	O	detected
O	O	mutations
O	O	in
O	O	76
O	O	%
O	O	of
O	O	Costa
O	O	Rican
O	O	patients
O	O	(
O	O	3
O	O	)
O	O	,
O	O	50
O	O	%
O	O	of
O	O	Norwegian
O	O	patients
O	O	(
O	O	1
O	O	)
O	O	,
O	O	25
O	O	%
O	O	of
O	O	Polish
O	O	patients
O	O	(
O	O	4
O	O	)
O	O	,
O	O	and
O	O	14
O	O	%
O	O	of
O	O	Italian
O	O	patients
O	O	(
O	O	1
O	O	)
O	O	,
O	O	as
O	O	well
O	O	as
O	O	in
O	O	patients
O	O	of
B	O	Amish
O	O	/
B	O	Mennonite
O	O	and
O	O	Irish
O	O	English
O	O	backgrounds
O	O	.
O	O	Additional
O	O	mutations
O	O	were
O	O	observed
O	O	in
O	O	Japanese
O	O	,
O	O	Utah
O	O	Mormon
O	O	,
O	O	and
O	O	African
O	O	American
O	O	patients
O	O	.
O	O	These
O	O	assays
O	O	should
O	O	facilitate
O	O	screening
O	O	for
B	B	A
I	I	-
I	I	T
O	O	heterozygotes
O	O	in
O	O	the
O	O	populations
O	O	studied
O	O	.
O	O	.
O	O	The
B	B	von
I	I	Hippel
I	I	-
I	I	Lindau
I	I	tumor
O	O	suppressor
O	O	gene
O	O	is
O	O	required
O	O	for
O	O	cell
O	O	cycle
O	O	exit
O	O	upon
O	O	serum
O	O	withdrawal
O	O	.
O	O	The
O	O	inactivation
O	O	of
O	O	the
B	B	von
I	I	Hippel
I	I	-
I	I	Lindau
O	I	(
B	I	VHL
O	I	)
I	I	tumor
O	O	suppressor
O	O	gene
O	O	predisposes
O	O	affected
O	O	individuals
O	O	to
O	O	the
O	O	human
B	B	VHL
I	I	cancer
I	I	syndrome
O	O	and
O	O	is
O	O	associated
O	O	with
B	B	sporadic
B	I	renal
I	I	cell
I	I	carcinomas
O	O	(
B	B	RCC
O	O	)
O	O	and
B	B	brain
I	I	hemangioblastomas
O	O	.
B	O	VHL
O	O	-
O	O	negative
O	O	786
O	O	-
O	O	0
O	B	RCC
O	O	cells
O	O	are
O	O	tumorigenic
O	O	in
O	O	nude
O	O	mice
O	O	which
O	O	is
O	O	suppressed
O	O	by
O	O	the
O	O	reintroduction
O	O	of
B	B	VHL
O	O	.
O	O	Remarkably
O	O	,
O	O	this
O	O	occurs
O	O	without
O	O	affecting
O	O	the
O	O	growth
O	O	rate
O	O	and
O	O	cell
O	O	cycle
O	O	profile
O	O	of
O	O	these
O	O	cells
O	O	in
O	O	culture
O	O	.
O	O	The
O	O	786
O	O	-
O	O	0
O	O	cell
O	O	line
O	O	,
O	O	like
O	O	many
B	B	cancer
O	O	cells
O	O	,
O	O	fails
O	O	to
O	O	exit
O	O	the
O	O	cell
O	O	cycle
O	O	upon
O	O	serum
O	O	withdrawal
O	O	.
O	O	Here
O	O	,
O	O	it
O	O	is
O	O	shown
O	O	that
O	O	reintroduction
O	O	of
O	O	the
O	O	wild
O	O	-
O	O	type
B	B	VHL
O	O	gene
O	O	restores
O	O	the
O	O	ability
O	O	of
B	O	VHL
O	O	-
O	O	negative
B	B	RCC
I	I	cancer
O	O	cells
O	O	to
O	O	exit
O	O	the
O	O	cell
O	O	cycle
O	O	and
O	O	enter
O	O	G0
O	O	/
O	O	quiescence
O	O	in
O	O	low
O	O	serum
O	O	.
O	O	Both
B	O	VHL
O	O	-
O	O	positive
O	O	and
B	O	VHL
O	O	-
O	O	negative
B	B	RCC
O	O	cells
O	O	exit
O	O	the
O	O	cell
O	O	cycle
O	O	by
O	O	contact
O	O	inhibition
O	O	.
O	O	The
O	O	cyclin
O	O	-
O	O	dependent
O	O	kinase
O	O	inhibitor
O	O	,
O	O	p27
O	O	,
O	O	accumulates
O	O	upon
O	O	serum
O	O	withdrawal
O	O	,
O	O	only
O	O	in
O	O	the
O	O	presence
O	O	of
B	B	VHL
O	O	,
O	O	as
O	O	a
O	O	result
O	O	of
O	O	the
O	O	stabilization
O	O	of
O	O	the
O	O	protein
O	O	.
O	O	We
O	O	propose
O	O	that
O	O	the
O	O	loss
O	O	of
O	O	wild
O	O	-
O	O	type
B	B	VHL
O	O	gene
O	O	results
O	O	in
O	O	a
O	O	specific
O	O	cellular
O	O	defect
O	O	in
O	O	serum
O	O	-
O	O	dependent
O	O	growth
O	O	control
O	O	,
O	O	which
O	O	may
O	O	initiate
B	B	tumor
O	O	formation
O	O	.
O	O	This
O	O	is
O	O	corrected
O	O	by
O	O	the
O	O	reintroduction
O	O	of
O	O	wild
O	O	-
O	O	type
B	B	VHL
O	O	,
O	O	implicating
B	B	VHL
O	O	as
O	O	the
O	O	first
B	B	tumor
O	O	suppressor
O	O	involved
O	O	in
O	O	the
O	O	regulation
O	O	of
O	O	cell
O	O	cycle
O	O	exit
O	O	,
O	O	which
O	O	is
O	O	consistent
O	O	with
O	O	its
O	O	gatekeeper
O	O	function
O	O	in
O	O	the
O	O	kidney
O	O	.
O	O	.
B	B	Piebaldism
O	O	with
B	B	deafness
O	O	:
O	O	molecular
O	O	evidence
O	O	for
O	O	an
O	O	expanded
O	O	syndrome
O	O	.
O	O	In
O	O	a
O	O	South
O	O	African
O	O	girl
O	O	of
B	O	Xhosa
O	O	stock
O	O	with
O	O	severe
B	B	piebaldism
O	O	and
O	O	profound
B	O	congenital
I	B	sensorineural
I	I	deafness
O	O	we
O	O	identified
O	O	a
O	O	novel
O	O	missense
O	O	substitution
O	O	at
O	O	a
O	O	highly
O	O	conserved
O	O	residue
O	O	in
O	O	the
O	O	intracellular
O	O	kinase
O	O	domain
O	O	of
O	O	the
O	O	KIT
O	O	proto
O	O	-
O	O	oncogene
O	O	,
O	O	R796G
O	O	.
O	O	Though
B	B	auditory
I	I	anomalies
O	O	have
O	O	been
O	O	observed
O	O	in
O	O	mice
O	O	with
O	O	dominant
O	O	white
O	O	spotting
O	O	(
O	O	W
O	O	)
O	O	due
O	O	to
O	O	KIT
O	O	mutations
O	O	,
B	B	deafness
O	O	is
O	O	not
O	O	typical
O	O	in
O	O	human
B	B	piebaldism
O	O	.
O	O	Thus
O	O	,
O	O	the
O	O	occurrence
O	O	of
B	B	sensorineural
I	I	deafness
O	O	in
O	O	this
O	O	patient
O	O	extends
O	O	considerably
O	O	the
O	O	phenotypic
O	O	range
O	O	of
B	B	piebaldism
O	O	due
O	O	to
O	O	KIT
O	O	gene
O	O	mutation
O	O	in
O	O	humans
O	O	and
O	O	tightens
O	O	the
O	O	clinical
O	O	similarity
O	O	between
B	B	piebaldism
O	O	and
O	O	the
O	O	various
O	O	forms
O	O	of
B	B	Waardenburg
I	I	syndrome
O	O	.
O	O	.
O	O	Cycloheximide
O	O	facilitates
O	O	the
O	O	identification
O	O	of
O	O	aberrant
O	O	transcripts
O	O	resulting
O	O	from
O	O	a
O	O	novel
O	O	splice
O	O	-
O	O	site
O	O	mutation
O	O	in
O	O	COL17A1
O	O	in
O	O	a
O	O	patient
O	O	with
B	O	generalized
B	B	atrophic
I	I	benign
I	I	epidermolysis
I	I	bullosa
O	O	.
O	O	Patients
O	O	with
B	O	generalized
I	B	atrophic
I	I	benign
I	I	epidermolysis
I	I	bullosa
O	O	often
O	O	show
O	O	decreased
O	O	expression
O	O	of
O	O	type
I	O	XVII
O	O	collagen
O	O	,
O	O	a
O	O	transmembrane
O	O	hemidesmosomal
O	O	protein
O	O	encoded
O	O	by
O	O	COL17A1
O	O	.
O	O	This
O	O	report
O	O	documents
O	O	a
O	O	novel
O	O	splice
O	O	-
O	O	site
O	O	mutation
O	O	in
O	O	COL17A1
O	O	in
O	O	a
O	O	patient
O	O	with
B	O	generalized
B	B	atrophic
I	I	benign
I	I	epidermolysis
I	I	bullosa
O	O	,
O	O	and
O	O	applies
O	O	a
O	O	new
O	O	methodology
O	O	to
O	O	define
O	O	and
O	O	characterize
O	O	the
O	O	resulting
O	O	mRNA
O	O	splice
O	O	variants
O	O	.
O	O	Mutational
O	O	analysis
O	O	of
O	O	COL17A1
O	O	identified
O	O	a
O	O	maternally
O	O	inherited
O	O	G
O	O	-
O	O	to
O	O	-
O	O	T
O	O	transversion
O	O	at
O	O	the
O	O	-
O	O	1
O	O	position
O	O	of
O	O	exon
O	O	32
O	O	.
O	O	This
O	O	acceptor
O	O	splice
O	O	-
O	O	site
O	O	mutation
O	O	led
O	O	to
O	O	the
O	O	formation
O	O	of
O	O	aberrant
O	O	transcripts
O	O	present
O	O	at
O	O	extremely
O	O	low
O	O	levels
O	O	.
O	O	Based
O	O	on
O	O	our
O	O	recent
O	O	finding
O	O	that
O	O	cycloheximide
O	O	stabilized
O	O	mutant
O	O	COL17A1
O	O	transcripts
O	O	in
O	O	keratinocytes
O	O	homozygous
O	O	for
O	O	a
O	O	frameshift
O	O	mutation
O	O	,
O	O	the
O	O	effects
O	O	of
O	O	the
O	O	splice
O	O	-
O	O	site
O	O	mutation
O	O	on
O	O	splicing
O	O	of
O	O	COL17A1
O	O	transcripts
O	O	were
O	O	determined
O	O	using
O	O	reverse
O	O	transcriptase
O	O	polymerase
O	O	chain
O	O	reaction
O	O	of
O	O	total
O	O	RNA
O	O	from
O	O	keratinocytes
O	O	incubated
O	O	for
O	O	2
O	O	.
O	O	5
O	O	h
O	O	in
O	O	the
O	O	presence
O	O	or
O	O	absence
O	O	of
O	O	10
O	O	microg
O	O	cycloheximide
O	O	per
O	O	ml
O	O	.
O	O	Using
O	O	this
O	O	approach
O	O	,
O	O	an
O	O	abnormally
O	O	spliced
O	O	transcript
O	O	was
O	O	identified
O	O	that
O	O	contains
O	O	an
O	O	extra
O	O	264
O	O	bases
O	O	upstream
O	O	from
O	O	exon
O	O	32
O	O	,
O	O	resulting
O	O	in
O	O	a
O	O	premature
O	O	termination
O	O	codon
O	O	27
O	O	bp
O	O	downstream
O	O	from
O	O	the
O	O	cryptic
O	O	splice
O	O	site
O	O	.
O	O	Three
O	O	other
O	O	splice
O	O	variants
O	O	,
O	O	including
O	O	one
O	O	derived
O	O	from
O	O	the
O	O	skipping
O	O	of
O	O	exon
O	O	32
O	O	,
O	O	were
O	O	also
O	O	identified
O	O	.
O	O	These
O	O	results
O	O	indicate
O	O	the
O	O	usefulness
O	O	of
O	O	cycloheximide
O	O	treatment
O	O	in
O	O	evaluating
O	O	the
O	O	abnormal
O	O	processing
O	O	of
O	O	mRNA
O	O	due
O	O	to
O	O	splice
O	O	-
O	O	site
O	O	mutations
O	O	,
O	O	because
O	O	(
O	O	i
O	O	)
O	O	aberrant
O	O	splicing
O	O	often
O	O	generates
O	O	a
O	O	premature
O	O	termination
O	O	codon
O	O	,
O	O	(
O	O	ii
O	O	)
O	O	transcripts
O	O	with
O	O	premature
O	O	termination
O	O	codons
O	O	can
O	O	occur
O	O	at
O	O	low
O	O	or
O	O	undetectable
O	O	levels
O	O	due
O	O	to
O	O	nonsense
O	O	-
O	O	mediated
O	O	mRNA
O	O	decay
O	O	,
O	O	and
O	O	(
O	O	iii
O	O	)
O	O	the
O	O	levels
O	O	of
O	O	these
O	O	transcripts
O	O	can
O	O	be
O	O	increased
O	O	by
O	O	cycloheximide
O	O	.
O	O	A
O	O	deletion
O	O	mutation
O	O	in
O	O	COL17A1
O	O	in
O	O	five
O	O	Austrian
O	O	families
O	O	with
B	O	generalized
B	B	atrophic
I	I	benign
I	I	epidermolysis
I	I	bullosa
O	O	represents
O	O	propagation
O	O	of
O	O	an
O	O	ancestral
O	O	allele
O	O	.
O	O	Patients
O	O	with
B	O	generalized
B	B	atrophic
I	I	benign
I	I	epidermolysis
I	I	bullosa
O	O	,
O	O	a
O	O	usually
O	O	nonlethal
O	O	form
O	O	of
B	B	junctional
I	I	epidermolysis
I	I	bullosa
O	O	,
O	O	have
B	O	generalized
B	B	blistering
O	O	,
B	B	nail
I	I	dystrophy
O	O	,
B	B	patchy
I	I	alopecia
O	O	,
O	O	and
B	B	dental
I	I	abnormalities
B	O	.
B	B	Skin
O	I	fragility
O	O	in
O	O	most
O	O	cases
O	O	is
O	O	due
O	O	to
O	O	mutations
O	O	in
O	O	the
O	O	gene
O	O	encoding
O	O	type
O	O	XVII
O	O	collagen
O	O	(
O	O	COL17A1
O	O	)
O	O	.
O	O	Recently
O	O	,
O	O	we
O	O	reported
O	O	five
O	O	Austrian
O	O	families
O	O	with
B	O	generalized
B	B	atrophic
I	I	benign
I	I	epidermolysis
I	I	bullosa
O	O	who
O	O	share
O	O	the
O	O	same
O	O	COL17A1
O	O	mutation
O	O	.
O	O	Affected
O	O	individuals
O	O	in
O	O	three
O	O	families
O	O	are
O	O	homozygous
O	O	for
O	O	4003delTC
O	O	,
O	O	whereas
O	O	those
O	O	in
O	O	two
O	O	others
O	O	are
O	O	compound
O	O	heterozygotes
O	O	.
O	O	To
O	O	determine
O	O	if
O	O	the
O	O	occurrence
O	O	of
O	O	4003delTC
O	O	in
O	O	these
O	O	unrelated
O	O	families
O	O	signifies
O	O	propagation
O	O	of
O	O	an
O	O	ancestral
O	O	allele
O	O	or
O	O	a
O	O	mutational
O	O	hot
O	O	spot
O	O	,
O	O	haplotypes
O	O	were
O	O	determined
O	O	for
O	O	polymorphisms
O	O	both
O	O	within
O	O	and
O	O	flanking
O	O	COL17A1
O	O	.
O	O	Five
O	O	intragenic
O	O	polymorphisms
O	O	were
O	O	chosen
O	O	based
O	O	on
O	O	their
O	O	informativeness
O	O	.
O	O	One
O	O	of
O	O	these
O	O	,
O	O	not
O	O	previously
O	O	reported
O	O	,
O	O	was
O	O	2988
O	O	A
O	O	or
O	O	C
O	O	that
O	O	introduces
O	O	a
O	O	new
O	O	restriction
O	O	site
O	O	for
O	O	Eco0109
O	O	I
O	O	.
O	O	All
O	O	the
O	O	4003delTC
O	O	alleles
O	O	showed
O	O	the
O	O	same
O	O	haplotype
O	O	for
O	O	these
O	O	five
O	O	polymorphic
O	O	markers
O	O	.
O	O	Fourteen
O	O	microsatellite
O	O	polymorphisms
O	O	were
O	O	selected
O	O	based
O	O	on
O	O	their
O	O	high
O	O	heterozygosity
O	O	and
O	O	their
O	O	location
O	O	within
O	O	10q23
O	O	-
O	O	q25
O	O	near
O	O	COL17A1
O	O	.
O	O	Three
O	O	families
O	O	shared
O	O	microsatellite
O	O	polymorphisms
O	O	covering
O	O	at
O	O	most
O	O	19
O	O	cM
O	O	,
O	O	whereas
O	O	the
O	O	others
O	O	shared
O	O	smaller
O	O	regions
O	O	consistent
O	O	with
O	O	cross
O	O	-
O	O	over
O	O	events
O	O	during
O	O	passage
O	O	of
O	O	this
O	O	mutation
O	O	through
O	O	several
O	O	generations
O	O	.
O	O	These
O	O	results
O	O	indicate
O	O	that
O	O	4003delTC
O	O	occurs
O	O	on
O	O	a
O	O	single
O	O	ancestral
O	O	allele
O	O	.
O	O	.
O	O	The
O	O	haptoglobin
O	O	-
O	O	gene
O	O	deletion
O	O	responsible
O	O	for
B	B	anhaptoglobinemia
O	O	.
O	O	We
O	O	have
O	O	found
O	O	an
O	O	allelic
O	O	deletion
O	O	of
O	O	the
O	O	haptoglobin
O	O	(
O	O	Hp
O	O	)
O	O	gene
O	O	from
O	O	an
O	O	individual
O	O	with
B	B	anhaptoglobinemia
O	O	.
O	O	The
O	O	Hp
O	O	gene
O	O	cluster
O	O	consists
O	O	of
O	O	coding
O	O	regions
O	O	of
O	O	the
O	O	alpha
O	O	chain
O	O	and
O	O	beta
O	O	chain
O	O	of
O	O	the
O	O	haptoglobin
O	O	gene
O	O	(
O	O	Hp
O	O	)
O	O	and
O	O	of
O	O	the
O	O	alpha
O	O	chain
O	O	and
O	O	beta
O	O	chain
O	O	of
O	O	the
O	O	haptoglobin
O	O	-
O	O	related
O	O	gene
O	O	(
O	O	Hpr
O	O	)
O	O	,
O	O	in
O	O	tandem
O	O	from
O	O	the
O	O	5
O	O	side
O	O	.
O	O	Southern
O	O	blot
O	O	and
O	O	PCR
O	O	analyses
O	O	have
O	O	indicated
O	O	that
O	O	the
O	O	individual
O	O	with
B	B	anhaptoglobinemia
O	O	was
O	O	homozygous
O	O	for
O	O	the
O	O	gene
O	O	deletion
O	O	and
O	O	that
O	O	the
O	O	gene
O	O	deletion
O	O	was
O	O	included
O	O	at
O	O	least
O	O	from
O	O	the
O	O	promoter
O	O	region
O	O	of
O	O	Hp
O	O	to
O	O	Hpr
O	O	alpha
O	O	but
O	O	not
O	O	to
O	O	Hpr
O	O	beta
O	O	(
O	O	Hpdel
O	O	)
O	O	.
O	O	In
O	O	addition
O	O	,
O	O	we
O	O	found
O	O	seven
O	O	individuals
O	O	with
B	B	hypohaptoglobinemia
O	O	in
O	O	three
O	O	families
O	O	,
O	O	and
O	O	the
O	O	genotypes
O	O	of
O	O	six
O	O	of
O	O	the
O	O	seven
O	O	individuals
O	O	were
O	O	found
O	O	to
O	O	be
O	O	Hp2
O	O	/
O	O	Hpdel
O	O	.
O	O	The
O	O	phenotypes
O	O	and
O	O	genotypes
O	O	in
O	O	one
O	O	of
O	O	these
O	O	three
O	O	families
O	O	showed
O	O	the
O	O	father
O	O	to
O	O	be
B	B	hypohaptoglobinemic
O	O	(
O	O	Hp2
O	O	)
O	O	and
O	O	Hp2
O	O	/
O	O	Hpdel
O	O	,
O	O	the
O	O	mother
O	O	to
O	O	be
O	O	Hp2
O	O	-
O	O	1
O	O	and
O	O	Hp1
O	O	/
O	O	Hp2
O	O	,
O	O	one
O	O	of
O	O	the
O	O	two
O	O	children
O	O	to
O	O	be
B	B	hypohaptoglobinemic
O	O	(
O	O	Hp2
O	O	)
O	O	and
O	O	Hp2
O	O	/
O	O	Hpdel
O	O	,
O	O	and
O	O	the
O	O	other
O	O	child
O	O	to
O	O	be
O	O	Hp1
O	O	and
O	O	Hp1
O	O	/
O	O	Hpdel
O	O	,
O	O	showing
O	O	an
O	O	anomalous
O	O	inheritance
O	O	of
O	O	Hp
O	O	phenotypes
O	O	in
O	O	the
O	O	child
O	O	with
O	O	Hp1
O	O	.
O	O	The
O	O	Hp2
O	O	/
O	O	Hpdel
O	O	individuals
O	O	had
O	O	an
O	O	extremely
O	O	low
O	O	level
O	O	of
O	O	Hp
O	O	(
O	O	mean
O	O	+
O	O	/
O	O	-
O	O	SD
O	O	=
O	O	0
O	O	.
O	O	049
O	O	+
O	O	/
O	O	-
O	O	0
O	O	.
O	O	043
O	O	mg
O	O	/
O	O	ml
O	O	;
O	O	n
O	O	=
O	O	6
O	O	)
O	O	,
O	O	compared
O	O	with
O	O	the
O	O	level
O	O	(
O	O	1
O	O	.
O	O	64
O	O	+
O	O	/
O	O	-
O	O	1
O	O	.
O	O	07
O	O	mg
O	O	/
O	O	ml
O	O	)
O	O	obtained
O	O	from
O	O	52
O	O	healthy
O	O	volunteers
O	O	having
O	O	phenotype
O	O	Hp2
O	O	,
O	O	whereas
O	O	the
O	O	serum
O	O	Hp
O	O	level
O	O	of
O	O	an
O	O	individual
O	O	with
O	O	Hp1
O	O	/
O	O	Hpdel
O	O	was
O	O	0
O	O	.
O	O	50
O	O	mg
O	O	/
O	O	ml
O	O	,
O	O	which
O	O	was
O	O	approximately
O	O	half
O	O	the
O	O	level
O	O	of
O	O	Hp
O	O	in
O	O	control
O	O	sera
O	O	from
O	O	the
O	O	Hp1
O	O	phenotype
O	O	(
O	O	1
O	O	.
O	O	26
O	O	+
O	O	/
O	O	-
O	O	0
O	O	.
O	O	33
O	O	mg
O	O	/
O	O	ml
O	O	;
O	O	n
O	O	=
O	O	9
O	O	)
O	O	,
O	O	showing
O	O	a
O	O	gene
O	O	-
O	O	dosage
O	O	effect
O	O	.
O	O	The
O	O	other
O	O	allele
O	O	(
O	O	Hp2
O	O	)
O	O	of
O	O	individuals
O	O	with
O	O	Hp2
O	O	/
O	O	Hpdel
O	O	was
O	O	found
O	O	to
O	O	have
O	O	,
O	O	in
O	O	all
O	O	exons
O	O	,
O	O	no
O	O	mutation
O	O	,
O	O	by
O	O	DNA
O	O	sequencing
O	O	.
O	O	On
O	O	the
O	O	basis
O	O	of
O	O	the
O	O	present
O	O	study
O	O	,
O	O	the
O	O	mechanism
O	O	of
B	B	anhaptoglobinemia
O	O	and
O	O	the
O	O	mechanism
O	O	of
O	O	anomalous
O	O	inheritance
O	O	of
B	O	Hp
O	O	phenotypes
O	O	were
O	O	well
O	O	explained
O	O	.
O	O	However
O	O	,
O	O	the
O	O	mechanism
O	O	of
B	B	hypohaptoglobinemia
O	O	remains
O	O	unknown
O	O	ATM
O	O	mutations
O	O	and
O	O	phenotypes
O	O	in
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	families
O	O	in
O	O	the
O	O	British
O	O	Isles
O	O	:
O	O	expression
O	O	of
O	O	mutant
O	O	ATM
O	O	and
O	O	the
O	O	risk
O	O	of
B	B	leukemia
O	O	,
B	B	lymphoma
O	O	,
O	O	and
B	B	breast
I	I	cancer
O	O	.
O	O	We
O	O	report
O	O	the
O	O	spectrum
O	O	of
O	O	59
O	O	ATM
O	O	mutations
O	O	observed
O	O	in
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	(
B	B	A
I	I	-
I	I	T
O	O	)
O	O	patients
O	O	in
O	O	the
O	O	British
O	O	Isles
O	O	.
O	O	Of
O	O	51
O	O	ATM
O	O	mutations
O	O	identified
O	O	in
O	O	families
O	O	native
O	O	to
O	O	the
O	O	British
O	O	Isles
O	O	,
O	O	11
O	O	were
O	O	founder
O	O	mutations
O	O	,
O	O	and
O	O	2
O	O	of
O	O	these
O	O	11
O	O	conferred
O	O	a
O	O	milder
O	O	clinical
O	O	phenotype
O	O	with
O	O	respect
O	O	to
O	O	both
B	B	cerebellar
I	I	degeneration
O	O	and
O	O	cellular
O	O	features
O	O	.
O	O	We
O	O	report
O	O	,
O	O	in
O	O	two
B	B	A
I	I	-
I	I	T
O	O	families
O	O	,
O	O	an
O	O	ATM
O	O	mutation
O	O	(
O	O	7271T
O	O	-
O	O	-
O	O	>
O	O	G
O	O	)
O	O	that
O	O	may
O	O	be
O	O	associated
O	O	with
O	O	an
O	O	increased
O	O	risk
O	O	of
B	B	breast
I	I	cancer
O	O	in
O	O	both
O	O	homozygotes
O	O	and
O	O	heterozygotes
O	O	(
O	O	relative
O	O	risk
O	O	12
O	O	.
O	O	7
O	O	;
O	O	P
O	O	=
O	O	.
O	O	0025
O	O	)
O	O	,
O	O	although
O	O	there
O	O	is
O	O	a
O	O	less
O	O	severe
B	B	A
I	I	-
I	I	T
O	O	phenotype
O	O	in
O	O	terms
O	O	of
O	O	the
O	O	degree
O	O	of
B	B	cerebellar
I	I	degeneration
O	O	.
O	O	This
O	O	mutation
O	O	(
O	O	7271T
O	O	-
O	O	-
O	O	>
O	O	G
O	O	)
O	O	also
O	O	allows
O	O	expression
O	O	of
O	O	full
O	O	-
O	O	length
O	O	ATM
O	O	protein
O	O	at
O	O	a
O	O	level
O	O	comparable
O	O	with
O	O	that
O	O	in
O	O	unaffected
O	O	individuals
O	O	.
O	O	In
O	O	addition
O	O	,
O	O	we
O	O	have
O	O	studied
O	O	18
B	B	A
I	I	-
I	I	T
O	O	patients
O	O	,
O	O	in
O	O	15
O	O	families
O	O	,
O	O	who
O	O	developed
B	B	leukemia
O	O	,
B	B	lymphoma
O	O	,
B	O	preleukemic
O	O	T
O	O	-
O	O	cell
O	O	proliferation
O	O	,
O	O	or
B	B	Hodgkin
I	I	lymphoma
O	O	,
O	O	mostly
O	O	in
O	O	childhood
O	O	.
O	O	A
O	O	wide
O	O	variety
O	O	of
O	O	ATM
O	O	mutation
O	O	types
O	O	,
O	O	including
O	O	missense
O	O	mutations
O	O	and
O	O	in
O	O	-
O	O	frame
O	O	deletions
O	O	,
O	O	were
O	O	seen
O	O	in
O	O	these
O	O	patients
O	O	.
O	O	We
O	O	also
O	O	show
O	O	that
O	O	25
O	O	%
O	O	of
O	O	all
B	B	A
I	I	-
I	I	T
O	O	patients
O	O	carried
O	O	in
O	O	-
O	O	frame
O	O	deletions
O	O	or
O	O	missense
O	O	mutations
O	O	,
O	O	many
O	O	of
O	O	which
O	O	were
O	O	also
O	O	associated
O	O	with
O	O	expression
O	O	of
O	O	mutant
O	O	ATM
O	O	protein
O	O	.
O	O	The
O	O	DMPK
O	O	gene
O	O	of
O	O	severely
O	O	affected
B	B	myotonic
I	I	dystrophy
O	O	patients
O	O	is
O	O	hypermethylated
O	O	proximal
O	O	to
O	O	the
O	O	largely
O	O	expanded
O	O	CTG
O	O	repeat
O	O	.
O	O	Using
O	O	methylation
O	O	-
O	O	sensitive
O	O	restriction
O	O	enzymes
O	O	,
O	O	we
O	O	characterized
O	O	the
O	O	methylation
O	O	pattern
O	O	on
O	O	the
O	O	5
O	O	side
O	O	of
O	O	the
O	O	CTG
O	O	repeat
O	O	in
O	O	the
O	O	DMPK
O	O	gene
O	O	of
O	O	normal
O	O	individuals
O	O	and
O	O	of
O	O	patients
O	O	affected
O	O	with
B	B	myotonic
I	I	dystrophy
O	O	,
O	O	showing
O	O	expansions
O	O	of
O	O	the
O	O	repetitive
O	O	sequence
O	O	.
O	O	The
O	O	gene
O	O	segment
O	O	analyzed
O	O	corresponds
O	O	to
O	O	the
O	O	genomic
O	O	SacI
O	O	-
O	O	HindIII
O	O	fragment
O	O	carrying
O	O	exons
O	O	11
O	O	-
O	O	15
O	O	.
O	O	There
O	O	is
O	O	constitutive
O	O	methylation
O	O	in
O	O	intron
O	O	12
O	O	at
O	O	restriction
O	O	sites
O	O	of
O	O	SacII
O	O	and
O	O	HhaI
O	O	,
O	O	localized
O	O	1
O	O	,
O	O	159
O	O	-
O	O	1
O	O	,
O	O	232
O	O	bp
O	O	upstream
O	O	of
O	O	the
O	O	CTG
O	O	repeat
O	O	,
O	O	whereas
O	O	most
O	O	,
O	O	if
O	O	not
O	O	all
O	O	,
O	O	of
O	O	the
O	O	other
O	O	sites
O	O	of
O	O	SacII
O	O	,
O	O	HhaI
O	O	,
O	O	and
O	O	HpaII
O	O	in
O	O	this
O	O	region
O	O	are
O	O	unmethylated
O	O	,
O	O	in
O	O	normal
O	O	individuals
O	O	and
O	O	most
O	O	of
O	O	the
O	O	patients
O	O	.
O	O	In
O	O	a
O	O	number
O	O	of
O	O	young
O	O	and
O	O	severely
O	O	affected
O	O	patients
O	O	,
O	O	however
O	O	,
O	O	complete
O	O	methylation
O	O	of
O	O	these
O	O	restriction
O	O	sites
O	O	was
O	O	found
O	O	in
O	O	the
O	O	mutated
O	O	allele
O	O	.
O	O	In
O	O	most
O	O	of
O	O	these
O	O	patients
O	O	,
O	O	the
O	O	onset
O	O	of
O	O	the
O	O	disease
O	O	was
O	O	congenital
O	O	.
O	O	Preliminary
O	O	in
O	O	vivo
O	O	footprinting
O	O	data
O	O	gave
O	O	evidence
O	O	for
O	O	protein
O	O	-
O	O	DNA
O	O	contact
O	O	in
O	O	normal
O	O	genes
O	O	at
O	O	an
O	O	Sp1
O	O	consensus
O	O	binding
O	O	site
O	O	upstream
O	O	of
O	O	the
O	O	CTG
O	O	repeat
O	O	and
O	O	for
O	O	a
O	O	significant
O	O	reduction
O	O	of
O	O	this
O	O	interaction
O	O	in
O	O	cells
O	O	with
O	O	a
O	O	hypermethylated
O	O	DMPK
O	O	gene
O	O	.
O	O	.
O	O	The
B	B	hemochromatosis
O	O	gene
O	O	product
O	O	complexes
O	O	with
O	O	the
O	O	transferrin
O	O	receptor
O	O	and
O	O	lowers
O	O	its
O	O	affinity
O	O	for
O	O	ligand
O	O	binding
O	O	.
O	O	We
O	O	recently
O	O	reported
O	O	the
O	O	positional
O	O	cloning
O	O	of
O	O	a
O	O	candidate
O	O	gene
O	O	for
B	B	hereditary
I	I	hemochromatosis
O	O	called
O	O	HFE
O	O	.
O	O	The
O	O	gene
O	O	product
O	O	,
O	O	a
O	O	member
O	O	of
O	O	the
O	O	major
O	O	histocompatibility
O	O	complex
O	O	class
O	O	I
O	O	-
O	O	like
O	O	family
O	O	,
O	O	was
O	O	found
O	O	to
O	O	have
O	O	a
O	O	mutation
O	O	,
O	O	Cys
O	O	-
O	O	282
O	O	-
O	O	-
O	O	>
O	O	Tyr
O	O	(
O	O	C282Y
O	O	)
O	O	,
O	O	in
O	O	85
O	O	%
O	O	of
O	O	patient
O	O	chromosomes
O	O	.
O	O	This
O	O	mutation
O	O	eliminates
O	O	the
O	O	ability
O	O	of
O	O	HFE
O	O	to
O	O	associate
O	O	with
O	O	beta2
O	O	-
O	O	microglobulin
O	O	(
O	O	beta2m
O	O	)
O	O	and
O	O	prevents
O	O	cell
O	O	-
O	O	surface
O	O	expression
O	O	.
O	O	A
O	O	second
O	O	mutation
O	O	that
O	O	has
O	O	no
O	O	effect
O	O	on
O	O	beta2m
O	O	association
O	O	,
O	O	H63D
O	O	,
O	O	was
O	O	found
O	O	in
O	O	eight
O	O	out
O	O	of
O	O	nine
O	O	patients
O	O	heterozygous
O	O	for
O	O	the
O	O	C282Y
O	O	mutant
O	O	.
O	O	In
O	O	this
O	O	report
O	O	,
O	O	we
O	O	demonstrate
O	O	in
O	O	cultured
O	O	293
O	O	cells
O	O	overexpressing
O	O	wild
O	O	-
O	O	type
O	O	or
O	O	mutant
O	O	HFE
O	O	proteins
O	O	that
O	O	both
O	O	the
O	O	wild
O	O	-
O	O	type
O	O	and
O	O	H63D
O	O	HFE
O	O	proteins
O	O	form
O	O	stable
O	O	complexes
O	O	with
O	O	the
O	O	transferrin
O	O	receptor
O	O	(
O	O	TfR
O	O	)
O	O	.
O	O	The
O	O	C282Y
O	O	mutation
O	O	nearly
O	O	completely
O	O	prevents
O	O	the
O	O	association
O	O	of
O	O	the
O	O	mutant
O	O	HFE
O	O	protein
O	O	with
O	O	the
O	O	TfR
O	O	.
O	O	Studies
O	O	on
O	O	cell
O	O	-
O	O	associated
O	O	transferrin
O	O	at
O	O	37
O	O	degrees
O	O	C
O	O	suggest
O	O	that
O	O	the
O	O	overexpressed
O	O	wild
O	O	-
O	O	type
O	O	HFE
O	O	protein
O	O	decreases
O	O	the
O	O	affinity
O	O	of
O	O	the
O	O	TfR
O	O	for
O	O	transferrin
O	O	.
O	O	The
O	O	overexpressed
O	O	H63D
O	O	protein
O	O	does
O	O	not
O	O	have
O	O	this
O	O	effect
O	O	,
O	O	providing
O	O	the
O	O	first
O	O	direct
O	O	evidence
O	O	for
O	O	a
O	O	functional
O	O	consequence
O	O	of
O	O	the
O	O	H63D
O	O	mutation
O	O	.
O	O	Addition
O	O	of
O	O	soluble
O	O	wild
O	O	-
O	O	type
O	O	HFE
O	O	/
O	O	beta2m
O	O	heterodimers
O	O	to
O	O	cultured
O	O	cells
O	O	also
O	O	decreased
O	O	the
O	O	apparent
O	O	affinity
O	O	of
O	O	the
O	O	TfR
O	O	for
O	O	its
O	O	ligand
O	O	under
O	O	steady
O	O	-
O	O	state
O	O	conditions
O	O	,
O	O	both
O	O	in
O	O	293
O	O	cells
O	O	and
O	O	in
O	O	HeLa
O	O	cells
O	O	.
O	O	Furthermore
O	O	,
O	O	at
O	O	4
O	O	degrees
O	O	C
O	O	,
O	O	the
O	O	added
O	O	soluble
O	O	complex
O	O	of
O	O	HFE
O	O	/
O	O	beta2m
O	O	inhibited
O	O	binding
O	O	of
O	O	transferrin
O	O	to
O	O	HeLa
O	O	cell
O	O	TfR
O	O	in
O	O	a
O	O	concentration
O	O	-
O	O	dependent
O	O	manner
O	O	.
O	O	Scatchard
O	O	plots
O	O	of
O	O	these
O	O	data
O	O	indicate
O	O	that
O	O	the
O	O	added
O	O	heterodimer
O	O	substantially
O	O	reduced
O	O	the
O	O	affinity
O	O	of
O	O	TfR
O	O	for
O	O	transferrin
O	O	.
O	O	These
O	O	results
O	O	establish
O	O	a
O	O	molecular
O	O	link
O	O	between
O	O	HFE
O	O	and
O	O	a
O	O	key
O	O	protein
O	O	involved
O	O	in
O	O	iron
O	O	transport
O	O	,
O	O	the
O	O	TfR
O	O	,
O	O	and
O	O	raise
O	O	the
O	O	possibility
O	O	that
O	O	alterations
O	O	in
O	O	this
O	O	regulatory
O	O	mechanism
O	O	may
O	O	play
O	O	a
O	O	role
O	O	in
O	O	the
O	O	pathogenesis
O	O	of
B	B	hereditary
I	I	hemochromatosis
O	O	.
O	O	.
O	O	Genomic
O	O	organization
O	O	of
O	O	the
O	O	UBE3A
O	O	/
O	O	E6
O	O	-
O	O	AP
O	O	gene
O	O	and
O	O	related
O	O	pseudogenes
O	O	.
O	O	The
O	O	UBE3A
O	O	gene
O	O	encodes
O	O	the
O	O	E6
O	O	-
O	O	AP
O	O	ubiquitin
O	O	-
O	O	protein
O	O	ligase
O	O	and
O	O	has
O	O	recently
O	O	been
O	O	shown
O	O	to
O	O	be
O	O	mutated
O	O	in
B	B	Angelman
I	I	syndrome
O	O	patients
O	O	who
O	O	lack
O	O	15q11
O	O	-
O	O	q13
O	O	deletions
O	O	or
O	O	chromosome
O	O	15
O	O	paternal
I	B	uniparental
I	I	disomy
O	O	.
O	O	Previous
O	O	UBE3A
O	O	cDNA
O	O	analysis
O	O	has
O	O	shown
O	O	a
O	O	coding
O	O	region
O	O	of
O	O	approximately
O	O	2
O	O	.
O	O	6
O	O	kb
O	O	and
O	O	a
O	O	3
O	O	-
O	O	untranslated
O	O	region
O	O	(
O	O	UTR
O	O	)
O	O	of
O	O	<
O	O	50
O	O	bp
O	O	,
O	O	whereas
O	O	Northern
O	O	analysis
O	O	has
O	O	indicated
O	O	mRNA
O	O	sizes
O	O	of
O	O	5
O	O	-
O	O	8
O	O	kb
O	O	.
O	O	We
O	O	have
O	O	analyzed
O	O	additional
O	O	cDNA
O	O	clones
O	O	and
O	O	provide
O	O	evidence
O	O	for
O	O	an
O	O	additional
O	O	0
O	O	.
O	O	5
O	O	kb
O	O	of
O	O	5
O	O	-
O	O	UTR
O	O	and
O	O	>
O	O	2
O	O	kb
O	O	of
O	O	3
O	O	-
O	O	UTR
O	O	.
O	O	We
O	O	have
O	O	established
O	O	the
O	O	genomic
O	O	organization
O	O	of
O	O	UBE3A
O	O	and
O	O	the
O	O	sequence
O	O	of
O	O	intron
O	O	-
O	O	exon
O	O	borders
O	O	.
O	O	We
O	O	have
O	O	also
O	O	mapped
O	O	two
O	O	highly
O	O	homologous
O	O	processed
O	O	pseudogenes
O	O	,
O	O	UBE3AP1
O	O	and
O	O	UBE3AP2
O	O	,
O	O	to
O	O	chromosomes
O	O	2
O	O	and
O	O	21
O	O	,
O	O	respectively
O	O	,
O	O	and
O	O	determined
O	O	their
O	O	genomic
O	O	organization
O	O	.
O	O	These
O	O	results
O	O	will
O	O	form
O	O	the
O	O	basis
O	O	for
O	O	studies
O	O	of
O	O	mutation
O	O	and
O	O	imprinting
O	O	of
O	O	UBE3A
O	O	.
O	O	Mutation
O	O	spectrum
O	O	and
O	O	genotype
O	O	-
O	O	phenotype
O	O	analyses
O	O	in
B	B	Cowden
I	I	disease
O	O	and
B	B	Bannayan
I	I	-
I	I	Zonana
I	I	syndrome
O	O	,
O	O	two
B	B	hamartoma
I	I	syndromes
O	O	with
O	O	germline
O	O	PTEN
O	O	mutation
O	O	.
O	O	The
B	B	tumour
O	O	suppressor
O	O	gene
O	O	PTEN
O	O	,
O	O	which
O	O	maps
O	O	to
O	O	10q23
O	O	.
O	O	3
O	O	and
O	O	encodes
O	O	a
O	O	403
O	O	amino
O	O	acid
O	O	dual
O	O	specificity
O	O	phosphatase
O	O	(
O	O	protein
O	O	tyrosine
O	O	phosphatase
O	O	;
O	O	PTPase
O	O	)
O	O	,
O	O	was
O	O	shown
O	O	recently
O	O	to
O	O	play
O	O	a
O	O	broad
O	O	role
O	O	in
O	O	human
B	B	malignancy
O	O	.
O	O	Somatic
O	O	PTEN
O	O	deletions
O	O	and
O	O	mutations
O	O	were
O	O	observed
O	O	in
O	B	sporadic
B	I	breast
I	I	,
I	I	brain
I	I	,
I	I	prostate
I	I	and
I	I	kidney
I	I	cancer
O	O	cell
O	O	lines
O	O	and
O	O	in
O	O	several
B	O	primary
I	B	tumours
O	O	such
O	O	as
B	B	endometrial
I	I	carcinomas
O	O	,
B	B	malignant
I	I	melanoma
O	O	and
B	B	thyroid
I	I	tumours
O	O	.
O	O	In
O	O	addition
O	O	,
O	O	PTEN
O	O	was
O	O	identified
O	O	as
O	O	the
O	O	susceptibility
O	O	gene
O	O	for
O	O	two
B	B	hamartoma
I	I	syndromes
B	B	Cowden
I	I	disease
O	O	(
B	B	CD
O	O	;
O	O	MIM
O	O	158350
O	O	)
O	O	and
B	B	Bannayan
I	I	-
I	I	Zonana
O	I	(
B	I	BZS
O	I	)
O	I	or
B	I	Ruvalcaba
I	I	-
O	I	Riley
I	I	-
O	I	Smith
I	I	syndrome
O	O	(
O	O	MIM
O	O	153480
O	O	)
O	O	.
O	O	Constitutive
O	O	DNA
O	O	from
O	O	37
B	B	CD
O	O	families
O	O	and
O	O	seven
B	B	BZS
O	O	families
O	O	was
O	O	screened
O	O	for
O	O	germline
O	O	PTEN
O	O	mutations
O	O	.
O	O	PTEN
O	O	mutations
O	O	were
O	O	identified
O	O	in
O	O	30
O	O	of
O	O	37
O	O	(
O	O	81
O	O	%
O	O	)
O	B	CD
O	O	families
O	O	,
O	O	including
O	O	missense
O	O	and
O	O	nonsense
O	O	point
O	O	mutations
O	O	,
O	O	deletions
O	O	,
O	O	insertions
O	O	,
O	O	a
O	O	deletion
O	O	/
O	O	insertion
O	O	and
O	O	splice
O	O	site
O	O	mutations
O	O	.
O	O	These
O	O	mutations
O	O	were
O	O	scattered
O	O	over
O	O	the
O	O	entire
O	O	length
O	O	of
O	O	PTEN
O	O	,
O	O	with
O	O	the
O	O	exception
O	O	of
O	O	the
O	O	first
O	O	,
O	O	fourth
O	O	and
O	O	last
O	O	exons
O	O	.
O	O	A
O	O	hot
O	O	spot
O	O	for
O	O	PTEN
O	O	mutation
O	O	in
O	B	CD
O	O	was
O	O	identified
O	O	in
O	O	exon
O	O	5
O	O	that
O	O	contains
O	O	the
O	O	PTPase
O	O	core
O	O	motif
O	O	,
O	O	with
O	O	13
O	O	of
O	O	30
O	O	(
O	O	43
O	O	%
O	O	)
O	B	CD
O	O	mutations
O	O	identified
O	O	in
O	O	this
O	O	exon
O	O	.
O	O	Seven
O	O	of
O	O	30
O	O	(
O	O	23
O	O	%
O	O	)
O	O	were
O	O	within
O	O	the
O	O	core
O	O	motif
O	O	,
O	O	the
O	O	majority
O	O	(
O	O	five
O	O	of
O	O	seven
O	O	)
O	O	of
O	O	which
O	O	were
O	O	missense
O	O	mutations
O	O	,
O	O	possibly
O	O	pointing
O	O	to
O	O	the
O	O	functional
O	O	significance
O	O	of
O	O	this
O	O	region
O	O	.
O	O	Germline
O	O	PTEN
O	O	mutations
O	O	were
O	O	identified
O	O	in
O	O	four
O	O	of
O	O	seven
O	O	(
O	O	57
O	O	%
O	O	)
B	B	BZS
O	O	families
O	O	studied
O	O	.
O	O	Interestingly
O	O	,
O	O	none
O	O	of
O	O	these
O	O	mutations
O	O	was
O	O	observed
O	O	in
O	O	the
O	O	PTPase
O	O	core
O	O	motif
O	O	.
O	O	It
O	O	is
O	O	also
O	O	worthy
O	O	of
O	O	note
O	O	that
O	O	a
O	O	single
O	O	nonsense
O	O	point
O	O	mutation
O	O	,
O	O	R233X
O	O	,
O	O	was
O	O	observed
O	O	in
O	O	the
O	O	germline
O	O	DNA
O	O	from
O	O	two
O	O	unrelated
B	B	CD
O	O	families
O	O	and
O	O	one
B	B	BZS
O	O	family
O	O	.
O	O	Genotype
O	O	-
O	O	phenotype
O	O	studies
O	O	were
O	O	not
O	O	performed
O	O	on
O	O	this
O	O	small
O	O	group
O	O	of
B	B	BZS
O	O	families
O	O	.
O	O	However
O	O	,
O	O	genotype
O	O	-
O	O	phenotype
O	O	analysis
O	O	inthe
O	O	group
O	O	of
O	B	CD
O	O	families
O	O	revealed
O	O	two
O	O	possible
O	O	associations
O	O	worthy
O	O	of
O	O	follow
O	O	-
O	O	up
O	O	in
O	O	independent
O	O	analyses
O	O	.
O	O	The
O	O	first
O	O	was
O	O	an
O	O	association
O	O	noted
O	O	in
O	O	the
O	O	group
O	O	of
B	B	CD
O	O	families
O	O	with
B	B	breast
I	I	disease
O	O	.
O	O	A
O	O	correlation
O	O	was
O	O	observed
O	O	between
O	O	the
O	O	presence
O	O	/
O	O	absence
O	O	of
O	O	a
O	O	PTEN
O	O	mutation
O	O	and
O	O	the
O	O	type
O	O	of
O	O	breast
O	O	involvement
O	O	(
O	O	unaffected
O	O	versus
O	O	benign
O	O	versus
B	O	malignant
O	O	)
O	O	.
O	O	Specifically
O	O	and
O	O	more
O	O	directly
O	O	,
O	O	an
O	O	association
O	O	was
O	O	also
O	O	observed
O	O	between
O	O	the
O	O	presence
O	O	of
O	O	a
O	O	PTEN
O	O	mutation
O	O	and
B	B	malignant
I	I	breast
I	I	disease
O	O	.
O	O	Secondly
O	O	,
O	O	there
O	O	appeared
O	O	to
O	O	be
O	O	an
O	O	interdependent
O	O	association
O	O	between
O	O	mutations
O	O	upstream
O	O	and
O	O	within
O	O	the
O	O	PTPase
O	O	core
O	O	motif
O	O	,
O	O	the
O	O	core
O	O	motif
O	O	containing
O	O	the
O	O	majority
O	O	of
O	O	missense
O	O	mutations
O	O	,
O	O	and
O	O	the
O	O	involvement
O	O	of
O	O	all
O	O	major
O	O	organ
O	O	systems
O	O	(
O	O	central
O	O	nervous
O	O	system
O	O	,
O	O	thyroid
O	O	,
O	O	breast
O	O	,
O	O	skin
O	O	and
O	O	gastrointestinal
O	O	tract
O	O	)
O	O	.
O	O	However
O	O	,
O	O	these
O	O	observations
O	O	would
O	O	need
O	O	to
O	O	be
O	O	confirmed
O	O	by
O	O	studying
O	O	a
O	O	larger
O	O	number
O	O	of
O	B	CD
O	O	families
O	O	.
B	O	Molecular
O	O	defects
O	O	leading
O	O	to
O	O	human
B	B	complement
I	I	component
I	I	C6
I	I	deficiency
O	O	in
O	O	an
O	O	African
O	O	-
O	O	American
O	O	family
O	O	.
B	B	Complement
I	I	component
I	I	C6
I	I	deficiency
O	O	(
B	B	C6D
O	O	)
O	O	was
O	O	diagnosed
O	O	in
O	O	a
O	O	16
O	O	-
O	O	year
O	O	-
O	O	old
O	O	African
O	O	-
O	O	American
O	O	male
O	O	with
B	B	meningococcal
I	I	meningitis
O	O	.
O	O	The
O	O	patients
O	O	father
O	O	and
O	O	two
O	O	brothers
O	O	also
O	O	had
B	B	C6D
O	O	,
O	O	but
O	O	gave
O	O	no
O	O	history
O	O	of
B	B	meningitis
O	O	or
O	O	other
B	B	neisserial
O	I	infection
O	O	.
O	O	By
O	O	using
O	O	exon
O	O	-
O	O	specific
O	O	polymerase
O	O	chain
O	O	reaction
O	O	(
O	O	PCR
O	O	)
O	O	/
O	O	single
O	O	-
O	O	strand
O	O	conformation
O	O	polymorphism
O	O	as
O	O	a
O	O	screening
O	O	step
O	O	and
O	O	nucleotide
O	O	sequencing
O	O	of
O	O	target
O	O	exons
O	O	,
O	O	we
O	O	determined
O	O	that
O	O	the
O	O	proband
O	O	was
O	O	a
O	O	compound
O	O	heterozygote
O	O	for
O	O	two
O	O	C6
O	O	gene
O	O	mutations
O	O	.
O	O	The
O	O	first
O	O	,
O	O	1195delC
O	O	located
O	O	in
O	O	exon
O	O	7
O	O	,
O	O	is
O	O	a
O	O	novel
O	O	mutation
O	O	,
O	O	while
O	O	the
O	O	second
O	O	,
O	O	1936delG
O	O	in
O	O	exon
O	O	12
O	O	,
O	O	has
O	O	been
O	O	described
O	O	before
O	O	to
O	O	cause
B	B	C6D
O	O	in
O	O	an
O	O	unrelated
O	O	African
O	O	-
O	O	American
O	O	individual
O	O	.
O	O	Both
O	O	mutations
O	O	result
O	O	in
O	O	premature
O	O	termination
O	O	codons
O	O	and
O	O	C6
O	O	null
O	O	alleles
O	O	.
O	O	Allele
O	O	-
O	O	specific
O	O	PCR
O	O	indicated
O	O	that
O	O	the
O	O	probands
O	O	two
O	O	brothers
O	O	also
O	O	inherited
O	O	the
O	O	1195delC
O	O	mutation
O	O	from
O	O	their
O	O	heterozygous
O	O	mother
O	O	and
O	O	the
O	O	1936delG
O	O	mutation
O	O	from
O	O	their
O	O	homozygous
O	O	father
O	O	.
O	O	.
O	O	PAX6
O	O	mutations
O	O	reviewed
O	O	.
O	O	Mutations
O	O	in
O	O	PAX6
O	O	are
O	O	responsible
O	O	for
O	O	human
B	B	aniridia
O	O	and
O	O	have
O	O	also
O	O	been
O	O	found
O	O	in
O	O	patients
O	O	with
B	B	Peters
I	I	anomaly
O	O	,
O	O	with
B	B	congenital
I	I	cataracts
O	O	,
O	O	with
B	B	autosomal
I	I	dominant
I	I	keratitis
O	O	,
O	O	and
O	O	with
O	B	isolated
B	I	foveal
I	I	hypoplasia
O	O	.
O	O	No
O	O	locus
O	O	other
O	O	than
O	O	chromosome
O	O	11p13
O	O	has
O	O	been
O	O	implicated
O	O	in
B	B	aniridia
O	O	,
O	O	and
O	O	PAX6
O	O	is
O	O	clearly
O	O	the
O	O	major
O	O	,
O	O	if
O	O	not
O	O	only
O	O	,
O	O	gene
O	O	responsible
O	O	.
O	O	Twenty
O	O	-
O	O	eight
O	O	percent
O	O	of
O	O	identified
O	O	PAX6
O	O	mutations
O	O	are
O	O	C
O	O	-
O	O	T
O	O	changes
O	O	at
O	O	CpG
O	O	dinucleotides
O	O	,
O	O	20
O	O	%
O	O	are
O	O	splicing
O	O	errors
O	O	,
O	O	and
O	O	more
O	O	than
O	O	30
O	O	%
O	O	are
O	O	deletion
O	O	or
O	O	insertion
O	O	events
O	O	.
O	O	There
O	O	is
O	O	a
O	O	noticeably
O	O	elevated
O	O	level
O	O	of
O	O	mutation
O	O	in
O	O	the
O	O	paired
O	O	domain
O	O	compared
O	O	with
O	O	the
O	O	rest
O	O	of
O	O	the
O	O	gene
O	O	.
O	O	Increased
O	O	mutation
O	O	in
O	O	the
O	O	homeodomain
O	O	is
O	O	accounted
O	O	for
O	O	by
O	O	the
O	O	hypermutable
O	O	CpG
O	O	dinucleotide
O	O	in
O	O	codon
O	O	240
O	O	.
O	O	Very
O	O	nearly
O	O	all
O	O	mutations
O	O	appear
O	O	to
O	O	cause
O	O	loss
O	O	of
O	O	function
O	O	of
O	O	the
O	O	mutant
O	O	allele
O	O	,
O	O	and
O	O	more
O	O	than
O	O	80
O	O	%
O	O	of
O	O	exonic
O	O	substitutions
O	O	result
O	O	in
O	O	nonsense
O	O	codons
O	O	.
O	O	In
O	O	a
O	O	gene
O	O	with
O	O	such
O	O	extraordinarily
O	O	high
O	O	sequence
O	O	conservation
O	O	throughout
O	O	evolution
O	O	,
O	O	there
O	O	are
O	O	presumed
O	O	undiscovered
O	O	missense
O	O	mutations
O	O	,
O	O	these
O	O	are
O	O	hypothesized
O	O	to
O	O	exist
O	O	in
O	O	as
O	O	-
O	O	yet
O	O	unidentified
O	O	phenotypes
O	O	.
O	O	.
O	O	Genetic
O	O	heterogeneity
O	O	and
O	O	penetrance
O	O	analysis
O	O	of
O	O	the
O	O	BRCA1
O	O	and
O	O	BRCA2
O	O	genes
O	O	in
B	B	breast
I	I	cancer
O	O	families
O	O	.
O	O	The
B	B	Breast
I	I	Cancer
O	O	Linkage
O	O	Consortium
O	O	.
O	O	The
O	O	contribution
O	O	of
O	O	BRCA1
O	O	and
O	O	BRCA2
O	O	to
B	B	inherited
I	I	breast
I	I	cancer
O	O	was
O	O	assessed
O	O	by
O	O	linkage
O	O	and
O	O	mutation
O	O	analysis
O	O	in
O	O	237
O	O	families
O	O	,
O	O	each
O	O	with
O	O	at
O	O	least
O	O	four
O	O	cases
O	O	of
B	B	breast
I	I	cancer
O	O	,
O	O	collected
O	O	by
O	O	the
B	B	Breast
I	I	Cancer
O	O	Linkage
O	O	Consortium
O	O	.
O	O	Families
O	O	were
O	O	included
O	O	without
O	O	regard
O	O	to
O	O	the
O	O	occurrence
O	O	of
B	B	ovarian
I	I	or
I	I	other
I	I	cancers
O	O	.
O	O	Overall
O	O	,
O	O	disease
O	O	was
O	O	linked
O	O	to
O	O	BRCA1
O	O	in
O	O	an
O	O	estimated
O	O	52
O	O	%
O	O	of
O	O	families
O	O	,
O	O	to
O	O	BRCA2
O	O	in
O	O	32
O	O	%
O	O	of
O	O	families
O	O	,
O	O	and
O	O	to
O	O	neither
O	O	gene
O	O	in
O	O	16
O	O	%
O	O	(
O	O	95
O	O	%
O	O	confidence
O	O	interval
O	O	[
O	O	CI
O	O	]
O	O	6
O	O	%
O	O	-
O	O	28
O	O	%
O	O	)
O	O	,
O	O	suggesting
O	O	other
O	O	predisposition
O	O	genes
O	O	.
O	O	The
O	O	majority
O	O	(
O	O	81
O	O	%
O	O	)
O	O	of
O	O	the
B	B	breast
I	I	-
I	I	ovarian
I	I	cancer
O	O	families
O	O	were
O	O	due
O	O	to
O	O	BRCA1
O	O	,
O	O	with
O	O	most
O	O	others
O	O	(
O	O	14
O	O	%
O	O	)
O	O	due
O	O	to
O	O	BRCA2
O	O	.
O	O	Conversely
O	O	,
O	O	the
O	O	majority
O	O	of
O	O	families
O	O	with
B	B	male
O	I	and
B	I	female
I	I	breast
I	I	cancer
O	O	were
O	O	due
O	O	to
O	O	BRCA2
O	O	(
O	O	76
O	O	%
O	O	)
O	O	.
O	O	The
O	O	largest
O	O	proportion
O	O	(
O	O	67
O	O	%
O	O	)
O	O	of
O	O	families
O	O	due
O	O	to
O	O	other
O	O	genes
O	O	was
O	O	found
O	O	in
O	O	families
O	O	with
O	O	four
O	O	or
O	O	five
O	O	cases
O	O	of
B	O	female
B	B	breast
I	I	cancer
O	O	only
O	O	.
O	O	These
O	O	estimates
O	O	were
O	O	not
O	O	substantially
O	O	affected
O	O	either
O	O	by
O	O	changing
O	O	the
O	O	assumed
O	O	penetrance
O	O	model
O	O	for
O	O	BRCA1
O	O	or
O	O	by
O	O	including
O	O	or
O	O	excluding
O	O	BRCA1
O	O	mutation
O	O	data
O	O	.
O	O	Among
O	O	those
O	O	families
O	O	with
O	O	disease
O	O	due
O	O	to
O	O	BRCA1
O	O	that
O	O	were
O	O	tested
O	O	by
O	O	one
O	O	of
O	O	the
O	O	standard
O	O	screening
O	O	methods
O	O	,
O	O	mutations
O	O	were
O	O	detected
O	O	in
O	O	the
O	O	coding
O	O	sequence
O	O	or
O	O	splice
O	O	sites
O	O	in
O	O	an
O	O	estimated
O	O	63
O	O	%
O	O	(
O	O	95
O	O	%
O	O	CI
O	O	51
O	O	%
O	O	-
O	O	77
O	O	%
O	O	)
O	O	.
O	O	The
O	O	estimated
O	O	sensitivity
O	O	was
O	O	identical
O	O	for
O	O	direct
O	O	sequencing
O	O	and
O	O	other
O	O	techniques
O	O	.
O	O	The
O	O	penetrance
O	O	of
O	O	BRCA2
O	O	was
O	O	estimated
O	O	by
O	O	maximizing
O	O	the
O	O	LOD
O	O	score
O	O	in
O	O	BRCA2
O	O	-
O	O	mutation
O	O	families
O	O	,
O	O	over
O	O	all
O	O	possible
O	O	penetrance
O	O	functions
O	O	.
O	O	The
O	O	estimated
O	O	cumulative
O	O	risk
O	O	of
B	B	breast
I	I	cancer
O	O	reached
O	O	28
O	O	%
O	O	(
O	O	95
O	O	%
O	O	CI
O	O	9
O	O	%
O	O	-
O	O	44
O	O	%
O	O	)
O	O	by
O	O	age
O	O	50
O	O	years
O	O	and
O	O	84
O	O	%
O	O	(
O	O	95
O	O	%
O	O	CI
O	O	43
O	O	%
O	O	-
O	O	95
O	O	%
O	O	)
O	O	by
O	O	age
O	O	70
O	O	years
O	O	.
O	O	The
O	O	corresponding
B	B	ovarian
I	I	cancer
O	O	risks
O	O	were
O	O	0
O	O	.
O	O	4
O	O	%
O	O	(
O	O	95
O	O	%
O	O	CI
O	O	0
O	O	%
O	O	-
O	O	1
O	O	%
O	O	)
O	O	by
O	O	age
O	O	50
O	O	years
O	O	and
O	O	27
O	O	%
O	O	(
O	O	95
O	O	%
O	O	CI
O	O	0
O	O	%
O	O	-
O	O	47
O	O	%
O	O	)
O	O	by
O	O	age
O	O	70
O	O	years
O	O	.
O	O	The
O	O	lifetime
O	O	risk
O	O	of
B	B	breast
I	I	cancer
O	O	appears
O	O	similar
O	O	to
O	O	the
O	O	risk
O	O	in
O	O	BRCA1
O	O	carriers
O	O	,
O	O	but
O	O	there
O	O	was
O	O	some
O	O	suggestion
O	O	of
O	O	a
O	O	lower
O	O	risk
O	O	in
O	O	BRCA2
O	O	carriers
O	O	<
O	O	50
O	O	years
O	O	of
O	O	age
O	O	.
B	B	Eye
I	I	movement
I	I	abnormalities
O	O	correlate
O	O	with
O	O	genotype
O	O	in
B	O	autosomal
O	O	dominant
I	B	cerebellar
I	I	ataxia
I	I	type
I	I	I
O	O	.
O	O	We
O	O	compared
O	O	horizontal
O	O	eye
O	O	movements
O	O	(
O	O	visually
O	O	guided
O	O	saccades
O	O	,
O	O	antisaccades
O	O	,
O	O	and
O	O	smooth
O	O	pursuit
O	O	)
O	O	in
O	O	control
O	O	subjects
O	O	(
O	O	n
O	O	=
O	O	14
O	O	)
O	O	and
O	O	patients
O	O	with
O	O	three
O	O	forms
O	O	of
O	O	autosomal
O	O	dominant
B	B	cerebellar
I	I	ataxias
I	I	type
I	I	I
B	B	spinocerebellar
I	I	ataxias
I	I	1
O	I	and
I	I	2
O	O	(
B	B	SCA1
O	O	,
O	O	n
O	O	=
O	O	11
O	O	;
O	B	SCA2
O	O	,
O	O	n
O	O	=
O	O	10
O	O	)
O	O	and
B	B	SCA3
O	O	/
B	B	Machado
I	I	-
I	I	Joseph
I	I	disease
O	O	(
B	B	MJD
O	O	)
O	O	(
O	O	n
O	O	=
O	O	16
O	O	)
O	O	.
O	O	In
B	B	SCA1
O	O	,
O	O	saccade
O	O	amplitude
O	O	was
O	O	significantly
O	O	increased
O	O	,
O	O	resulting
O	O	in
B	B	hypermetria
O	O	.
O	O	The
O	O	smooth
O	O	pursuit
O	O	gain
O	O	was
O	O	decreased
O	O	.
O	O	In
B	B	SCA2
O	O	,
O	O	saccade
O	O	velocity
O	O	was
O	O	markedly
O	O	decreased
O	O	.
O	O	The
O	O	percentage
O	O	of
O	O	errors
O	O	in
O	O	antisaccades
O	O	was
O	O	greatly
O	O	increased
O	O	and
O	O	was
O	O	significantly
O	O	correlated
O	O	with
O	O	age
O	O	at
O	O	disease
O	O	onset
O	O	.
O	O	In
O	O	addition
O	O	,
O	O	a
O	O	correlation
O	O	between
O	O	smooth
O	O	pursuit
O	O	gain
O	O	and
O	O	the
O	O	number
O	O	of
O	O	trinucleotide
O	O	repeats
O	O	was
O	O	found
O	O	.
O	O	In
B	B	SCA3
O	O	,
O	B	gaze
O	I	-
O	I	evoked
I	I	nystagmus
O	O	was
O	O	often
O	O	present
O	O	as
O	O	was
B	O	saccade
I	O	hypometria
O	O	and
O	O	smooth
O	O	pursuit
O	O	gain
O	O	was
O	O	markedly
O	O	decreased
O	O	.
O	O	Three
O	O	major
O	O	criteria
O	O	,
O	O	saccade
O	O	amplitude
O	O	,
O	O	saccade
O	O	velocity
O	O	,
O	O	and
O	O	presence
O	O	of
O	B	gaze
O	I	-
O	I	evoked
I	I	nystagmus
O	O	,
O	O	permitted
O	O	the
O	O	correct
O	O	assignment
O	O	of
O	O	90
O	O	%
O	O	of
O	O	the
B	B	SCA1
O	O	,
O	O	90
O	O	%
O	O	of
O	O	the
B	B	SCA2
O	O	,
O	O	and
O	O	93
O	O	%
O	O	of
O	O	the
O	O	patients
O	O	with
B	B	SCA3
O	O	to
O	O	their
O	O	genetically
O	O	confirmed
O	O	patient
O	O	group
O	O	and
O	O	,
O	O	therefore
O	O	,
O	O	may
O	O	help
O	O	orient
O	O	diagnoses
O	O	of
B	B	SCA1
O	O	,
B	B	SCA2
O	O	,
O	O	and
B	B	SCA3
O	O	at
O	O	early
O	O	clinical
O	O	stages
O	O	of
O	O	the
O	O	diseases
O	O	.
O	O	.
O	O	Genetic
O	O	basis
O	O	and
O	O	molecular
O	O	mechanism
O	O	for
B	B	idiopathic
I	I	ventricular
I	I	fibrillation
O	O	.
B	B	Ventricular
I	I	fibrillation
O	O	causes
O	O	more
O	O	than
O	O	300
O	O	,
O	O	000
O	O	sudden
O	O	deaths
O	O	each
O	O	year
O	O	in
O	O	the
O	O	USA
O	O	alone
O	O	.
O	O	In
O	O	approximately
O	O	5
O	O	-
O	O	12
O	O	%
O	O	of
O	O	these
O	O	cases
O	O	,
O	O	there
O	O	are
O	O	no
O	O	demonstrable
B	O	cardiac
O	O	or
O	O	non
O	O	-
O	O	cardiac
O	O	causes
O	O	to
O	O	account
O	O	for
O	O	the
O	O	episode
O	O	,
O	O	which
O	O	is
O	O	therefore
O	O	classified
O	O	as
B	B	idiopathic
I	I	ventricular
I	I	fibrillation
O	O	(
B	B	IVF
O	O	)
O	O	.
O	O	A
O	O	distinct
O	O	group
O	O	of
B	B	IVF
O	O	patients
O	O	has
O	O	been
O	O	found
O	O	to
O	O	present
O	O	with
O	O	a
O	O	characteristic
O	O	electrocardiographic
O	O	pattern
O	O	.
O	O	Because
O	O	of
O	O	the
O	O	small
O	O	size
O	O	of
O	O	most
O	O	pedigrees
O	O	and
O	O	the
O	O	high
O	O	incidence
O	O	of
B	B	sudden
O	I	death
O	O	,
O	O	however
O	O	,
O	O	molecular
O	O	genetic
O	O	studies
O	O	of
B	B	IVF
O	O	have
O	O	not
O	O	yet
O	O	been
O	O	done
O	O	.
O	O	Because
B	B	IVF
O	O	causes
B	O	cardiac
O	O	rhythm
O	O	disturbance
O	O	,
O	O	we
O	O	investigated
O	O	whether
O	O	malfunction
O	O	of
O	O	ion
O	O	channels
O	O	could
O	O	cause
O	O	the
O	O	disorder
O	O	by
O	O	studying
O	O	mutations
O	O	in
O	O	the
O	O	cardiac
O	O	sodium
O	O	channel
O	O	gene
O	O	SCN5A
O	O	.
O	O	We
O	O	have
O	O	now
O	O	identified
O	O	a
O	O	missense
O	O	mutation
O	O	,
O	O	a
O	O	splice
O	O	-
O	O	donor
O	O	mutation
O	O	,
O	O	and
O	O	a
O	O	frameshift
O	O	mutation
O	O	in
O	O	the
O	O	coding
O	O	region
O	O	of
O	O	SCN5A
O	O	in
O	O	three
B	B	IVF
O	O	families
O	O	.
O	O	We
O	O	show
O	O	that
O	O	sodium
O	O	channels
O	O	with
O	O	the
O	O	missense
O	O	mutation
O	O	recover
O	O	from
O	O	inactivation
O	O	more
O	O	rapidly
O	O	than
O	O	normal
O	O	and
O	O	that
O	O	the
O	O	frameshift
O	O	mutation
O	O	causes
O	O	the
O	O	sodium
O	O	channel
O	O	to
O	O	be
O	O	non
O	O	-
O	O	functional
O	O	.
O	O	Our
O	O	results
O	O	indicate
O	O	that
O	O	mutations
O	O	in
O	O	cardiac
O	O	ion
O	O	-
O	O	channel
O	O	genes
O	O	contribute
O	O	to
O	O	the
O	O	risk
O	O	of
O	O	developing
B	B	IVF
O	O	.
O	O	.
O	O	Molecular
O	O	heterogeneity
O	O	in
B	B	mucopolysaccharidosis
I	I	IVA
O	O	in
O	O	Australia
O	O	and
O	O	Northern
O	O	Ireland
O	O	:
O	O	nine
O	O	novel
O	O	mutations
O	O	including
O	O	T312S
O	O	,
O	O	a
O	O	common
O	O	allele
O	O	that
O	O	confers
O	O	a
O	O	mild
O	O	phenotype
O	O	.
B	B	Mucopolysaccharidosis
I	I	IVA
O	O	(
B	B	MPS
I	I	IVA
O	O	)
O	O	is
O	O	an
B	B	autosomal
I	I	recessive
I	I	lysosomal
I	I	storage
I	I	disorder
O	O	caused
O	O	by
O	O	a
B	B	genetic
O	I	defect
O	O	in
B	O	N
I	O	-
O	O	acetylgalactosamine
O	O	-
O	O	6
O	O	-
O	O	sulfate
O	O	sulfatase
O	O	(
B	O	GALNS
O	O	)
O	O	.
O	O	Previous
O	O	studies
O	O	of
O	O	patients
O	O	from
O	O	a
O	O	British
O	O	-
O	O	Irish
O	O	population
O	O	showed
O	O	that
O	O	the
O	O	I113F
O	O	mutation
O	O	is
O	O	the
O	O	most
O	O	common
O	O	single
O	O	mutation
O	O	among
B	B	MPS
I	I	IVA
O	O	patients
O	O	and
O	O	produces
O	O	a
O	O	severe
O	O	clinical
O	O	phenotype
O	O	.
O	O	We
O	O	studied
O	O	mutations
O	O	in
O	O	the
O	O	GALNS
O	O	gene
O	O	from
O	O	23
O	O	additional
B	B	MPS
I	I	IVA
O	O	patients
O	O	(
O	O	15
O	O	from
O	O	Australia
O	O	,
O	O	8
O	O	from
O	O	Northern
O	O	Ireland
O	O	)
O	O	,
O	O	with
O	O	various
O	O	clinical
O	O	phenotypes
O	O	(
O	O	severe
O	O	,
O	O	16
O	O	cases
O	O	;
O	O	intermediate
O	O	,
O	O	4
O	O	cases
O	O	;
O	O	mild
O	O	,
O	O	3
O	O	cases
O	O	)
O	O	.
O	O	We
O	O	found
O	O	two
O	O	common
O	O	mutations
O	O	that
O	O	together
O	O	accounted
O	O	for
O	O	32
O	O	%
O	O	of
O	O	the
O	O	44
O	O	unrelated
O	O	alleles
O	O	in
O	O	these
O	O	patients
O	O	.
O	O	One
O	O	is
O	O	the
O	O	T312S
O	O	mutation
O	O	,
O	O	a
O	O	novel
O	O	mutation
O	O	found
O	O	exclusively
O	O	in
O	O	milder
O	O	patients
O	O	.
O	O	The
O	O	other
O	O	is
O	O	the
O	O	previously
O	O	described
O	O	I113F
O	O	that
O	O	produces
O	O	a
O	O	severe
O	O	phenotype
O	O	.
O	O	The
O	O	I113F
O	O	and
O	O	T312S
O	O	mutations
O	O	accounted
O	O	for
O	O	8
O	O	(
O	O	18
O	O	%
O	O	)
O	O	and
O	O	6
O	O	(
O	O	14
O	O	%
O	O	)
O	O	of
O	O	44
O	O	unrelated
O	O	alleles
O	O	,
O	O	respectively
O	O	.
O	O	The
O	O	relatively
O	O	high
O	O	residual
O	O	GALNS
O	O	activity
O	O	seen
O	O	when
O	O	the
O	O	T312S
O	O	mutant
O	O	cDNA
O	O	is
O	O	overexpressed
O	O	in
O	O	mutant
O	O	cells
O	O	provides
O	O	an
O	O	explanation
O	O	for
O	O	the
O	O	mild
O	O	phenotype
O	O	in
O	O	patients
O	O	with
O	O	this
O	O	mutation
O	O	.
O	O	The
O	O	distribution
O	O	and
O	O	relative
O	O	frequencies
O	O	of
O	O	the
O	O	I113F
O	O	and
O	O	T312S
O	O	mutations
O	O	in
O	O	Australia
O	O	corresponded
O	O	to
O	O	those
O	O	observed
O	O	in
O	O	Northern
O	O	Ireland
O	O	and
O	O	are
O	O	unique
O	O	to
O	O	these
O	O	two
O	O	populations
O	O	,
O	O	suggesting
O	O	that
O	O	both
O	O	mutations
O	O	were
O	O	probably
O	O	introduced
O	O	to
O	O	Australia
O	O	by
O	O	Irish
O	O	migrants
O	O	during
O	O	the
O	O	19th
O	O	century
O	O	.
O	O	Haplotype
O	O	analysis
O	O	using
O	O	6
O	O	RFLPs
O	O	provides
O	O	additional
O	O	data
O	O	that
O	O	the
O	O	I113F
O	O	mutation
O	O	originated
O	O	from
O	O	a
O	O	common
O	O	ancestor
O	O	.
O	O	The
O	O	other
O	O	9
O	O	novel
O	O	mutations
O	O	identified
O	O	in
O	O	these
O	O	23
O	O	patients
O	O	were
O	O	each
O	O	limited
O	O	to
O	O	a
O	O	single
O	O	family
O	O	.
O	O	These
O	O	data
O	O	provide
O	O	further
O	O	evidence
O	O	for
O	O	extensive
O	O	allelic
O	O	heterogeneity
O	O	in
B	B	MPS
I	I	IVA
O	O	in
O	O	British
O	O	-
O	O	Irish
O	O	patients
O	O	and
O	O	provide
O	O	evidence
O	O	for
O	O	their
O	O	transmission
O	O	to
O	O	Australia
O	O	by
O	O	British
O	O	-
O	O	Irish
O	O	migrants
O	O	.
O	O	.
O	O	Identification
O	O	of
O	O	constitutional
O	O	WT1
O	O	mutations
O	O	,
O	O	in
O	O	patients
O	O	with
O	O	isolated
B	B	diffuse
B	I	mesangial
I	I	sclerosis
O	O	,
O	O	and
O	O	analysis
O	O	of
O	O	genotype
O	O	/
O	O	phenotype
O	O	correlations
O	O	by
O	O	use
O	O	of
O	O	a
O	O	computerized
O	O	mutation
O	O	database
O	O	.
O	O	Constitutional
O	O	mutations
O	O	of
O	O	the
O	O	WT1
O	O	gene
O	O	,
O	O	encoding
O	O	a
O	O	zinc
O	O	-
O	O	finger
O	O	transcription
O	O	factor
O	O	involved
O	O	in
B	O	renal
I	O	and
I	O	gonadal
O	O	development
O	O	,
O	O	are
O	O	found
O	O	in
O	O	most
O	O	patients
O	O	with
B	B	Denys
I	I	-
I	I	Drash
I	I	syndrome
O	O	(
B	B	DDS
O	O	)
O	O	,
O	O	or
B	B	diffuse
B	I	mesangial
I	I	sclerosis
O	O	(
B	B	DMS
O	O	)
O	O	associated
O	O	with
B	B	pseudohermaphroditism
O	O	and
O	O	/
O	O	or
B	B	Wilms
I	I	tumor
O	O	(
B	B	WT
O	O	)
O	O	.
O	O	Most
O	O	mutations
O	O	in
B	B	DDS
O	O	patients
O	O	lie
O	O	in
O	O	exon
O	O	8
O	O	or
O	O	exon
O	O	9
O	O	,
O	O	encoding
O	O	zinc
O	O	finger
O	O	2
O	O	or
O	O	zinc
O	O	finger
O	O	3
O	O	,
O	O	respectively
O	O	,
O	O	with
O	O	a
O	O	hot
O	O	spot
O	O	(
O	O	R394W
O	O	)
O	O	in
O	O	exon
O	O	9
O	O	.
O	O	We
O	O	analyzed
O	O	a
O	O	series
O	O	of
O	O	24
O	O	patients
O	O	,
O	O	10
O	O	with
O	B	isolated
B	I	DMS
O	O	(
B	B	IDMS
O	O	)
O	O	,
O	O	10
O	O	with
B	B	DDS
O	O	,
O	O	and
O	O	4
O	O	with
B	B	urogenital
I	I	abnormalities
O	O	and
O	O	/
O	O	or
B	B	WT
O	O	.
O	O	We
O	O	report
O	O	WT1
O	O	heterozygous
O	O	mutations
O	O	in
O	O	16
O	O	patients
O	O	,
O	O	4
O	O	of
O	O	whom
O	O	presented
O	O	with
B	B	IDMS
O	O	.
O	O	One
O	O	male
O	O	and
O	O	two
O	O	female
B	B	IDMS
O	O	patients
O	O	with
O	O	WT1
O	O	mutations
O	O	underwent
O	O	normal
O	O	puberty
O	O	.
O	O	Two
O	O	mutations
O	O	associated
O	O	with
B	B	IDMS
O	O	are
O	O	different
O	O	from
O	O	those
O	O	described
O	O	in
B	B	DDS
O	O	patients
O	O	.
O	O	No
O	O	WT1
O	O	mutations
O	O	were
O	O	detected
O	O	in
O	O	the
O	O	six
O	O	other
B	B	IDMS
O	O	patients
O	O	,
O	O	suggesting
O	O	genetic
O	O	heterogeneity
O	O	of
O	O	this
O	O	disease
O	O	.
O	O	We
O	O	analyzed
O	O	genotype
O	O	/
O	O	phenotype
O	O	correlations
O	O	,
O	O	on
O	O	the
O	O	basis
O	O	of
O	O	the
O	O	constitution
O	O	of
O	O	a
O	O	WT1
O	O	mutation
O	O	database
O	O	of
O	O	84
O	O	germ
O	O	-
O	O	line
O	O	mutations
O	O	,
O	O	to
O	O	compare
O	O	the
O	O	distribution
O	O	and
O	O	type
O	O	of
O	O	mutations
O	O	,
O	O	according
O	O	to
O	O	the
O	O	different
O	O	symptoms
O	O	.
O	O	This
O	O	demonstrated
O	O	(
O	O	1
O	O	)
O	O	the
O	O	association
O	O	between
O	O	mutations
O	O	in
O	O	exons
O	O	8
O	O	and
O	O	9
O	O	and
B	B	DMS
O	O	;
O	O	(
O	O	2
O	O	)
O	O	among
O	O	patients
O	O	with
B	B	DMS
O	O	,
O	O	a
O	O	higher
O	O	frequency
O	O	of
O	O	exon
O	O	8
O	O	mutations
O	O	among
O	O	46
O	O	,
O	O	XY
O	O	patients
O	O	with
O	O	female
O	O	phenotype
O	O	than
O	O	among
O	O	46
O	O	,
O	O	XY
O	O	patients
O	O	with
O	O	sexual
O	O	ambiguity
O	O	or
O	O	male
O	O	phenotype
O	O	;
O	O	and
O	O	(
O	O	3
O	O	)
O	O	statistically
O	O	significant
O	O	evidence
O	O	that
O	O	mutations
O	O	in
O	O	exons
O	O	8
O	O	and
O	O	9
O	O	preferentially
O	O	affect
O	O	amino
O	O	acids
O	O	with
O	O	different
O	O	functions
O	O	.
O	O	.
O	O	The
O	O	185delAG
O	O	BRCA1
O	O	mutation
O	O	originated
O	O	before
O	O	the
O	O	dispersion
O	O	of
O	O	Jews
O	O	in
O	O	the
O	O	diaspora
O	O	and
O	O	is
O	O	not
O	O	limited
O	O	to
O	O	Ashkenazim
O	O	.
O	O	The
O	O	185delAG
O	O	mutation
O	O	in
O	O	BRCA1
O	O	is
O	O	detected
O	O	in
O	O	Ashkenazi
O	O	Jews
O	O	both
O	O	in
B	B	familial
I	I	breast
I	I	and
I	I	ovarian
I	I	cancer
O	O	and
O	O	in
O	O	the
O	O	general
O	O	population
O	O	.
O	O	All
O	O	tested
O	O	Ashkenazi
O	O	mutation
O	O	carriers
O	O	share
O	O	the
O	O	same
O	O	allelic
O	O	pattern
O	O	at
O	O	the
O	O	BRCA1
O	O	locus
O	O	.
O	O	Our
O	O	previous
O	O	study
O	O	showed
O	O	that
O	O	this
O	O	Ashkenazi
O	O	mutation
O	O	also
O	O	occurs
O	O	in
O	O	Iraqi
O	O	Jews
O	O	with
O	O	a
O	O	similar
O	O	allelic
O	O	pattern
O	O	.
O	O	We
O	O	extended
O	O	our
O	O	analysis
O	O	to
O	O	other
O	O	non
O	O	-
O	O	Ashkenazi
O	O	subsets
O	O	354
O	O	of
O	O	Moroccan
O	O	origin
O	O	,
O	O	200
O	O	Yemenites
O	O	and
O	O	150
O	O	Iranian
O	O	Jews
O	O	.
O	O	Heteroduplex
O	O	analysis
O	O	complemented
O	O	by
O	O	direct
O	O	DNA
O	O	sequencing
O	O	of
O	O	abnormally
O	O	migrating
O	O	bands
O	O	were
O	O	employed
O	O	.
O	O	Four
O	O	of
O	O	Moroccan
O	O	origin
O	O	(
O	O	1
O	O	.
O	O	1
O	O	%
O	O	)
O	O	and
O	O	none
O	O	of
O	O	the
O	O	Yemenites
O	O	or
O	O	Iranians
O	O	was
O	O	a
O	O	carrier
O	O	of
O	O	the
O	O	185delAG
O	O	mutation
O	O	.
O	O	BRCA1
O	O	allelic
O	O	patterns
O	O	were
O	O	determined
O	O	for
O	O	four
O	O	of
O	O	these
O	O	individuals
O	O	and
O	O	for
O	O	12
O	O	additional
O	O	non
O	O	-
O	O	Ashkenazi
O	O	185delAG
O	O	mutation
O	O	carriers
O	O	who
O	O	had
B	B	breast
I	I	/
I	I	ovarian
I	I	cancer
O	O	.
O	O	Six
O	O	non
O	O	-
O	O	Ashkenazi
O	O	individuals
O	O	shared
O	O	the
O	O	common
O	O	Ashkenazi
O	O	haplotype
O	O	,
O	O	four
O	O	had
O	O	a
O	O	closely
O	O	related
O	O	pattern
O	O	,
O	O	and
O	O	the
O	O	rest
O	O	(
O	O	n
O	O	=
O	O	6
O	O	)
O	O	displayed
O	O	a
O	O	distinct
O	O	BRCA1
O	O	allelic
O	O	pattern
O	O	.
O	O	We
O	O	conclude
O	O	that
O	O	the
O	O	185delAG
O	O	BRCA1
O	O	mutation
O	O	occurs
O	O	in
O	O	some
O	O	non
O	O	-
O	O	Ashkenazi
O	O	populations
O	O	at
O	O	rates
O	O	comparable
O	O	with
O	O	that
O	O	of
O	O	Ashkenazim
O	O	.
O	O	The
O	O	majority
O	O	of
O	O	Jewish
O	O	185delAG
O	O	mutation
O	O	carriers
O	O	have
O	O	a
O	O	common
O	O	allelic
O	O	pattern
O	O	,
O	O	supporting
O	O	the
O	O	founder
O	O	effect
O	O	notion
O	O	,
O	O	but
O	O	dating
O	O	the
O	O	mutations
O	O	origin
O	O	to
O	O	an
O	O	earlier
O	O	date
O	O	than
O	O	currently
O	O	estimated
O	O	.
O	O	However
O	O	,
O	O	the
O	O	different
O	O	allelic
O	O	pattern
O	O	at
O	O	the
O	O	BRCA1
O	O	locus
O	O	even
O	O	in
O	O	some
O	O	Jewish
O	O	mutation
O	O	carriers
O	O	,
O	O	might
O	O	suggest
O	O	that
O	O	the
O	O	mutation
O	O	arose
O	O	independently
O	O	.
O	O	.
O	O	Crystal
O	O	structure
O	O	of
O	O	the
B	B	hemochromatosis
O	O	protein
O	O	HFE
O	O	and
O	O	characterization
O	O	of
O	O	its
O	O	interaction
O	O	with
O	O	transferrin
O	O	receptor
O	O	.
O	O	HFE
O	O	is
O	O	an
O	O	MHC
O	O	-
O	O	related
O	O	protein
O	O	that
O	O	is
O	O	mutated
O	O	in
O	O	the
O	B	iron
I	I	-
I	I	overload
O	I	disease
B	B	hereditary
I	I	hemochromatosis
O	O	.
O	O	HFE
O	O	binds
O	O	to
O	O	transferrin
O	O	receptor
O	O	(
O	O	TfR
O	O	)
O	O	and
O	O	reduces
O	O	its
O	O	affinity
O	O	for
O	O	iron
O	O	-
O	O	loaded
O	O	transferrin
O	O	,
O	O	implicating
O	O	HFE
O	O	in
O	O	iron
O	O	metabolism
O	O	.
O	O	The
O	O	2
O	O	.
O	O	6
O	O	A
O	O	crystal
O	O	structure
O	O	of
O	O	HFE
O	O	reveals
O	O	the
O	O	locations
O	O	of
B	B	hemochromatosis
O	O	mutations
O	O	and
O	O	a
O	O	patch
O	O	of
O	O	histidines
O	O	that
O	O	could
O	O	be
O	O	involved
O	O	in
O	O	pH
O	O	-
O	O	dependent
O	O	interactions
O	O	.
O	O	We
O	O	also
O	O	demonstrate
O	O	that
O	O	soluble
O	O	TfR
O	O	and
O	O	HFE
O	O	bind
O	O	tightly
O	O	at
O	O	the
O	O	basic
O	O	pH
O	O	of
O	O	the
O	O	cell
O	O	surface
O	O	,
O	O	but
O	O	not
O	O	at
O	O	the
O	O	acidic
O	O	pH
O	O	of
O	O	intracellular
O	O	vesicles
O	O	.
O	O	TfR
O	O	HFE
O	O	stoichiometry
O	O	(
O	O	2
O	O	1
O	O	)
O	O	differs
O	O	from
O	O	TfR
O	O	transferrin
O	O	stoichiometry
O	O	(
O	O	2
O	O	2
O	O	)
O	O	,
O	O	implying
O	O	a
O	O	different
O	O	mode
O	O	of
O	O	binding
O	O	for
O	O	HFE
O	O	and
O	O	transferrin
O	O	to
O	O	TfR
O	O	,
O	O	consistent
O	O	with
O	O	our
O	O	demonstration
O	O	that
O	O	HFE
O	O	,
O	O	transferrin
O	O	,
O	O	and
O	O	TfR
O	O	form
O	O	a
O	O	ternary
O	O	complex
O	O	.
O	O	Identification
O	O	of
O	O	three
O	O	novel
O	O	mutations
O	O	and
O	O	a
O	O	high
O	O	frequency
O	O	of
O	O	the
O	O	Arg778Leu
O	O	mutation
O	O	in
O	O	Korean
O	O	patients
O	O	with
B	B	Wilson
I	I	disease
O	O	.
O	O	Four
O	O	mutations
O	O	-
O	O	-
O	O	R778L
O	O	,
O	O	A874V
O	O	,
O	O	L1083F
O	O	,
O	O	and
O	O	2304delC
O	O	-
O	O	-
O	O	in
O	O	the
O	O	copper
O	O	-
O	O	transporting
O	O	enzyme
O	O	,
O	O	P
O	O	-
O	O	type
O	O	ATPase
O	O	(
O	O	ATP7B
O	O	)
O	O	,
O	O	were
O	O	identified
O	O	in
O	O	Korean
O	O	Patients
O	O	with
B	B	Wilson
I	I	disease
O	O	.
O	O	Arg778Leu
O	O	,
O	O	the
O	O	most
O	O	frequently
O	O	reported
O	O	mutation
O	O	of
O	O	this
O	O	enzyme
O	O	,
O	O	was
O	O	found
O	O	in
O	O	six
O	O	of
O	O	eight
O	O	unrelated
O	O	patients
O	O	studied
O	O	,
O	O	an
O	O	allele
O	O	frequency
O	O	of
O	O	37
O	O	.
O	O	5
O	O	%
O	O	,
O	O	which
O	O	is
O	O	considerably
O	O	higher
O	O	than
O	O	those
O	O	in
O	O	other
O	O	Asian
O	O	populations
O	O	.
O	O	The
O	O	novel
O	O	single
O	O	nucleotide
O	O	deletion
O	O	,
O	O	2304delC
O	O	,
O	O	was
O	O	found
O	O	in
O	O	one
O	O	patient
O	O	.
O	O	Since
O	O	a
O	O	mutation
O	O	at
O	O	cDNA
O	O	nucleotide
O	O	2302
O	O	(
O	O	2302insC
O	O	)
O	O	had
O	O	been
O	O	previously
O	O	described
O	O	,
O	O	this
O	O	region
O	O	of
O	O	the
O	O	ATP7B
O	O	gene
O	O	may
O	O	be
O	O	susceptible
O	O	to
O	O	gene
O	O	rearrangements
O	O	causing
B	B	Wilson
O	I	disease
O	O	.
O	O	Disruption
O	O	of
O	O	splicing
O	O	regulated
O	O	by
O	O	a
O	O	CUG
O	O	-
O	O	binding
O	O	protein
O	O	in
B	B	myotonic
I	I	dystrophy
O	O	.
B	B	Myotonic
I	I	dystrophy
O	O	(
B	B	DM
O	O	)
O	O	is
O	O	caused
O	O	by
O	O	a
O	O	CTG
O	O	expansion
O	O	in
O	O	the
O	O	3
O	O	untranslated
O	O	region
O	O	of
O	O	the
B	B	DM
O	O	gene
O	O	.
O	O	One
O	O	model
O	O	of
B	B	DM
O	O	pathogenesis
O	O	suggests
O	O	that
O	O	RNAs
O	O	from
O	O	the
O	O	expanded
O	O	allele
O	O	create
O	O	a
O	O	gain
O	O	-
O	O	of
O	O	-
O	O	function
O	O	mutation
O	O	by
O	O	the
O	O	inappropriate
O	O	binding
O	O	of
O	O	proteins
O	O	to
O	O	the
O	O	CUG
O	O	repeats
O	O	.
O	O	Data
O	O	presented
O	O	here
O	O	indicate
O	O	that
O	O	the
O	O	conserved
O	O	heterogeneous
O	O	nuclear
O	O	ribonucleoprotein
O	O	,
O	O	CUG
O	O	-
O	O	binding
O	O	protein
O	O	(
O	O	CUG
O	O	-
O	O	BP
O	O	)
O	O	,
O	O	may
O	O	mediate
O	O	the
O	O	trans
O	O	-
O	O	dominant
O	O	effect
O	O	of
O	O	the
O	O	RNA
O	O	.
O	O	CUG
O	O	-
O	O	BP
O	O	was
O	O	found
O	O	to
O	O	bind
O	O	to
O	O	the
O	O	human
O	O	cardiac
O	O	troponin
O	O	T
O	O	(
O	O	cTNT
O	O	)
O	O	pre
O	O	-
O	O	messenger
O	O	RNA
O	O	and
O	O	regulate
O	O	its
O	O	alternative
O	O	splicing
O	O	.
O	O	Splicing
O	O	of
O	O	cTNT
O	O	was
O	O	disrupted
O	O	in
B	B	DM
O	O	striated
O	O	muscle
O	O	and
O	O	in
O	O	normal
O	O	cells
O	O	expressing
O	O	transcripts
O	O	that
O	O	contain
O	O	CUG
O	O	repeats
O	O	.
O	O	Altered
O	O	expression
O	O	of
O	O	genes
O	O	regulated
O	O	posttranscriptionally
O	O	by
O	O	CUG
O	O	-
O	O	BP
O	O	therefore
O	O	may
O	O	contribute
O	O	to
B	B	DM
O	O	pathogenesis
O	O	.
O	O	.
O	O	Identification
O	O	of
O	O	a
O	O	novel
O	O	nonsense
O	O	mutation
O	O	and
O	O	a
O	O	missense
O	O	substitution
O	O	in
O	O	the
O	O	vasopressin
O	O	-
O	O	neurophysin
O	O	II
O	O	gene
O	O	in
O	O	two
O	O	Spanish
O	O	kindreds
O	O	with
B	B	familial
I	I	neurohypophyseal
I	I	diabetes
I	I	insipidus
O	O	.
B	B	Familial
I	I	neurohypophyseal
I	I	diabetes
I	I	insipidus
O	O	(
B	B	FNDI
O	O	)
O	O	is
O	O	an
B	B	autosomal
I	I	dominant
I	I	disease
O	O	caused
O	O	by
B	O	deficiency
I	O	in
I	O	the
O	O	antidiuretic
O	O	hormone
O	O	arginine
O	O	vasopressin
O	O	(
O	O	AVP
O	O	)
O	O	encoded
O	O	by
O	O	the
O	O	AVP
O	O	-
O	O	neurophysin
O	O	II
O	O	(
O	O	AVP
O	O	-
O	O	NPII
O	O	)
O	O	gene
O	O	on
O	O	chromosome
O	O	20p13
O	O	.
O	O	In
O	O	this
O	O	study
O	O	,
O	O	we
O	O	analyzed
O	O	two
O	O	families
O	O	with
B	B	FNDI
O	O	using
O	O	direct
O	O	automated
O	O	fluorescent
O	O	,
O	O	solid
O	O	phase
O	O	,
O	O	single
O	O	-
O	O	stranded
O	O	DNA
O	O	sequencing
O	O	of
O	O	PCR
O	O	-
O	O	amplified
O	O	AVP
O	O	-
O	O	NPII
O	O	DNA
O	O	.
O	O	In
O	O	one
O	O	of
O	O	the
O	O	families
O	O	,
O	O	affected
O	O	individuals
O	O	presented
O	O	a
O	O	novel
O	O	nonsense
O	O	mutation
O	O	in
O	O	exon
O	O	3
O	O	of
O	O	the
O	O	gene
O	O	,
O	O	consisting
O	O	in
O	O	a
O	O	G
O	O	to
O	O	T
O	O	transition
O	O	at
O	O	nucleotide
O	O	2101
O	O	,
O	O	which
O	O	produces
O	O	a
O	O	stop
O	O	signal
O	O	in
O	O	codon
O	O	82
O	O	(
O	O	Glu
O	O	)
O	O	of
O	O	NPII
O	O	.
O	O	The
O	O	premature
O	O	termination
O	O	eliminates
O	O	part
O	O	of
O	O	the
O	O	C
O	O	-
O	O	terminal
O	O	domain
O	O	of
O	O	NPII
O	O	,
O	O	including
O	O	a
O	O	cysteine
O	O	residue
O	O	in
O	O	position
O	O	85
O	O	,
O	O	which
O	O	could
O	O	be
O	O	involved
O	O	in
O	O	the
O	O	correct
O	O	folding
O	O	of
O	O	the
O	O	prohormone
O	O	.
O	O	In
O	O	the
O	O	second
O	O	family
O	O	,
O	O	a
O	O	G279A
O	O	substitution
O	O	at
O	O	position
O	O	-
O	O	1
O	O	of
O	O	the
O	O	signal
O	O	peptide
O	O	was
O	O	observed
O	O	in
O	O	all
O	O	affected
O	O	individuals
O	O	.
O	O	This
O	O	missense
O	O	mutation
O	O	,
O	O	which
O	O	replaces
O	O	Ala
O	O	with
O	O	Thr
O	O	,
O	O	is
O	O	frequent
O	O	among
B	B	FNDI
O	O	patients
O	O	and
O	O	is
O	O	thought
O	O	to
O	O	reduce
O	O	the
O	O	efficiency
O	O	of
O	O	cleavage
O	O	by
O	O	signal
O	O	peptidases
O	O	.
O	O	.
O	O	Genetic
O	O	heterogeneity
O	O	of
B	B	Saethre
I	I	-
I	I	Chotzen
I	I	syndrome
O	O	,
O	O	due
O	O	to
O	O	TWIST
O	O	and
O	O	FGFR
O	O	mutations
O	O	.
O	O	Thirty
O	O	-
O	O	two
O	O	unrelated
O	O	patients
O	O	with
O	O	features
O	O	of
B	B	Saethre
I	I	-
I	I	Chotzen
I	I	syndrome
O	O	,
O	O	a
O	O	common
O	B	autosomal
O	I	dominant
O	I	condition
O	O	of
B	B	craniosynostosis
O	O	and
B	B	limb
I	I	anomalies
O	O	,
O	O	were
O	O	screened
O	O	for
O	O	mutations
O	O	in
O	O	TWIST
O	O	,
O	O	FGFR2
O	O	,
O	O	and
O	O	FGFR3
O	O	.
O	O	Nine
O	O	novel
O	O	and
O	O	three
O	O	recurrent
O	O	TWIST
O	O	mutations
O	O	were
O	O	found
O	O	in
O	O	12
O	O	families
O	O	.
O	O	Seven
O	O	families
O	O	were
O	O	found
O	O	to
O	O	have
O	O	the
O	O	FGFR3
O	O	P250R
O	O	mutation
O	O	,
O	O	and
O	O	one
O	O	individual
O	O	was
O	O	found
O	O	to
O	O	have
O	O	an
O	O	FGFR2
O	O	VV269
O	O	-
O	O	270
O	O	deletion
O	O	.
O	O	To
O	O	date
O	O	,
O	O	our
O	O	detection
O	O	rate
O	O	for
O	O	TWIST
O	O	or
O	O	FGFR
O	O	mutations
O	O	is
O	O	68
O	O	%
O	O	in
O	O	our
B	B	Saethre
I	I	-
I	I	Chotzen
I	I	syndrome
O	O	patients
O	O	,
O	O	including
O	O	our
O	O	five
O	O	patients
O	O	elsewhere
O	O	reported
O	O	with
O	O	TWIST
O	O	mutations
O	O	.
O	O	More
O	O	than
O	O	35
O	O	different
O	O	TWIST
O	O	mutations
O	O	are
O	O	now
O	O	known
O	O	in
O	O	the
O	O	literature
O	O	.
O	O	The
O	O	most
O	O	common
O	O	phenotypic
O	O	features
O	O	,
O	O	present
O	O	in
O	O	more
O	O	than
O	O	a
O	O	third
O	O	of
O	O	our
O	O	patients
O	O	with
O	O	TWIST
O	O	mutations
O	O	,
O	O	are
B	B	coronal
I	I	synostosis
O	O	,
B	B	brachycephaly
O	O	,
B	B	low
I	I	frontal
I	I	hairline
O	O	,
B	B	facial
I	I	asymmetry
O	O	,
B	B	ptosis
O	O	,
B	B	hypertelorism
O	O	,
O	B	broad
I	I	great
I	I	toes
O	O	,
O	O	and
B	B	clinodactyly
O	O	.
O	O	Significant
O	O	intra
O	O	-
O	O	and
O	O	interfamilial
O	O	phenotypic
O	O	variability
O	O	is
O	O	present
O	O	for
O	O	either
O	O	TWIST
O	O	mutations
O	O	or
O	O	FGFR
O	O	mutations
O	O	.
O	O	The
O	O	overlap
O	O	in
O	O	clinical
O	O	features
O	O	and
O	O	the
O	O	presence
O	O	,
O	O	in
O	O	the
O	O	same
O	O	genes
O	O	,
O	O	of
O	O	mutations
O	O	for
O	O	more
O	O	than
O	O	one
B	B	craniosynostotic
I	I	condition
O	O	-
O	O	such
O	O	as
B	B	Saethre
I	I	-
I	I	Chotzen
I	I	,
I	I	Crouzon
I	I	,
I	I	and
B	I	Pfeiffer
I	I	syndromes
O	O	-
O	O	support
O	O	the
O	O	hypothesis
O	O	that
O	O	TWIST
O	O	and
O	O	FGFRs
O	O	are
O	O	components
O	O	of
O	O	the
O	O	same
O	O	molecular
O	O	pathway
O	O	involved
O	O	in
O	O	the
O	O	modulation
O	O	of
B	O	craniofacial
O	O	and
O	O	limb
O	O	development
O	O	in
O	O	humans
O	O	.
O	O	.
O	O	Mutation
O	O	analysis
O	O	of
O	O	UBE3A
O	O	in
B	B	Angelman
I	I	syndrome
O	O	patients
O	O	.
O	B	Angelman
I	I	syndrome
O	O	(
B	B	AS
O	O	)
O	O	is
O	O	caused
O	O	by
O	O	chromosome
O	O	15q11
O	O	-
O	O	q13
O	O	deletions
O	O	of
O	O	maternal
O	O	origin
O	O	,
O	O	by
B	O	paternal
I	B	uniparental
I	I	disomy
O	O	(
B	B	UPD
I	O	)
I	O	15
O	O	,
O	O	by
O	O	imprinting
O	O	defects
O	O	,
O	O	and
O	O	by
O	O	mutations
O	O	in
O	O	the
O	O	UBE3A
O	O	gene
O	O	.
O	O	UBE3A
O	O	encodes
O	O	a
O	O	ubiquitin
O	O	-
O	O	protein
O	O	ligase
O	O	and
O	O	shows
O	O	brain
O	O	-
O	O	specific
O	O	imprinting
O	O	.
O	O	Here
O	O	we
O	O	describe
O	O	UBE3A
O	O	coding
O	O	-
O	O	region
O	O	mutations
O	O	detected
O	O	by
O	O	SSCP
O	O	analysis
O	O	in
O	O	13
B	B	AS
O	O	individuals
O	O	or
O	O	families
O	O	.
O	O	Two
O	O	identical
O	O	de
O	O	novo
O	O	5
O	O	-
O	O	bp
O	O	duplications
O	O	in
O	O	exon
O	O	16
O	O	were
O	O	found
O	O	.
O	O	Among
O	O	the
O	O	other
O	O	11
O	O	unique
O	O	mutations
O	O	,
O	O	8
O	O	were
O	O	small
O	O	deletions
O	O	or
O	O	insertions
O	O	predicted
O	O	to
O	O	cause
O	O	frameshifts
O	O	,
O	O	1
O	O	was
O	O	a
O	O	mutation
O	O	to
O	O	a
O	O	stop
O	O	codon
O	O	,
O	O	1
O	O	was
O	O	a
O	O	missense
O	O	mutation
O	O	,
O	O	and
O	O	1
O	O	was
O	O	predicted
O	O	to
O	O	cause
O	O	insertion
O	O	of
O	O	an
O	O	isoleucine
O	O	in
O	O	the
O	O	hect
O	O	domain
O	O	of
O	O	the
O	O	UBE3A
O	O	protein
O	O	,
O	O	which
O	O	functions
O	O	in
O	O	E2
O	O	binding
O	O	and
O	O	ubiquitin
O	O	transfer
O	O	.
O	O	Eight
O	O	of
O	O	the
O	O	cases
O	O	were
O	O	familial
O	O	,
O	O	and
O	O	five
O	O	were
O	O	sporadic
O	O	.
O	O	In
O	O	two
O	O	familial
O	O	cases
O	O	and
O	O	one
O	O	sporadic
O	O	case
O	O	,
O	O	mosaicism
O	O	for
O	O	UBE3A
O	O	mutations
O	O	was
O	O	detected
O	O	in
O	O	the
O	O	mother
O	O	of
O	O	three
B	B	AS
O	O	sons
O	O	,
O	O	in
O	O	the
O	O	maternal
O	O	grandfather
O	O	of
O	O	two
B	B	AS
O	O	first
O	O	cousins
O	O	,
O	O	and
O	O	in
O	O	the
O	O	mother
O	O	of
O	O	an
B	B	AS
O	O	daughter
O	O	.
O	O	The
O	O	frequencies
O	O	with
O	O	which
O	O	we
O	O	detected
O	O	mutations
O	O	were
O	O	5
O	O	(
O	O	14
O	O	%
O	O	)
O	O	of
O	O	35
O	O	in
O	O	sporadic
O	O	cases
O	O	and
O	O	8
O	O	(
O	O	80
O	O	%
O	O	)
O	O	of
O	O	10
O	O	in
O	O	familial
O	O	cases
O	O	.
O	O	.
O	O	The
B	B	hemochromatosis
O	O	845
O	O	G
O	O	-
O	O	-
O	O	>
O	O	A
O	O	and
O	O	187
O	O	C
O	O	-
O	O	-
O	O	>
O	O	G
O	O	mutations
O	O	:
O	O	prevalence
O	O	in
O	O	non
O	O	-
O	O	Caucasian
O	O	populations
O	O	.
B	B	Hemochromatosis
O	O	,
O	O	the
B	B	inherited
I	I	disorder
I	I	of
O	I	iron
O	I	metabolism
O	O	,
O	O	leads
O	O	,
O	O	if
O	O	untreated
O	O	,
O	O	to
O	O	progressive
O	B	iron
O	I	overload
O	O	and
O	B	premature
O	I	death
O	O	.
O	O	The
B	B	hemochromatosis
O	O	gene
O	O	,
O	O	HFE
O	O	,
O	O	recently
O	O	has
O	O	been
O	O	identified
O	O	,
O	O	and
O	O	characterization
O	O	of
O	O	this
O	O	gene
O	O	has
O	O	shown
O	O	that
O	O	it
O	O	contains
O	O	two
O	O	mutations
O	O	that
O	O	result
O	O	in
O	O	amino
O	O	acid
O	O	substitutions
O	O	-
O	O	cDNA
O	O	nucleotides
O	O	845
O	O	G
O	O	-
O	O	-
O	O	>
O	O	A
O	O	(
O	O	C282Y
O	O	)
O	O	and
O	O	187
O	O	C
O	O	-
O	O	-
O	O	>
O	O	G
O	O	(
O	O	H63D
O	O	)
O	O	.
O	O	Although
B	B	hemochromatosis
O	O	is
O	O	common
O	O	in
O	O	Caucasians
O	O	,
O	O	affecting
O	O	>
O	O	=
O	O	1
O	O	/
O	O	300
O	O	individuals
O	O	of
O	O	northern
O	O	European
O	O	origin
O	O	,
O	O	it
O	O	has
O	O	not
O	O	been
O	O	recognized
O	O	in
O	O	other
O	O	populations
O	O	.
O	O	The
O	O	present
O	O	study
O	O	used
O	O	PCR
O	O	and
O	O	restriction
O	O	-
O	O	enzyme
O	O	digestion
O	O	to
O	O	analyze
O	O	the
O	O	frequency
O	O	of
O	O	the
O	O	845
O	O	G
O	O	-
O	O	-
O	O	>
O	O	A
O	O	and
O	O	187
O	O	C
O	O	-
O	O	-
O	O	>
O	O	G
O	O	mutations
O	O	in
O	O	HLA
O	O	-
O	O	typed
O	O	samples
O	O	from
O	O	non
O	O	-
O	O	Caucasian
O	O	populations
O	O	,
O	O	comprising
O	O	Australian
O	O	Aboriginal
O	O	,
O	O	Chinese
O	O	,
O	O	and
O	O	Pacific
O	O	Islanders
O	O	.
O	O	Results
O	O	showed
O	O	that
O	O	the
O	O	845
O	O	G
O	O	-
O	O	-
O	O	>
O	O	A
O	O	mutation
O	O	was
O	O	present
O	O	in
O	O	these
O	O	populations
O	O	(
O	O	allele
O	O	frequency
O	O	0
O	O	.
O	O	32
O	O	%
O	O	)
O	O	,
O	O	and
O	O	,
O	O	furthermore
O	O	,
O	O	it
O	O	was
O	O	always
O	O	seen
O	O	in
O	O	conjunction
O	O	with
O	O	HLA
O	O	haplotypes
O	O	common
O	O	in
O	O	Caucasians
O	O	,
O	O	suggesting
O	O	that
O	O	845
O	O	G
O	O	-
O	O	-
O	O	>
O	O	A
O	O	may
O	O	have
O	O	been
O	O	introduced
O	O	into
O	O	these
O	O	populations
O	O	by
O	O	Caucasian
O	O	admixture
O	O	.
O	O	187
O	O	C
O	O	-
O	O	-
O	O	>
O	O	G
O	O	was
O	O	present
O	O	at
O	O	an
O	O	allele
O	O	frequency
O	O	of
O	O	2
O	O	.
O	O	68
O	O	%
O	O	in
O	O	the
O	O	two
O	O	populations
O	O	analyzed
O	O	(
O	O	Australian
O	O	Aboriginal
O	O	and
O	O	Chinese
O	O	)
O	O	.
O	O	In
O	O	the
O	O	Australian
O	O	Aboriginal
O	O	samples
O	O	,
O	O	187
O	O	C
O	O	-
O	O	-
O	O	>
O	O	G
O	O	was
O	O	found
O	O	to
O	O	be
O	O	associated
O	O	with
O	O	HLA
O	O	haplotypes
O	O	common
O	O	in
O	O	Caucasians
O	O	,
O	O	suggesting
O	O	that
O	O	it
O	O	was
O	O	introduced
O	O	by
O	O	recent
O	O	admixture
O	O	.
O	O	In
O	O	the
O	O	Chinese
O	O	samples
O	O	analyzed
O	O	,
O	O	187
O	O	C
O	O	-
O	O	-
O	O	>
O	O	G
O	O	was
O	O	present
O	O	in
O	O	association
O	O	with
O	O	a
O	O	wide
O	O	variety
O	O	of
O	O	HLA
O	O	haplotypes
O	O	,
O	O	showing
O	O	this
O	O	mutation
O	O	to
O	O	be
O	O	widespread
O	O	and
O	O	likely
O	O	to
O	O	predate
O	O	the
O	O	more
O	O	genetically
O	O	restricted
O	O	845
O	O	G
O	O	-
O	O	-
O	O	>
O	O	A
O	O	mutation
O	O	.
O	O	Genotype
O	O	-
O	O	phenotype
O	O	correlations
O	O	in
B	B	attenuated
I	I	adenomatous
I	I	polyposis
I	I	coli
O	O	.
O	O	Germ
O	O	-
O	O	line
O	O	mutations
O	O	of
O	O	the
B	B	tumor
O	O	suppressor
B	O	APC
O	O	are
O	O	implicated
O	O	in
B	B	attenuated
I	I	adenomatous
I	I	polyposis
I	I	coli
O	O	(
B	B	AAPC
O	O	)
O	O	,
O	O	a
O	O	variant
O	O	of
B	B	familial
I	I	adenomatous
I	I	polyposis
O	O	(
B	B	FAP
O	O	)
O	O	.
B	B	AAPC
O	O	is
O	O	recognized
O	O	by
O	O	the
O	O	occurrence
O	O	of
O	O	<
O	O	100
B	B	colonic
I	I	adenomas
O	O	and
O	O	a
O	O	later
O	O	onset
O	O	of
B	B	colorectal
I	I	cancer
O	O	(
O	O	age
O	O	>
O	O	40
O	O	years
O	O	)
O	O	.
O	O	The
O	O	aim
O	O	of
O	O	this
O	O	study
O	O	was
O	O	to
O	O	assess
O	O	genotype
O	O	-
O	O	phenotype
O	O	correlations
O	O	in
B	B	AAPC
O	O	families
O	O	.
O	O	By
O	O	protein
O	O	-
O	O	truncation
O	O	test
O	O	(
O	O	PTT
O	O	)
O	O	assay
O	O	,
O	O	the
O	O	entire
O	O	coding
O	O	region
O	O	of
O	O	the
B	B	APC
O	O	gene
O	O	was
O	O	screened
O	O	in
O	O	affected
O	O	individuals
O	O	from
O	O	11
B	B	AAPC
O	O	kindreds
O	O	,
O	O	and
O	O	their
O	O	phenotypic
O	O	differences
O	O	were
O	O	examined
O	O	.
O	O	Five
O	O	novel
O	O	germ
O	O	-
O	O	line
B	B	APC
O	O	mutations
O	O	were
O	O	identified
O	O	in
O	O	seven
O	O	kindreds
O	O	.
O	O	Mutations
O	O	were
O	O	located
O	O	in
O	O	three
O	O	different
O	O	regions
O	O	of
O	O	the
B	B	APC
O	O	gene
O	O	(
O	O	1
O	O	)
O	O	at
O	O	the
O	O	5
O	O	end
O	O	spanning
O	O	exons
O	O	4
O	O	and
O	O	5
O	O	,
O	O	(
O	O	2
O	O	)
O	O	within
O	O	exon
O	O	9
O	O	,
O	O	and
O	O	(
O	O	3
O	O	)
O	O	at
O	O	the
O	O	3
O	O	distal
O	O	end
O	O	of
O	O	the
O	O	gene
O	O	.
O	O	Variability
O	O	in
O	O	the
O	O	number
O	O	of
B	B	colorectal
I	I	adenomas
O	O	was
O	O	most
O	O	apparent
O	O	in
O	O	individuals
O	O	with
O	O	mutations
O	O	in
O	O	region
O	O	1
O	O	,
O	O	and
B	O	upper
I	O	-
I	O	gastrointestinal
O	O	manifestations
O	O	were
O	O	more
O	O	severe
O	O	in
O	O	them
O	O	.
O	O	In
O	O	individuals
O	O	with
O	O	mutations
O	O	in
O	O	either
O	O	region
O	O	2
O	O	or
O	O	region
O	O	3
O	O	,
O	O	the
O	O	average
O	O	number
O	O	of
B	B	adenomas
O	O	tended
O	O	to
O	O	be
O	O	lower
O	O	than
O	O	those
O	O	in
O	O	individuals
O	O	with
O	O	mutations
O	O	in
O	O	region
O	O	1
O	O	,
O	O	although
O	O	age
O	O	at
O	O	diagnosis
O	O	was
O	O	similar
O	O	.
O	O	In
O	O	all
B	B	AAPC
O	O	kindreds
O	O	,
O	O	a
O	O	predominance
O	O	of
B	O	right
I	O	-
I	O	sided
I	B	colorectal
I	I	adenomas
O	O	and
B	B	rectal
I	I	polyp
O	O	sparing
O	O	was
O	O	observed
O	O	.
O	O	No
B	B	desmoid
I	I	tumors
O	O	were
O	O	found
O	O	in
O	O	these
O	O	kindreds
O	O	.
O	O	Our
O	O	data
O	O	suggest
O	O	that
O	O	,
O	O	in
B	B	AAPC
O	O	families
O	O	,
O	O	the
O	O	location
O	O	of
O	O	the
B	B	APC
O	O	mutation
O	O	may
O	O	partially
O	O	predict
O	O	specific
O	O	phenotypic
O	O	expression
O	O	.
O	O	This
O	O	should
O	O	help
O	O	in
O	O	the
O	O	design
O	O	of
O	O	tailored
O	O	clinical
O	O	-
O	O	management
O	O	protocols
O	O	in
O	O	this
O	O	subset
O	O	of
B	B	FAP
O	O	patients
O	O	.
O	O	.
B	B	Wilms
O	I	'
O	I	tumor
O	O	1
O	O	and
O	O	Dax
O	O	-
O	O	1
O	O	modulate
O	O	the
O	O	orphan
O	O	nuclear
O	O	receptor
O	O	SF
O	O	-
O	O	1
O	O	in
O	O	sex
O	O	-
O	O	specific
O	O	gene
O	O	expression
O	O	.
O	O	Products
O	O	of
O	O	steroidogenic
O	O	factor
O	O	1
O	O	(
O	O	SF
O	O	-
O	O	1
O	O	)
O	O	and
B	B	Wilms
I	I	tumor
O	O	1
O	O	(
O	O	WT1
O	O	)
O	O	genes
O	O	are
O	O	essential
O	O	for
O	O	mammalian
O	O	gonadogenesis
O	O	prior
O	O	to
O	O	sexual
O	O	differentiation
O	O	.
O	O	In
O	O	males
O	O	,
O	O	SF
O	O	-
O	O	1
O	O	participates
O	O	in
O	O	sexual
O	O	development
O	O	by
O	O	regulating
O	O	expression
O	O	of
O	O	the
O	O	polypeptide
O	O	hormone
O	O	Mullerian
O	O	inhibiting
O	O	substance
O	O	(
B	O	MIS
O	O	)
O	O	.
O	O	Here
O	O	,
O	O	we
O	O	show
O	O	that
O	O	WT1
O	O	-
O	O	KTS
O	O	isoforms
O	O	associate
O	O	and
O	O	synergize
O	O	with
O	O	SF
O	O	-
O	O	1
O	O	to
O	O	promote
B	O	MIS
O	O	expression
O	O	.
O	O	In
O	O	contrast
O	O	,
O	O	WT1
O	O	missense
O	O	mutations
O	O	,
O	O	associated
O	O	with
B	B	male
B	I	pseudohermaphroditism
O	O	in
B	B	Denys
I	I	-
I	I	Drash
I	I	syndrome
O	O	,
O	O	fail
O	O	to
O	O	synergize
O	O	with
O	O	SF
O	O	-
O	O	1
O	O	.
O	O	Additionally
O	O	,
O	O	the
O	O	X
O	O	-
O	O	linked
O	O	,
O	O	candidate
O	O	dosage
O	O	-
O	O	sensitive
O	O	sex
O	O	-
O	O	reversal
O	O	gene
O	O	,
O	O	Dax
O	O	-
O	O	1
O	O	,
O	O	antagonizes
O	O	synergy
O	O	between
O	O	SF
O	O	-
O	O	1
O	O	and
O	O	WT1
O	O	,
O	O	most
O	O	likely
O	O	through
O	O	a
O	O	direct
O	O	interaction
O	O	with
O	O	SF
O	O	-
O	O	1
O	O	.
O	O	We
O	O	propose
O	O	that
O	O	WT1
O	O	and
O	O	Dax
O	O	-
O	O	1
O	O	functionally
O	O	oppose
O	O	each
O	O	other
O	O	in
O	O	testis
O	O	development
O	O	by
O	O	modulating
O	O	SF
O	O	-
O	O	1
O	O	-
O	O	mediated
O	O	transactivation
O	O	.
O	O	.
O	O	A
O	O	mouse
O	O	model
O	O	for
B	B	Prader
I	I	-
I	I	Willi
I	I	syndrome
O	O	imprinting
O	O	-
O	O	centre
O	O	mutations
O	O	.
O	O	Imprinting
O	O	in
O	O	the
O	O	15q11
O	O	-
O	O	q13
O	O	region
O	O	involves
O	O	an
O	O	imprinting
O	O	centre
O	O	(
O	O	IC
O	O	)
O	O	,
O	O	mapping
O	O	in
O	O	part
O	O	to
O	O	the
O	O	promoter
O	O	and
O	O	first
O	O	exon
O	O	of
O	O	SNRPN
O	O	.
O	O	Deletion
O	O	of
O	O	this
O	O	IC
O	O	abolishes
O	O	local
O	O	paternally
O	O	derived
O	O	gene
O	O	expression
O	O	and
O	O	results
O	O	in
B	B	Prader
I	I	-
I	I	Willi
I	I	syndrome
O	O	(
B	B	PWS
O	O	)
O	O	.
O	O	We
O	O	have
O	O	created
O	O	two
O	O	deletion
O	O	mutations
O	O	in
O	O	mice
O	O	to
O	O	understand
B	B	PWS
O	O	and
O	O	the
O	O	mechanism
O	O	of
O	O	this
B	O	IC
O	O	.
O	O	Mice
O	O	harbouring
O	O	an
O	O	intragenic
O	O	deletion
O	O	in
O	O	Snrpn
O	O	are
O	O	phenotypically
O	O	normal
O	O	,
O	O	suggesting
O	O	that
O	O	mutations
O	O	of
O	O	SNRPN
O	O	are
O	O	not
O	O	sufficient
O	O	to
O	O	induce
B	B	PWS
O	O	.
O	O	Mice
O	O	with
O	O	a
O	O	larger
O	O	deletion
O	O	involving
O	O	both
O	O	Snrpn
O	O	and
O	O	the
O	O	putative
B	O	PWS
O	O	-
O	O	IC
O	O	lack
O	O	expression
O	O	of
O	O	the
O	O	imprinted
O	O	genes
O	O	Zfp127
O	O	(
O	O	mouse
O	O	homologue
O	O	of
O	O	ZNF127
O	O	)
O	O	,
O	O	Ndn
O	O	and
O	O	Ipw
O	O	,
O	O	and
O	O	manifest
O	O	several
O	O	phenotypes
O	O	common
O	O	to
B	B	PWS
O	O	infants
O	O	.
O	O	These
O	O	data
O	O	demonstrate
O	O	that
O	O	both
O	O	the
O	O	position
O	O	of
O	O	the
O	O	IC
O	O	and
O	O	its
O	O	role
O	O	in
O	O	the
O	O	coordinate
O	O	expression
O	O	of
O	O	genes
O	O	is
O	O	conserved
O	O	between
O	O	mouse
O	O	and
O	O	human
O	O	,
O	O	and
O	O	indicate
O	O	that
O	O	the
O	O	mouse
O	O	is
O	O	a
O	O	suitable
O	O	model
O	O	system
O	O	in
O	O	which
O	O	to
O	O	investigate
O	O	the
O	O	molecular
O	O	mechanisms
O	O	of
O	O	imprinting
O	O	in
O	O	this
O	O	region
O	O	of
O	O	the
O	O	genome
O	O	.
O	O	.
O	O	Mutations
O	O	of
O	O	the
O	O	ATM
O	O	gene
O	O	detected
O	O	in
O	O	Japanese
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	patients
O	O	:
O	O	possible
O	O	preponderance
O	O	of
O	O	the
O	O	two
O	O	founder
O	O	mutations
O	O	4612del165
O	O	and
O	O	7883del5
O	O	.
O	O	The
O	O	ATM
O	O	(
O	O	A
O	O	-
O	O	T
O	O	,
O	O	mutated
O	O	)
O	O	gene
O	O	on
O	O	human
O	O	chromosome
O	O	11q22
O	O	.
O	O	3
O	O	has
O	O	recently
O	O	been
O	O	identified
O	O	as
O	O	the
O	O	gene
O	O	responsible
O	O	for
O	O	the
O	O	human
B	B	recessive
I	I	disease
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	(
B	B	A
I	I	-
I	I	T
O	O	)
O	O	.
O	O	In
O	O	order
O	O	to
O	O	define
O	O	the
O	O	types
O	O	of
O	O	disease
O	O	-
O	O	causing
O	O	ATM
O	O	mutations
O	O	in
O	O	Japanese
B	B	A
I	I	-
I	I	T
O	O	patients
O	O	as
O	O	well
O	O	as
O	O	to
O	O	look
O	O	for
O	O	possible
O	O	mutational
O	O	hotspots
O	O	,
O	O	reverse
O	O	-
O	O	transcribed
O	O	RNA
O	O	derived
O	O	from
O	O	ten
O	O	patients
O	O	belonging
O	O	to
O	O	eight
O	O	unrelated
O	O	Japanese
B	B	A
I	I	-
I	I	T
O	O	families
O	O	was
O	O	analyzed
O	O	for
O	O	mutations
O	O	by
O	O	the
O	O	restriction
O	O	endonuclease
O	O	fingerprinting
O	O	method
O	O	.
O	O	As
O	O	has
O	O	been
O	O	reported
O	O	by
O	O	others
O	O	,
O	O	mutations
O	O	that
O	O	lead
O	O	to
O	O	exon
O	O	skipping
O	O	or
O	O	premature
O	O	protein
O	O	truncation
O	O	were
O	O	also
O	O	predominant
O	O	in
O	O	our
O	O	mutants
O	O	.
O	O	Six
O	O	different
O	O	mutations
O	O	were
O	O	identified
O	O	on
O	O	12
O	O	of
O	O	the
O	O	16
O	O	alleles
O	O	examined
O	O	.
O	O	Four
O	O	were
O	O	deletions
O	O	involving
O	O	a
O	O	loss
O	O	of
O	O	a
O	O	single
O	O	exon
O	O	exon
O	O	7
O	O	,
O	O	exon
O	O	16
O	O	,
O	O	exon
O	O	33
O	O	or
O	O	exon
O	O	35
O	O	.
O	O	The
O	O	others
O	O	were
O	O	minute
O	O	deletions
O	O	,
O	O	4649delA
O	O	in
O	O	exon
O	O	33
O	O	and
O	O	7883del5
O	O	in
O	O	exon
O	O	55
O	O	.
O	O	The
O	O	mutations
O	O	4612del165
O	O	and
O	O	7883del5
O	O	were
O	O	found
O	O	in
O	O	more
O	O	than
O	O	two
O	O	unrelated
O	O	families
O	O	;
O	O	44
O	O	%
O	O	(
O	O	7
O	O	of
O	O	16
O	O	)
O	O	of
O	O	the
O	O	mutant
O	O	alleles
O	O	had
O	O	one
O	O	of
O	O	the
O	O	two
O	O	mutations
O	O	.
O	O	The
O	O	4612del165
O	O	mutations
O	O	in
O	O	three
O	O	different
O	O	families
O	O	were
O	O	all
O	O	ascribed
O	O	to
O	O	the
O	O	same
O	O	T
O	O	-
O	O	-
O	O	>
O	O	A
O	O	substitution
O	O	at
O	O	the
O	O	splice
O	O	donor
O	O	site
O	O	in
O	O	intron
O	O	33
O	O	.
O	O	Microsatellite
O	O	genotyping
O	O	around
O	O	the
O	O	ATM
O	O	locus
O	O	also
O	O	indicated
O	O	that
O	O	a
O	O	common
O	O	haplotype
O	O	was
O	O	shared
O	O	by
O	O	the
O	O	mutant
O	O	alleles
O	O	in
O	O	both
O	O	mutations
O	O	.
O	O	This
O	O	suggests
O	O	that
O	O	these
O	O	two
O	O	founder
O	O	mutations
O	O	may
O	O	be
O	O	predominant
O	O	among
O	O	Japanese
O	O	ATM
O	O	mutant
O	O	alleles
O	O	.
O	O	W474C
O	O	amino
O	O	acid
O	O	substitution
O	O	affects
O	O	early
O	O	processing
O	O	of
O	O	the
O	O	alpha
O	O	-
O	O	subunit
O	O	of
O	O	beta
O	O	-
O	O	hexosaminidase
O	O	A
O	O	and
O	O	is
O	O	associated
O	O	with
B	O	subacute
I	B	G
I	I	(
I	I	M2
I	I	)
I	I	gangliosidosis
O	O	.
O	O	Mutations
O	O	in
O	O	the
O	O	HEXA
O	O	gene
O	O	,
O	O	encoding
O	O	the
O	O	alpha
O	O	-
O	O	subunit
O	O	of
O	O	beta
O	O	-
O	O	hexosaminidase
O	O	A
O	O	(
O	O	Hex
O	O	A
O	O	)
O	O	,
O	O	that
O	O	abolish
O	O	Hex
O	O	A
O	O	enzyme
O	O	activity
O	O	cause
B	B	Tay
I	I	-
I	I	Sachs
I	I	disease
O	O	(
B	B	TSD
O	O	)
O	O	,
O	O	the
O	O	fatal
O	B	infantile
O	I	form
O	I	of
B	I	G
I	I	(
I	I	M2
I	I	)
I	I	gangliosidosis
O	I	,
O	I	Type
O	I	1
O	O	.
O	O	Less
O	O	severe
O	O	,
O	O	subacute
O	O	(
O	O	juvenile
O	O	-
O	O	onset
O	O	)
O	O	and
O	O	chronic
O	O	(
O	O	adult
O	O	-
O	O	onset
O	O	)
O	O	variants
O	O	are
O	O	characterized
O	O	by
O	O	a
O	O	broad
O	O	spectrum
O	O	of
O	O	clinical
O	O	manifestations
O	O	and
O	O	are
O	O	associated
O	O	with
O	O	residual
O	O	levels
O	O	of
O	O	Hex
O	O	A
O	O	enzyme
O	O	activity
O	O	.
O	O	We
O	O	identified
O	O	a
O	O	1422
O	O	G
O	O	-
O	O	-
O	O	>
O	O	C
O	O	(
O	O	amino
O	O	acid
O	O	W474C
O	O	)
O	O	substitution
O	O	in
O	O	the
O	O	first
O	O	position
O	O	of
O	O	exon
O	O	13
O	O	of
O	O	HEXA
O	O	of
O	O	a
O	O	non
O	O	-
O	O	Jewish
O	O	proband
O	O	who
O	O	manifested
O	O	a
O	O	subacute
O	O	variant
O	O	of
B	B	G
O	I	(
O	I	M2
I	I	)
I	I	gangliosidosis
O	O	.
O	O	On
O	O	the
O	O	second
O	O	maternally
O	O	inherited
O	O	allele
O	O	,
O	O	we
O	O	identified
O	O	the
O	O	common
O	O	infantile
O	O	disease
O	O	-
O	O	causing
O	O	4
O	O	-
O	O	bp
O	O	insertion
O	O	,
O	O	+
O	O	TATC
O	O	1278
O	O	,
O	O	in
O	O	exon
O	O	11
O	O	.
O	O	Pulse
O	O	-
O	O	chase
O	O	analysis
O	O	using
O	O	proband
O	O	fibroblasts
O	O	revealed
O	O	that
O	O	the
O	O	W474C
O	O	-
O	O	containing
O	O	alpha
O	O	-
O	O	subunit
O	O	precursor
O	O	was
O	O	normally
O	O	synthesized
O	O	,
O	O	but
O	O	not
O	O	phosphorylated
O	O	or
O	O	secreted
O	O	,
O	O	and
O	O	the
O	O	mature
O	O	lysosomal
O	O	alpha
O	O	-
O	O	subunit
O	O	was
O	O	not
O	O	detected
O	O	.
O	O	When
O	O	the
O	O	W474C
O	O	-
O	O	containing
O	O	alpha
O	O	-
O	O	subunit
O	O	was
O	O	transiently
O	O	co
O	O	-
O	O	expressed
O	O	with
O	O	the
O	O	beta
O	O	-
O	O	subunit
O	O	to
O	O	produce
O	O	Hex
O	O	A
O	O	(
O	O	alphabeta
O	O	)
O	O	in
O	O	COS
O	O	-
O	O	7
O	O	cells
O	O	,
O	O	the
O	O	mature
O	O	alpha
O	O	-
O	O	subunit
O	O	was
O	O	present
O	O	,
O	O	but
O	O	its
O	O	level
O	O	was
O	O	much
O	O	lower
O	O	than
O	O	that
O	O	from
O	O	normal
O	O	alpha
O	O	-
O	O	subunit
O	O	transfections
O	O	,
O	O	although
O	O	higher
O	O	than
O	O	in
O	O	those
O	O	cells
O	O	transfected
O	O	with
O	O	an
O	O	alpha
O	O	-
O	O	subunit
O	O	associated
O	O	with
B	O	infantile
B	B	TSD
O	O	.
O	O	Furthermore
O	O	,
O	O	the
O	O	precursor
O	O	level
O	O	of
O	O	the
O	O	W474C
O	O	alpha
O	O	-
O	O	subunit
O	O	was
O	O	found
O	O	to
O	O	accumulate
O	O	in
O	O	comparison
O	O	to
O	O	the
O	O	normal
O	O	alpha
O	O	-
O	O	subunit
O	O	precursor
O	O	levels
O	O	.
O	O	We
O	O	conclude
O	O	that
O	O	the
O	O	1422
O	O	G
O	O	-
O	O	-
O	O	>
O	O	C
O	O	mutation
O	O	is
O	O	the
O	O	cause
O	O	of
B	B	Hex
I	I	A
I	I	enzyme
I	I	deficiency
O	O	in
O	O	the
O	O	proband
O	O	.
O	O	The
O	O	resulting
O	O	W474C
O	O	substitution
O	O	clearly
O	O	interferes
O	O	with
O	O	alpha
O	O	-
O	O	subunit
O	O	processing
O	O	,
O	O	but
O	O	because
O	O	the
O	O	base
O	O	substitution
O	O	falls
O	O	at
O	O	the
O	O	first
O	O	position
O	O	of
O	O	exon
O	O	13
O	O	,
O	O	aberrant
O	O	splicing
O	O	may
O	O	also
O	O	contribute
O	O	to
B	B	Hex
I	I	A
I	I	deficiency
O	O	in
O	O	this
O	O	proband
O	O	.
O	O	.
O	O	Two
O	O	frequent
O	O	missense
O	O	mutations
O	O	in
B	B	Pendred
I	I	syndrome
O	O	.
B	B	Pendred
I	I	syndrome
O	O	is
O	O	an
B	B	autosomal
I	I	recessive
I	I	disorder
O	O	characterized
O	O	by
O	O	early
O	O	childhood
B	B	deafness
O	O	and
B	B	goiter
O	O	.
O	O	A
O	O	century
O	O	after
O	O	its
O	O	recognition
O	O	as
O	O	a
O	O	syndrome
O	O	by
O	O	Vaughan
O	O	Pendred
O	O	,
O	O	the
O	O	disease
O	O	gene
O	O	(
B	O	PDS
O	O	)
O	O	was
O	O	mapped
O	O	to
O	O	chromosome
O	O	7q22
O	O	-
O	O	q31
O	O	.
O	O	1
O	O	and
O	O	,
O	O	recently
O	O	,
O	O	found
O	O	to
O	O	encode
O	O	a
O	O	putative
O	O	sulfate
O	O	transporter
O	O	.
O	O	We
O	O	performed
O	O	mutation
O	O	analysis
O	O	of
O	O	the
B	B	PDS
O	O	gene
O	O	in
O	O	patients
O	O	from
O	O	14
B	B	Pendred
O	O	families
O	O	originating
O	O	from
O	O	seven
O	O	countries
O	O	and
O	O	identified
O	O	all
O	O	mutations
O	O	.
O	O	The
O	O	mutations
O	O	include
O	O	three
O	O	single
O	O	base
O	O	deletions
O	O	,
O	O	one
O	O	splice
O	O	site
O	O	mutation
O	O	and
O	O	10
O	O	missense
O	O	mutations
O	O	.
O	O	One
O	O	missense
O	O	mutation
O	O	(
O	O	L236P
O	O	)
O	O	was
O	O	found
O	O	in
O	O	a
O	O	homozygous
O	O	state
O	O	in
O	O	two
O	O	consanguineous
O	O	families
O	O	and
O	O	in
O	O	a
O	O	heterozygous
O	O	state
O	O	in
O	O	five
O	O	additional
O	O	non
O	O	-
O	O	consanguineous
O	O	families
O	O	.
O	O	Another
O	O	missense
O	O	mutation
O	O	(
O	O	T416P
O	O	)
O	O	was
O	O	found
O	O	in
O	O	a
O	O	homozygous
O	O	state
O	O	in
O	O	one
O	O	family
O	O	and
O	O	in
O	O	a
O	O	heterozygous
O	O	state
O	O	in
O	O	four
O	O	families
O	O	.
O	B	Pendred
O	O	patients
O	O	in
O	O	three
O	O	non
O	O	-
O	O	consanguineous
O	O	families
O	O	were
O	O	shown
O	O	to
O	O	be
O	O	compound
O	O	heterozygotes
O	O	for
O	O	L236P
O	O	and
O	O	T416P
O	O	.
O	O	In
O	O	total
O	O	,
O	O	one
O	O	or
O	O	both
O	O	of
O	O	these
O	O	mutations
O	O	were
O	O	found
O	O	in
O	O	nine
O	O	of
O	O	the
O	O	14
O	O	families
O	O	analyzed
O	O	.
O	O	The
O	O	identification
O	O	of
O	O	two
O	O	frequent
B	B	PDS
O	O	mutations
O	O	will
O	O	facilitate
O	O	the
O	O	molecular
O	O	diagnosis
O	O	of
B	B	Pendred
I	I	syndrome
O	O	.
O	O	Insertional
O	O	mutation
O	O	by
O	O	transposable
O	O	element
O	O	,
O	O	L1
O	O	,
O	O	in
O	O	the
B	B	DMD
O	O	gene
O	O	results
O	O	in
B	B	X
I	I	-
I	I	linked
I	I	dilated
I	I	cardiomyopathy
O	O	.
B	B	X
I	I	-
I	I	linked
I	I	dilated
I	I	cardiomyopathy
O	O	(
B	B	XLDCM
O	O	)
O	O	is
O	O	a
O	O	clinical
O	O	phenotype
O	O	of
B	B	dystrophinopathy
O	O	which
O	O	is
O	O	characterized
O	O	by
O	O	preferential
B	B	myocardial
I	I	involvement
O	O	without
O	O	any
O	O	overt
O	O	clinical
O	O	signs
O	O	of
B	B	skeletal
I	I	myopathy
O	O	.
O	O	To
O	O	date
O	O	,
O	O	several
O	O	mutations
O	O	in
O	O	the
B	B	Duchenne
I	I	muscular
I	I	dystrophy
O	O	gene
O	O	,
B	O	DMD
O	O	,
O	O	have
O	O	been
O	O	identified
O	O	in
O	O	patients
O	O	with
B	B	XLDCM
O	O	,
O	O	but
O	O	a
O	O	pathogenic
O	O	correlation
O	O	of
O	O	these
O	O	cardiospecific
O	O	mutations
O	O	in
B	O	DMD
O	O	with
O	O	the
B	B	XLDCM
O	O	phenotype
O	O	has
O	O	remained
O	O	to
O	O	be
O	O	elucidated
O	O	.
O	O	We
O	O	report
O	O	here
O	O	the
O	O	identification
O	O	of
O	O	a
O	O	unique
O	O	de
O	O	novo
O	O	L1
O	O	insertion
O	O	in
O	O	the
O	O	muscle
O	O	exon
O	O	1
O	O	in
B	O	DMD
O	O	in
O	O	three
B	B	XLDCM
O	O	patients
O	O	from
O	O	two
O	O	unrelated
O	O	Japanese
O	O	families
O	O	.
O	O	The
O	O	insertion
O	O	was
O	O	a
O	O	5
O	O	-
O	O	truncated
O	O	form
O	O	of
O	O	human
O	O	L1
O	O	inversely
O	O	integrated
O	O	in
O	O	the
O	O	5
O	O	-
O	O	untranslated
O	O	region
O	O	in
O	O	the
O	O	muscle
O	O	exon
O	O	1
O	O	,
O	O	which
O	O	affected
O	O	the
O	O	transcription
O	O	or
O	O	the
O	O	stability
O	O	of
O	O	the
O	O	muscle
O	O	form
O	O	of
O	O	dystrophin
O	O	transcripts
O	O	but
O	O	not
O	O	that
O	O	of
O	O	the
O	O	brain
O	O	or
O	O	Purkinje
O	O	cell
O	O	form
O	O	,
O	O	probably
O	O	due
O	O	to
O	O	its
O	O	unique
O	O	site
O	O	of
O	O	integration
O	O	.
O	O	We
O	O	speculate
O	O	that
O	O	this
O	O	insertion
O	O	of
O	O	an
O	O	L1
O	O	sequence
O	O	in
B	O	DMD
O	O	is
O	O	responsible
O	O	for
O	O	some
O	O	of
O	O	the
O	O	population
O	O	of
O	O	Japanese
O	O	patients
O	O	with
B	B	XLDCM
O	O	.
O	O	.
O	O	Severe
O	O	early
O	O	-
O	O	onset
B	B	obesity
O	O	,
B	B	adrenal
I	I	insufficiency
O	O	and
B	O	red
I	O	hair
I	O	pigmentation
O	O	caused
O	O	by
B	O	POMC
O	O	mutations
O	O	in
O	O	humans
O	O	.
O	O	Sequential
O	O	cleavage
O	O	of
O	O	the
O	O	precursor
O	O	protein
O	O	pre
O	O	-
O	O	pro
O	O	-
O	O	opiomelanocortin
O	O	(
O	O	POMC
O	O	)
O	O	generates
O	O	the
O	O	melanocortin
O	O	peptides
O	O	adrenocorticotrophin
O	O	(
O	O	ACTH
O	O	)
O	O	,
O	O	melanocyte
O	O	-
O	O	stimulating
O	O	hormones
O	O	(
O	O	MSH
O	O	)
O	O	alpha
O	O	,
O	O	beta
O	O	and
O	O	gamma
O	O	as
O	O	well
O	O	as
O	O	the
O	O	opioid
O	O	-
O	O	receptor
O	O	ligand
O	O	beta
O	O	-
O	O	endorphin
O	O	.
O	O	While
O	O	a
O	O	few
O	O	cases
O	O	of
O	O	isolated
B	B	ACTH
I	I	deficiency
O	O	have
O	O	been
O	O	reported
O	O	(
O	O	OMIM
O	O	201400
O	O	)
O	O	,
O	O	an
O	O	inherited
B	O	POMC
I	O	defect
O	O	has
O	O	not
O	O	been
O	O	described
O	O	so
O	O	far
O	O	.
O	O	Recent
O	O	studies
O	O	in
O	O	animal
O	O	models
O	O	elucidated
O	O	a
O	O	central
O	O	role
O	O	of
O	O	alpha
O	O	-
O	O	MSH
O	O	in
O	O	the
O	O	regulation
O	O	of
O	O	food
O	O	intake
O	O	by
O	O	activation
O	O	of
O	O	the
O	O	brain
O	O	melanocortin
O	O	-
O	O	4
O	O	-
O	O	receptor
O	O	(
O	O	MC4
O	O	-
O	O	R
O	O	;
O	O	refs
O	O	3
O	O	-
O	O	5
O	O	)
O	O	and
O	O	the
O	O	linkage
O	O	of
O	O	human
B	B	obesity
O	O	to
O	O	chromosome
O	O	2
O	O	in
O	O	close
O	O	proximity
O	O	to
O	O	the
B	O	POMC
O	O	locus
O	O	,
O	O	led
O	O	to
O	O	the
O	O	proposal
O	O	of
O	O	an
O	O	association
O	O	of
B	O	POMC
O	O	with
O	O	human
B	B	obesity
O	O	.
O	O	The
O	O	dual
O	O	role
O	O	of
O	O	alpha
O	O	-
O	O	MSH
O	O	in
O	O	regulating
O	O	food
O	O	intake
O	O	and
O	O	influencing
O	O	hair
I	O	pigmentation
O	O	predicts
O	O	that
O	O	the
O	O	phenotype
O	O	associated
O	O	with
O	O	a
O	O	defect
O	O	in
B	O	POMC
O	O	function
O	O	would
O	O	include
B	B	obesity
O	O	,
O	O	alteration
O	O	in
O	O	pigmentation
O	O	and
B	B	ACTH
I	I	deficiency
O	O	.
O	O	The
O	O	observation
O	O	of
O	O	these
O	O	symptoms
O	O	in
O	O	two
O	O	probands
O	O	prompted
O	O	us
O	O	to
O	O	search
O	O	for
O	O	mutations
O	O	within
O	O	their
B	O	POMC
O	O	genes
O	O	.
O	O	Patient
O	O	1
O	O	was
O	O	found
O	O	to
O	O	be
O	O	a
O	O	compound
O	O	heterozygote
O	O	for
O	O	two
O	O	mutations
O	O	in
O	O	exon
O	O	3
O	O	(
O	O	G7013T
O	O	,
O	O	C7133delta
O	O	)
O	O	which
O	O	interfere
O	O	with
O	O	appropriate
O	O	synthesis
O	O	of
O	O	ACTH
O	O	and
O	O	alpha
O	O	-
O	O	MSH
O	O	.
O	O	Patient
O	O	2
O	O	was
O	O	homozygous
O	O	for
O	O	a
O	O	mutation
O	O	in
O	O	exon
O	O	2
O	O	(
O	O	C3804A
O	O	)
O	O	which
O	O	abolishes
O	O	POMC
O	O	translation
O	O	.
O	O	These
O	O	findings
O	O	represent
O	O	the
O	O	first
O	O	examples
O	O	of
O	O	a
B	B	genetic
O	I	defect
O	O	within
O	O	the
B	O	POMC
O	O	gene
O	O	and
O	O	define
O	O	a
O	O	new
O	B	monogenic
B	I	endocrine
I	I	disorder
O	O	resulting
O	O	in
O	O	early
O	O	-
O	O	onset
B	B	obesity
O	O	,
B	B	adrenal
I	I	insufficiency
O	O	and
B	O	red
I	O	hair
I	O	pigmentation
O	O	.
O	O	.
O	O	A
O	O	European
O	O	multicenter
O	O	study
O	O	of
B	B	phenylalanine
I	I	hydroxylase
I	I	deficiency
O	O	:
O	O	classification
O	O	of
O	O	105
O	O	mutations
O	O	and
O	O	a
O	O	general
O	O	system
O	O	for
O	O	genotype
O	O	-
O	O	based
O	O	prediction
O	O	of
O	O	metabolic
O	O	phenotype
O	O	.
B	B	Phenylketonuria
O	O	(
B	B	PKU
O	O	)
O	O	and
B	B	mild
B	I	hyperphenylalaninemia
O	O	(
B	B	MHP
O	O	)
O	O	are
B	B	allelic
I	I	disorders
O	O	caused
O	O	by
O	O	mutations
O	O	in
O	O	the
O	O	gene
O	O	encoding
O	O	phenylalanine
O	O	hydroxylase
O	O	(
O	O	PAH
O	O	)
O	O	.
O	O	Previous
O	O	studies
O	O	have
O	O	suggested
O	O	that
O	O	the
O	O	highly
O	O	variable
O	O	metabolic
O	O	phenotypes
O	O	of
B	B	PAH
I	I	deficiency
O	O	correlate
O	O	with
B	O	PAH
O	O	genotypes
O	O	.
O	O	We
O	O	identified
O	O	both
O	O	causative
O	O	mutations
O	O	in
O	O	686
O	O	patients
O	O	from
O	O	seven
O	O	European
O	O	centers
O	O	.
O	O	On
O	O	the
O	O	basis
O	O	of
O	O	the
O	O	phenotypic
O	O	characteristics
O	O	of
O	O	297
O	O	functionally
O	O	hemizygous
O	O	patients
O	O	,
O	O	105
O	O	of
O	O	the
O	O	mutations
O	O	were
O	O	assigned
O	O	to
O	O	one
O	O	of
O	O	four
O	O	arbitrary
O	O	phenotype
O	O	categories
O	O	.
O	O	We
O	O	proposed
O	O	and
O	O	tested
O	O	a
O	O	simple
O	O	model
O	O	for
O	O	correlation
O	O	between
O	O	genotype
O	O	and
O	O	phenotypic
O	O	outcome
O	O	.
O	O	The
O	O	observed
O	O	phenotype
O	O	matched
O	O	the
O	O	predicted
O	O	phenotype
O	O	in
O	O	79
O	O	%
O	O	of
O	O	the
O	O	cases
O	O	,
O	O	and
O	O	in
O	O	only
O	O	5
O	O	of
O	O	184
O	O	patients
O	O	was
O	O	the
O	O	observed
O	O	phenotype
O	O	more
O	O	than
O	O	one
O	O	category
O	O	away
O	O	from
O	O	that
O	O	expected
O	O	.
O	O	Among
O	O	the
O	O	seven
O	O	contributing
O	O	centers
O	O	,
O	O	the
O	O	proportion
O	O	of
O	O	patients
O	O	for
O	O	whom
O	O	the
O	O	observed
O	O	phenotype
O	O	did
O	O	not
O	O	match
O	O	the
O	O	predicted
O	O	phenotype
O	O	was
O	O	4
O	O	%
O	O	-
O	O	23
O	O	%
O	O	(
O	O	P
O	O	<
O	O	.
O	O	0001
O	O	)
O	O	,
O	O	suggesting
O	O	that
O	O	differences
O	O	in
O	O	methods
O	O	used
O	O	for
O	O	mutation
O	O	detection
O	O	or
O	O	phenotype
O	O	classification
O	O	may
O	O	account
O	O	for
O	O	a
O	O	considerable
O	O	proportion
O	O	of
O	O	genotype
O	O	-
O	O	phenotype
O	O	inconsistencies
O	O	.
O	O	Our
O	O	data
O	O	indicate
O	O	that
O	O	the
O	O	PAH
O	O	-
O	O	mutation
O	O	genotype
O	O	is
O	O	the
O	O	main
O	O	determinant
O	O	of
O	O	metabolic
O	O	phenotype
O	O	in
O	O	most
O	O	patients
O	O	with
B	B	PAH
I	I	deficiency
O	O	.
O	O	In
O	O	the
O	O	present
O	O	study
O	O	,
O	O	the
O	O	classification
O	O	of
O	O	105
O	O	PAH
O	O	mutations
O	O	may
O	O	allow
O	O	the
O	O	prediction
O	O	of
O	O	the
O	O	biochemical
O	O	phenotype
O	O	in
O	O	>
O	O	10
O	O	,
O	O	000
O	O	genotypes
O	O	,
O	O	which
O	O	may
O	O	be
O	O	useful
O	O	for
O	O	the
O	O	management
O	O	of
B	B	hyperphenylalaninemia
O	O	in
O	O	newborns
O	O	.
O	O	Somatic
O	O	instability
O	O	of
O	O	the
O	O	CTG
O	O	repeat
O	O	in
O	O	mice
O	O	transgenic
O	O	for
O	O	the
B	B	myotonic
I	I	dystrophy
O	O	region
O	O	is
O	O	age
O	O	dependent
O	O	but
O	O	not
O	O	correlated
O	O	to
O	O	the
O	O	relative
O	O	intertissue
O	O	transcription
O	O	levels
O	O	and
O	O	proliferative
O	O	capacities
O	O	.
O	O	A
O	O	(
O	O	CTG
O	O	)
O	O	nexpansion
O	O	in
O	O	the
O	O	3
O	O	-
O	O	untranslated
O	O	region
O	O	(
O	O	UTR
O	O	)
O	O	of
O	O	the
B	O	DM
O	O	protein
O	O	kinase
O	O	gene
O	O	(
O	O	DMPK
O	O	)
O	O	is
O	O	responsible
O	O	for
O	O	causing
B	B	myotonic
I	I	dystrophy
O	O	(
B	B	DM
O	O	)
O	O	.
O	O	Major
O	O	instability
O	O	,
O	O	with
O	O	very
O	O	large
O	O	expansions
O	O	between
O	O	generations
O	O	and
O	O	high
O	O	levels
O	O	of
O	O	somatic
O	O	mosaicism
O	O	,
O	O	is
O	O	observed
O	O	in
O	O	patients
O	O	.
O	O	There
O	O	is
O	O	a
O	O	good
O	O	correlation
O	O	between
O	O	repeat
O	O	size
O	O	(
O	O	at
O	O	least
O	O	in
O	O	leucocytes
O	O	)
O	O	,
O	O	clinical
O	O	severity
O	O	and
O	O	age
O	O	of
O	O	onset
O	O	.
O	O	The
O	O	trinucleotide
O	O	repeat
O	O	instability
O	O	mechanisms
O	O	involved
O	O	in
B	B	DM
O	O	and
O	O	other
O	O	human
B	B	genetic
O	I	diseases
O	O	are
O	O	unknown
O	O	.
O	O	We
O	O	studied
O	O	somatic
O	O	instability
O	O	by
O	O	measuring
O	O	the
O	O	CTG
O	O	repeat
O	O	length
O	O	at
O	O	several
O	O	ages
O	O	in
O	O	various
O	O	tissues
O	O	of
O	O	transgenic
O	O	mice
O	O	carrying
O	O	a
O	O	(
O	O	CTG
O	O	)
O	O	55expansion
O	O	surrounded
O	O	by
O	O	45
O	O	kb
O	O	of
O	O	the
O	O	human
B	B	DM
O	O	region
O	O	,
O	O	using
O	O	small
O	O	-
O	O	pool
O	O	PCR
O	O	.
O	O	These
O	O	mice
O	O	have
O	O	been
O	O	shown
O	O	to
O	O	reproduce
O	O	the
O	O	intergenerational
O	O	and
O	O	somatic
O	O	instability
O	O	of
O	O	the
O	O	55
O	O	CTG
O	O	repeat
O	O	suggesting
O	O	that
O	O	surrounding
O	O	sequences
O	O	and
O	O	the
O	O	chromatin
O	O	environment
O	O	are
O	O	involved
O	O	in
O	O	instability
O	O	mechanisms
O	O	.
O	O	As
O	O	observed
O	O	in
O	O	some
O	O	of
O	O	the
O	O	tissues
O	O	of
B	B	DM
O	O	patients
O	O	,
O	O	there
O	O	is
O	O	a
O	O	tendency
O	O	for
O	O	repeat
O	O	length
O	O	and
O	O	somatic
O	O	mosaicism
O	O	to
O	O	increase
O	O	with
O	O	the
O	O	age
O	O	of
O	O	the
O	O	mouse
O	O	.
O	O	Furthermore
O	O	,
O	O	we
O	O	observed
O	O	no
O	O	correlation
O	O	between
O	O	the
O	O	somatic
O	O	mutation
O	O	rate
O	O	and
O	O	tissue
O	O	proliferation
O	O	capacity
O	O	.
O	O	The
O	O	somatic
O	O	mutation
O	O	rates
O	O	in
O	O	different
O	O	tissues
O	O	were
O	O	also
O	O	not
O	O	correlated
O	O	to
O	O	the
O	O	relative
O	O	inter
O	O	-
O	O	tissue
O	O	difference
O	O	in
O	O	transcriptional
O	O	levels
O	O	of
O	O	the
O	O	three
O	O	genes
O	O	(
O	O	DMAHP
O	O	,
O	O	DMPK
O	O	and
O	O	59
O	O	)
O	O	surrounding
O	O	the
O	O	repeat
O	O	.
O	O	.
O	O	A
O	O	novel
O	O	missense
O	O	mutation
O	O	in
O	O	patients
O	O	from
O	O	a
B	B	retinoblastoma
O	O	pedigree
O	O	showing
O	O	only
O	O	mild
O	O	expression
O	O	of
O	O	the
B	B	tumor
O	O	phenotype
O	O	.
O	O	We
O	O	have
O	O	used
O	O	single
O	O	strand
O	O	conformation
O	O	polymorphism
O	O	analysis
O	O	to
O	O	study
O	O	the
O	O	27
O	O	exons
O	O	of
O	O	the
O	O	RB1
O	O	gene
O	O	in
O	O	individuals
O	O	from
O	O	a
O	O	family
O	O	showing
O	O	mild
O	O	expression
O	O	of
O	O	the
B	B	retinoblastoma
O	O	phenotype
O	O	.
O	O	In
O	O	this
O	O	family
O	O	affected
O	O	individuals
O	O	developed
B	B	unilateral
I	I	tumors
O	O	and
O	O	,
O	O	as
O	O	a
O	O	result
O	O	of
O	O	linkage
O	O	analysis
O	O	,
O	O	unaffected
O	O	mutation
O	O	carriers
O	O	were
O	O	also
O	O	identified
O	O	within
O	O	the
O	O	pedigree
O	O	.
O	O	A
O	O	single
O	O	band
O	O	shift
O	O	using
O	O	SSCP
O	O	was
O	O	identified
O	O	in
O	O	exon
O	O	21
O	O	which
O	O	resulted
O	O	in
O	O	a
O	O	missense
O	O	mutation
O	O	converting
O	O	a
O	O	cys
O	O	-
O	O	-
O	O	>
O	O	arg
O	O	at
O	O	nucleotide
O	O	position
O	O	28
O	O	in
O	O	the
O	O	exon
O	O	.
O	O	The
O	O	mutation
O	O	destroyed
O	O	an
O	O	NdeI
O	O	restriction
O	O	enzyme
O	O	site
O	O	.
O	O	Analysis
O	O	of
O	O	all
O	O	family
O	O	members
O	O	demonstrated
O	O	that
O	O	the
O	O	missense
O	O	mutation
O	O	co
O	O	-
O	O	segregated
O	O	with
O	O	patients
O	O	with
B	B	tumors
O	O	or
O	O	who
O	O	,
O	O	as
O	O	a
O	O	result
O	O	of
O	O	linkage
O	O	analysis
O	O	had
O	O	been
O	O	predicted
O	O	to
O	O	carry
O	O	the
O	O	predisposing
O	O	mutation
O	O	.
O	O	These
O	O	observations
O	O	point
O	O	to
O	O	another
O	O	region
O	O	of
O	O	the
O	O	RB1
O	O	gene
O	O	where
O	O	mutations
O	O	only
O	O	modify
O	O	the
O	O	function
O	O	of
O	O	the
O	O	gene
O	O	and
O	O	raise
O	O	important
O	O	questions
O	O	for
O	O	genetic
O	O	counseling
O	O	in
O	O	families
O	O	with
O	O	these
O	O	distinctive
O	O	phenotypes
O	O	.
O	O	.
B	B	Maternal
I	I	disomy
O	O	and
B	B	Prader
I	I	-
I	I	Willi
I	I	syndrome
O	O	consistent
O	O	with
O	O	gamete
O	O	complementation
O	O	in
O	O	a
O	O	case
O	O	of
O	O	familial
O	O	translocation
O	O	(
O	O	3
O	O	;
O	O	15
O	O	)
O	O	(
O	O	p25
O	O	;
O	O	q11
O	O	.
O	O	2
O	O	)
O	O	.
B	B	Maternal
I	I	uniparental
I	I	disomy
O	I	(
B	I	UPD
O	I	)
O	I	for
O	I	chromosome
O	I	15
O	O	is
O	O	responsible
O	O	for
O	O	an
O	O	estimated
O	O	30
O	O	%
O	O	of
O	O	cases
O	O	of
B	B	Prader
I	I	-
I	I	Willi
I	I	syndrome
O	O	(
B	B	PWS
O	O	)
O	O	.
O	O	We
O	O	report
O	O	on
O	O	an
O	O	unusual
O	O	case
O	O	of
B	B	maternal
I	I	disomy
I	I	15
O	O	in
B	B	PWS
O	O	that
O	O	is
O	O	most
O	O	consistent
O	O	with
O	O	adjacent
O	O	-
O	O	1
O	O	segregation
O	O	of
O	O	a
O	O	paternal
O	O	t
O	O	(
O	O	3
O	O	;
O	O	15
O	O	)
O	O	(
O	O	p25
O	O	;
O	O	q11
O	O	.
O	O	2
O	O	)
O	O	with
O	O	simultaneous
O	O	maternal
O	O	meiotic
O	O	nondisjunction
O	O	for
O	O	chromosome
O	O	15
O	O	.
O	O	The
O	O	patient
O	O	(
O	O	J
O	O	.
O	O	B
O	O	.
O	O	)
O	O	,
O	O	a
O	O	17
O	O	-
O	O	year
O	O	-
O	O	old
O	O	white
O	O	male
O	O	with
B	B	PWS
O	O	,
O	O	was
O	O	found
O	O	to
O	O	have
O	O	47
O	O	chromosomes
O	O	with
O	O	a
O	O	supernumerary
O	O	,
O	O	paternal
O	O	der
O	O	(
O	O	15
O	O	)
O	O	consisting
O	O	of
O	O	the
O	O	short
O	O	arm
O	O	and
O	O	the
O	O	proximal
O	O	long
O	O	arm
O	O	of
O	O	chromosome
O	O	15
O	O	,
O	O	and
O	O	distal
O	O	chromosome
O	O	arm
O	O	3p
O	O	.
O	O	The
O	O	t
O	O	(
O	O	3
O	O	;
O	O	15
O	O	)
O	O	was
O	O	present
O	O	in
O	O	the
O	O	balanced
O	O	state
O	O	in
O	O	the
O	O	patients
O	O	father
O	O	and
O	O	a
O	O	sister
O	O	.
O	O	Fluorescent
O	O	in
O	O	situ
O	O	hybridization
O	O	analysis
O	O	demonstrated
O	O	that
O	O	the
B	B	PWS
O	O	critical
O	O	region
O	O	resided
O	O	on
O	O	the
O	O	derivative
O	O	chromosome
O	O	3
O	O	and
O	O	that
O	O	there
O	O	was
O	O	no
O	O	deletion
O	O	of
O	O	the
B	B	PWS
O	O	region
O	O	on
O	O	the
O	O	normal
O	O	pair
O	O	of
O	O	15s
O	O	present
O	O	in
O	O	J
O	O	.
O	O	B
O	O	.
O	O	Methylation
O	O	analysis
O	O	at
O	O	exon
O	O	alpha
O	O	of
O	O	the
O	O	small
O	O	nuclear
O	O	ribonucleoprotein
O	O	-
O	O	associated
O	O	polypeptide
O	O	N
O	O	(
O	O	SNRPN
O	O	)
O	O	gene
O	O	showed
O	O	a
O	O	pattern
O	O	characteristic
O	O	of
O	O	only
O	O	the
O	O	maternal
O	O	chromosome
O	O	15
O	O	in
O	O	J
O	O	.
O	O	B
O	O	.
O	B	Maternal
I	I	disomy
O	O	was
O	O	confirmed
O	O	by
O	O	polymerase
O	O	chain
O	O	reaction
O	O	analysis
O	O	of
O	O	microsatellite
O	O	repeats
O	O	at
O	O	the
O	O	gamma
O	O	-
O	O	aminobutyric
O	O	acid
O	O	receptor
O	O	beta3
O	O	subunit
O	O	(
O	O	GABRB3
O	O	)
O	O	locus
O	O	.
O	O	A
O	O	niece
O	O	(
O	O	B
O	O	.
O	O	B
O	O	.
O	O	)
O	O	with
O	O	45
O	O	chromosomes
O	O	and
O	O	the
O	O	derivative
O	O	3
O	O	but
O	O	without
O	O	the
O	O	der
O	O	(
O	O	15
O	O	)
O	O	demonstrated
O	O	a
O	O	phenotype
O	O	consistent
O	O	with
O	O	that
O	O	reported
O	O	for
B	O	haploinsufficiency
I	O	of
I	O	distal
I	O	3
O	O	p
O	O	.
B	B	Uniparental
I	I	disomy
O	O	associated
O	O	with
O	O	unbalanced
O	O	segregation
O	O	of
O	O	non
O	O	-
O	O	Robertsonian
O	O	translocations
O	O	has
O	O	been
O	O	reported
O	O	previously
O	O	but
O	O	has
O	O	not
O	O	,
O	O	to
O	O	our
O	O	knowledge
O	O	,
O	O	been
O	O	observed
O	O	in
O	O	a
O	O	case
O	O	of
B	B	PWS
O	O	.
O	O	Furthermore
O	O	,
O	O	our
O	O	findings
O	O	are
O	O	best
O	O	interpreted
O	O	as
O	O	true
O	O	gamete
O	O	complementation
O	O	resulting
O	O	in
O	B	maternal
B	I	UPD
O	I	15
O	O	and
B	B	PWS
B	B	Schwartz
I	I	-
I	I	Jampel
I	I	syndrome
I	I	type
I	I	2
O	O	and
B	B	Stuve
I	I	-
I	I	Wiedemann
I	I	syndrome
O	O	:
O	O	a
O	O	case
O	O	for
O	O	""""
O	O	lumping
O	O	""""
O	O	.
O	O	Recent
O	O	studies
O	O	demonstrated
O	O	the
O	O	existence
O	O	of
O	O	a
O	O	genetically
O	O	distinct
O	O	,
O	O	usually
O	O	lethal
O	O	form
O	O	of
O	O	the
B	B	Schwartz
I	I	-
I	I	Jampel
I	I	syndrome
O	O	(
B	B	SJS
O	O	)
O	O	of
B	B	myotonia
O	O	and
B	B	skeletal
I	I	dysplasia
O	O	,
O	O	which
O	O	we
O	O	called
B	B	SJS
O	I	type
O	I	2
O	O	.
O	O	This
O	O	disorder
O	O	is
O	O	reminiscent
O	O	of
O	O	another
O	O	rare
O	O	condition
O	O	,
O	O	the
B	B	Stuve
I	I	-
I	I	Wiedemann
I	I	syndrome
O	O	(
B	B	SWS
O	O	)
O	O	,
O	O	which
O	O	comprises
B	B	campomelia
O	O	at
O	O	birth
O	O	with
B	B	skeletal
I	I	dysplasia
O	O	,
B	B	contractures
O	O	,
O	O	and
O	B	early
O	I	death
O	O	.
O	O	To
O	O	test
O	O	for
O	O	possible
O	O	nosologic
O	O	identity
O	O	between
O	O	these
O	O	disorders
O	O	,
O	O	we
O	O	reviewed
O	O	the
O	O	literature
O	O	and
O	O	obtained
O	O	a
O	O	follow
O	O	-
O	O	up
O	O	of
O	O	the
O	O	only
O	O	two
O	O	surviving
O	O	patients
O	O	,
O	O	one
O	O	with
B	B	SJS
I	I	type
I	I	2
O	O	at
O	O	age
O	O	10
O	O	years
O	O	and
O	O	another
O	O	with
B	B	SWS
O	O	at
O	O	age
O	O	7
O	O	years
O	O	.
O	O	Patients
O	O	reported
O	O	as
O	O	having
O	O	either
O	O	neonatal
B	B	SJS
O	O	or
B	B	SWS
O	O	presented
O	O	a
O	O	combination
O	O	of
O	O	a
O	O	severe
O	O	,
O	O	prenatal
O	O	-
O	O	onset
B	B	neuromuscular
I	I	disorder
O	O	(
O	O	with
B	B	congenital
I	I	joint
I	I	contractures
O	O	,
B	O	respiratory
I	O	and
O	O	feeding
I	O	difficulties
O	O	,
O	O	tendency
O	O	to
B	B	hyperthermia
O	O	,
O	O	and
O	O	frequent
O	O	death
O	O	in
O	O	infancy
O	O	)
O	O	with
O	O	a
O	O	distinct
B	B	campomelic
I	I	-
I	I	metaphyseal
I	I	skeletal
I	I	dysplasia
O	O	.
O	O	The
O	O	similarity
O	O	of
O	O	the
O	O	clinical
O	O	and
O	O	radiographic
O	O	findings
O	O	is
O	O	so
O	O	extensive
O	O	that
O	O	these
O	O	disorders
O	O	appear
O	O	to
O	O	be
O	O	a
O	O	single
O	O	entity
O	O	.
O	O	The
O	O	follow
O	O	-
O	O	up
O	O	observation
O	O	of
O	O	an
O	O	identical
O	O	and
O	O	unique
O	O	pattern
O	O	of
O	O	progressive
B	B	bone
I	I	dysplasia
O	O	in
O	O	the
O	O	two
O	O	patients
O	O	(
O	O	one
O	O	with
B	B	SJS
I	I	type
I	I	2
O	O	,
O	O	one
O	O	with
B	B	SWS
O	O	)
O	O	surviving
O	O	beyond
O	O	infancy
O	O	adds
O	O	to
O	O	the
O	O	evidence
O	O	in
O	O	favor
O	O	of
O	O	identity
O	O	.
O	O	The
O	O	hypothesis
O	O	that
B	B	SWS
O	O	and
B	B	SJS
I	I	type
I	I	2
O	O	are
O	O	the
O	O	same
O	O	disorder
O	O	should
O	O	be
O	O	testable
O	O	by
O	O	molecular
O	O	methods
O	O	.
O	O	.
O	O	A
O	O	mouse
O	O	model
O	O	of
O	O	severe
B	B	von
I	I	Willebrand
I	I	disease
O	O	:
O	O	defects
O	O	in
B	O	hemostasis
O	O	and
B	B	thrombosis
O	O	.
B	B	von
I	I	Willebrand
I	I	factor
I	I	(
B	I	vWf
I	I	)
I	I	deficiency
O	O	causes
O	O	severe
B	B	von
I	I	Willebrand
I	I	disease
O	O	in
O	O	humans
O	O	.
O	O	We
O	O	generated
O	O	a
O	O	mouse
O	O	model
O	O	for
O	O	this
O	O	disease
O	O	by
O	O	using
O	O	gene
O	O	targeting
O	O	.
B	B	vWf
I	I	-
O	I	deficient
O	O	mice
O	O	appeared
O	O	normal
O	O	at
O	O	birth
O	O	;
O	O	they
O	O	were
O	O	viable
O	O	and
O	O	fertile
O	O	.
O	O	Neither
O	O	vWf
O	O	nor
O	O	vWf
O	O	propolypeptide
O	O	(
B	B	von
I	I	Willebrand
O	O	antigen
O	O	II
O	O	)
O	O	were
O	O	detectable
O	O	in
O	O	plasma
O	O	,
O	O	platelets
O	O	,
O	O	or
O	O	endothelial
O	O	cells
O	O	of
O	O	the
O	O	homozygous
O	O	mutant
O	O	mice
O	O	.
O	O	The
O	O	mutant
O	O	mice
O	O	exhibited
O	O	defects
O	O	in
B	O	hemostasis
O	O	with
O	O	a
O	O	highly
O	O	prolonged
O	O	bleeding
O	O	time
O	O	and
O	O	spontaneous
O	O	bleeding
O	O	events
O	O	in
O	O	approximately
O	O	10
O	O	%
O	O	of
O	O	neonates
O	O	.
O	O	As
O	O	in
O	O	the
O	O	human
O	O	disease
O	O	,
O	O	the
O	O	factor
O	O	VIII
O	O	level
O	O	in
O	O	these
O	O	mice
O	O	was
O	O	reduced
O	O	strongly
O	O	as
O	O	a
O	O	result
O	O	of
O	O	the
O	O	lack
O	O	of
O	O	protection
O	O	provided
O	O	by
O	O	vWf
O	O	.
B	O	Defective
I	B	thrombosis
O	O	in
O	O	mutant
O	O	mice
O	O	was
O	O	also
O	O	evident
O	O	in
O	O	an
O	O	in
O	O	vivo
O	O	model
O	O	of
B	B	vascular
O	I	injury
O	O	.
O	O	In
O	O	this
O	O	model
O	O	,
O	O	the
O	O	exteriorized
O	O	mesentery
O	O	was
O	O	superfused
O	O	with
O	O	ferric
O	O	chloride
O	O	and
O	O	the
O	O	accumulation
O	O	of
O	O	fluorescently
O	O	labeled
O	O	platelets
O	O	was
O	O	observed
O	O	by
O	O	intravital
O	O	microscopy
O	O	.
O	O	We
O	O	conclude
O	O	that
O	O	these
O	O	mice
O	O	very
O	O	closely
O	O	mimic
O	O	severe
O	O	human
B	B	von
I	I	Willebrand
I	I	disease
O	O	and
O	O	will
O	O	be
O	O	very
O	O	useful
O	O	for
O	O	investigating
O	O	the
O	O	role
O	O	of
O	O	vWf
O	O	in
O	O	normal
O	O	physiology
O	O	and
O	O	in
O	O	disease
O	O	models
O	O	.
O	O	.
O	O	Oral
O	O	contraceptives
O	O	and
O	O	the
O	O	risk
O	O	of
B	B	hereditary
I	I	ovarian
I	I	cancer
O	O	.
B	B	Hereditary
I	I	Ovarian
I	I	Cancer
O	O	Clinical
O	O	Study
O	O	Group
O	O	.
O	O	BACKGROUND
O	O	Women
O	O	with
O	O	mutations
O	O	in
O	O	either
O	O	the
O	O	BRCA1
O	O	or
O	O	the
O	O	BRCA2
O	O	gene
O	O	have
O	O	a
O	O	high
O	O	lifetime
O	O	risk
O	O	of
B	B	ovarian
I	I	cancer
O	O	.
O	O	Oral
O	O	contraceptives
O	O	protect
O	O	against
B	B	ovarian
I	I	cancer
O	O	in
O	O	general
O	O	,
O	O	but
O	O	it
O	O	is
O	O	not
O	O	known
O	O	whether
O	O	they
O	O	also
O	O	protect
O	O	against
B	B	hereditary
O	I	forms
O	I	of
B	I	ovarian
I	I	cancer
O	O	.
O	O	METHODS
O	O	We
O	O	enrolled
O	O	207
O	O	women
O	O	with
B	B	hereditary
I	I	ovarian
I	I	cancer
O	O	and
O	O	161
O	O	of
O	O	their
O	O	sisters
O	O	as
O	O	controls
O	O	in
O	O	a
O	O	case
O	O	-
O	O	control
O	O	study
O	O	.
O	O	All
O	O	the
O	O	patients
O	O	carried
O	O	a
O	O	pathogenic
O	O	mutation
O	O	in
O	O	either
O	O	BRCA1
O	O	(
O	O	179
O	O	women
O	O	)
O	O	or
O	O	BRCA2
O	O	(
O	O	28
O	O	women
O	O	)
O	O	.
O	O	The
O	O	control
O	O	women
O	O	were
O	O	enrolled
O	O	regardless
O	O	of
O	O	whether
O	O	or
O	O	not
O	O	they
O	O	had
O	O	either
O	O	mutation
O	O	.
O	O	Lifetime
O	O	histories
O	O	of
O	O	oral
O	O	-
O	O	contraceptive
O	O	use
O	O	were
O	O	obtained
O	O	by
O	O	interview
O	O	or
O	O	by
O	O	written
O	O	questionnaire
O	O	and
O	O	were
O	O	compared
O	O	between
O	O	patients
O	O	and
O	O	control
O	O	women
O	O	,
O	O	after
O	O	adjustment
O	O	for
O	O	year
O	O	of
O	O	birth
O	O	and
O	O	parity
O	O	.
O	O	RESULTS
O	O	The
O	O	adjusted
O	O	odds
O	O	ratio
O	O	for
B	B	ovarian
I	I	cancer
O	O	associated
O	O	with
O	O	any
O	O	past
O	O	use
O	O	of
O	O	oral
O	O	contraceptives
O	O	was
O	O	0
O	O	.
O	O	5
O	O	(
O	O	95
O	O	percent
O	O	confidence
O	O	interval
O	O	,
O	O	0
O	O	.
O	O	3
O	O	to
O	O	0
O	O	.
O	O	8
O	O	)
O	O	.
O	O	The
O	O	risk
O	O	decreased
O	O	with
O	O	increasing
O	O	duration
O	O	of
O	O	use
O	O	(
O	O	P
O	O	for
O	O	trend
O	O	,
O	O	<
O	O	0
O	O	.
O	O	001
O	O	)
O	O	;
O	O	use
O	O	for
O	O	six
O	O	or
O	O	more
O	O	years
O	O	was
O	O	associated
O	O	with
O	O	a
O	O	60
O	O	percent
O	O	reduction
O	O	in
O	O	risk
O	O	.
O	O	Oral
O	O	-
O	O	contraceptive
O	O	use
O	O	protected
O	O	against
B	B	ovarian
I	I	cancer
O	O	both
O	O	for
O	O	carriers
O	O	of
O	O	the
O	O	BRCA1
O	O	mutation
O	O	(
O	O	odds
O	O	ratio
O	O	,
O	O	0
O	O	.
O	O	5
O	O	;
O	O	95
O	O	percent
O	O	confidence
O	O	interval
O	O	,
O	O	0
O	O	.
O	O	3
O	O	to
O	O	0
O	O	.
O	O	9
O	O	)
O	O	and
O	O	for
O	O	carriers
O	O	of
O	O	the
O	O	BRCA2
O	O	mutation
O	O	(
O	O	odds
O	O	ratio
O	O	,
O	O	0
O	O	.
O	O	4
O	O	;
O	O	95
O	O	percent
O	O	confidence
O	O	interval
O	O	,
O	O	0
O	O	.
O	O	2
O	O	to
O	O	1
O	O	.
O	O	1
O	O	)
O	O	.
O	O	CONCLUSIONS
O	O	Oral
O	O	-
O	O	contraceptive
O	O	use
O	O	may
O	O	reduce
O	O	the
O	O	risk
O	O	of
B	B	ovarian
I	I	cancer
O	O	in
O	O	women
O	O	with
O	O	pathogenic
O	O	mutations
O	O	in
O	O	the
O	O	BRCA1
O	O	or
O	O	BRCA2
O	O	gene
O	O	A
O	O	Japanese
O	O	family
O	O	with
B	B	adrenoleukodystrophy
O	O	with
O	O	a
O	O	codon
O	O	291
O	O	deletion
O	O	:
O	O	a
O	O	clinical
O	O	,
O	O	biochemical
O	O	,
O	O	pathological
O	O	,
O	O	and
O	O	genetic
O	O	report
O	O	.
O	O	We
O	O	report
O	O	a
O	O	Japanese
O	O	family
O	O	with
B	B	adrenoleukodystrophy
O	O	(
B	B	ALD
O	O	)
O	O	with
O	O	a
O	O	three
O	O	base
O	O	pair
O	O	deletion
O	O	(
O	O	delGAG
O	O	291
O	O	)
O	O	in
O	O	the
B	B	ALD
O	O	gene
O	O	.
O	O	A
O	O	variety
O	O	of
O	O	phenotypes
O	O	were
O	O	observed
O	O	within
O	O	this
O	O	family
O	O	.
O	O	While
O	O	the
O	O	proband
O	O	(
O	O	patient
O	O	1
O	O	)
O	O	was
O	O	classified
O	O	as
O	O	having
O	O	a
O	O	rare
O	O	intermediate
O	O	type
O	O	of
O	O	adult
O	O	cerebral
O	O	and
O	O	cerebello
O	O	-
O	O	brain
O	O	stem
O	O	forms
O	O	,
O	O	his
O	O	younger
O	O	brother
O	O	(
O	O	patient
O	O	2
O	O	)
O	O	and
O	O	nephew
O	O	(
O	O	patient
O	O	3
O	O	)
O	O	had
O	O	a
O	O	childhood
B	B	ALD
O	O	type
O	O	.
O	O	Another
O	O	nephew
O	O	(
O	O	patient
O	O	4
O	O	)
O	O	of
O	O	patient
O	O	1
O	O	was
O	O	classified
O	O	as
O	O	having
O	O	an
O	O	adolescent
O	O	form
O	O	.
O	O	The
O	O	tau
O	O	level
O	O	in
O	O	the
O	O	cerebrospinal
O	O	fluid
O	O	(
O	O	CSF
O	O	)
O	O	in
O	O	patient
O	O	1
O	O	was
O	O	as
O	O	high
O	O	as
O	O	that
O	O	of
O	O	patients
O	O	with
B	B	Alzheimers
I	I	disease
O	O	(
B	B	AD
O	O	)
O	O	.
O	O	His
O	O	brain
O	O	magnetic
O	O	resonance
O	O	image
O	O	(
O	O	MRI
O	O	)
O	O	showed
O	B	abnormalities
O	I	in
O	I	the
O	I	bilateral
O	I	cerebellar
O	I	hemispheres
O	O	and
O	O	brain
O	O	stem
O	O	,
O	O	but
O	O	not
O	O	in
O	O	the
O	O	cerebral
O	O	white
O	O	matter
O	O	,
O	O	where
O	O	marked
O	O	reductions
O	O	of
O	O	the
O	O	cerebral
O	O	blood
O	O	flow
O	O	and
O	O	oxygen
O	O	metabolism
O	O	were
O	O	clearly
O	O	demonstrated
O	O	by
O	O	positron
O	O	emission
O	O	tomography
O	O	(
O	O	PET
O	O	)
O	O	.
O	O	In
O	O	patients
O	O	2
O	O	and
O	O	3
O	O	,
O	O	the
O	O	autopsy
O	O	findings
O	O	showed
O	O	massive
O	B	demyelination
O	I	of
O	I	the
O	I	cerebral
I	I	white
I	I	matter
O	O	with
O	O	sparing
O	O	of
O	O	the
O	O	U
O	O	-
O	O	fibers
O	O	,
O	O	compatible
O	O	with
O	O	the
O	O	findings
O	O	of
O	O	childhood
B	B	ALD
O	O	.
O	O	Oleic
O	O	and
O	O	erucic
O	O	acids
O	O	(
O	O	Lorenzos
O	O	Oil
O	O	)
O	O	were
O	O	administered
O	O	to
O	O	patients
O	O	1
O	O	and
O	O	4
O	O	,
O	O	but
O	O	sufficient
O	O	effectiveness
O	O	was
O	O	not
O	O	obtained
O	O	.
O	O	The
O	O	findings
O	O	in
O	O	this
O	O	family
O	O	suggest
O	O	that
O	O	delGAG291
O	O	is
O	O	part
O	O	of
O	O	the
O	O	cause
O	O	of
O	O	Japanese
B	B	ALD
O	O	with
O	O	phenotypic
O	O	variations
O	O	.
O	O	Moreover
O	O	,
O	O	although
O	O	the
O	O	scale
O	O	of
O	O	the
O	O	study
O	O	is
O	O	limited
O	O	,
O	O	there
O	O	is
O	O	a
O	O	possibility
O	O	that
O	O	PET
O	O	can
O	O	detect
O	O	an
B	B	insidious
I	I	lesion
O	O	which
O	O	is
O	O	undetectable
O	O	by
O	O	computed
O	O	tomogram
O	O	(
O	O	CT
O	O	)
O	O	or
O	O	MRI
O	O	analysis
O	O	,
O	O	and
O	O	that
O	O	the
O	O	higher
O	O	level
O	O	of
O	O	tau
O	O	reflects
O	O	the
O	O	process
O	O	of
B	B	neuronal
I	I	degeneration
O	O	in
B	B	ALD
O	O	.
O	O	Lorenzos
O	O	Oil
O	O	should
O	O	be
O	O	given
O	O	in
O	O	the
O	O	early
O	O	stage
O	O	.
O	O	.
O	O	Nonsense
O	O	mutation
O	O	in
O	O	exon
O	O	4
O	O	of
O	O	human
O	O	complement
O	O	C9
O	O	gene
O	O	is
O	O	the
O	O	major
O	O	cause
O	O	of
O	O	Japanese
B	B	complement
I	I	C9
I	I	deficiency
O	O	.
B	B	Deficiency
I	I	of
I	I	the
I	I	ninth
I	I	component
I	I	of
I	I	human
I	I	complement
O	O	(
B	O	C9
O	O	)
O	O	is
O	O	the
O	O	most
O	O	common
B	B	complement
I	I	deficiency
O	O	in
O	O	Japan
O	O	but
O	O	is
O	O	rare
O	O	in
O	O	other
O	O	countries
O	O	.
O	O	We
O	O	studied
O	O	the
O	O	molecular
O	O	basis
O	O	of
B	B	C9
I	I	deficiency
O	O	in
O	O	four
O	O	Japanese
B	B	C9
I	I	-
I	I	deficient
O	O	patients
O	O	who
O	O	had
O	O	suffered
O	O	from
B	B	meningococcal
I	I	meningitis
O	O	.
O	O	Direct
O	O	sequencing
O	O	of
O	O	amplified
O	O	C9
O	O	cDNA
O	O	and
O	O	DNA
O	O	revealed
O	O	a
O	O	nonsense
O	O	substitution
O	O	(
O	O	CGA
O	O	-
O	O	-
O	O	>
O	O	TGA
O	O	)
O	O	at
O	O	codon
O	O	95
O	O	in
O	O	exon
O	O	4
O	O	in
O	O	the
O	O	four
B	B	C9
I	I	-
I	I	deficient
O	O	individuals
O	O	.
O	O	An
O	O	allele
O	O	-
O	O	specific
O	O	polymerase
O	O	chain
O	O	reaction
O	O	system
O	O	designed
O	O	to
O	O	detect
O	O	exclusively
O	O	only
O	O	one
O	O	of
O	O	the
O	O	normal
O	O	and
O	O	mutant
O	O	alleles
O	O	indicated
O	O	that
O	O	all
O	O	the
O	O	four
O	O	patients
O	O	were
O	O	homozygous
O	O	for
O	O	the
O	O	mutation
O	O	in
O	O	exon
O	O	4
O	O	and
O	O	that
O	O	the
O	O	parents
O	O	of
O	O	patient
O	O	2
O	O	were
O	O	heterozygous
O	O	.
O	O	The
O	O	common
O	O	mutation
O	O	at
O	O	codon
O	O	95
O	O	in
O	O	exon
O	O	4
O	O	might
O	O	be
O	O	responsible
O	O	for
O	O	most
O	O	Japanese
B	B	C9
I	I	deficiency
O	O	.
O	O	.
O	O	BRCA1
O	O	required
O	O	for
O	O	transcription
O	O	-
O	O	coupled
O	O	repair
O	O	of
O	O	oxidative
O	O	DNA
O	O	damage
O	O	.
O	O	The
B	B	breast
I	I	and
I	I	ovarian
I	I	cancer
O	O	susceptibility
O	O	gene
O	O	BRCA1
O	O	encodes
O	O	a
O	O	zinc
O	O	finger
O	O	protein
O	O	of
O	O	unknown
O	O	function
O	O	.
O	O	Association
O	O	of
O	O	the
O	O	BRCA1
O	O	protein
O	O	with
O	O	the
O	O	DNA
O	O	repair
O	O	protein
O	O	Rad51
O	O	and
O	O	changes
O	O	in
O	O	the
O	O	phosphorylation
O	O	and
O	O	cellular
O	O	localization
O	O	of
O	O	the
O	O	protein
O	O	after
O	O	exposure
O	O	to
O	O	DNA
O	O	-
O	O	damaging
O	O	agents
O	O	are
O	O	consistent
O	O	with
O	O	a
O	O	role
O	O	for
O	O	BRCA1
O	O	in
O	O	DNA
O	O	repair
O	O	.
O	O	Here
O	O	,
O	O	it
O	O	is
O	O	shown
O	O	that
O	O	mouse
O	O	embryonic
O	O	stem
O	O	cells
O	B	deficient
O	I	in
O	I	BRCA1
O	O	are
O	O	defective
O	O	in
O	O	the
O	O	ability
O	O	to
O	O	carry
O	O	out
O	O	transcription
O	O	-
O	O	coupled
O	O	repair
O	O	of
O	O	oxidative
O	O	DNA
O	O	damage
O	O	,
O	O	and
O	O	are
O	O	hypersensitive
O	O	to
O	O	ionizing
O	O	radiation
O	O	and
O	O	hydrogen
O	O	peroxide
O	O	.
O	O	These
O	O	results
O	O	suggest
O	O	that
O	O	BRCA1
O	O	participates
O	O	,
O	O	directly
O	O	or
O	O	indirectly
O	O	,
O	O	in
O	O	transcription
O	O	-
O	O	coupled
O	O	repair
O	O	of
O	O	oxidative
O	O	DNA
O	O	damage
O	O	.
O	O	.
O	O	Truncation
O	O	mutations
O	O	in
O	O	the
O	O	transactivation
O	O	region
O	O	of
O	O	PAX6
O	O	result
O	O	in
O	O	dominant
O	O	-
O	O	negative
O	O	mutants
O	O	.
O	O	PAX6
O	O	is
O	O	a
O	O	transcription
O	O	factor
O	O	with
O	O	two
O	O	DNA
O	O	-
O	O	binding
O	O	domains
O	O	(
O	O	paired
O	O	box
O	O	and
O	O	homeobox
O	O	)
O	O	and
O	O	a
O	O	proline
O	O	-
O	O	serine
O	O	-
O	O	threonine
O	O	(
O	O	PST
O	O	)
O	O	-
O	O	rich
O	O	transactivation
O	O	domain
O	O	.
O	O	PAX6
O	O	regulates
O	O	eye
O	O	development
O	O	in
O	O	animals
O	O	ranging
O	O	from
O	O	jellyfish
O	O	to
O	O	Drosophila
O	O	to
O	O	humans
O	O	.
O	O	Heterozygous
O	O	mutations
O	O	in
O	O	the
O	O	human
O	O	PAX6
O	O	gene
O	O	result
O	O	in
O	O	various
O	O	phenotypes
O	O	,
O	O	including
B	B	aniridia
O	O	,
B	B	Peters
I	I	anomaly
O	O	,
B	B	autosomal
I	I	dominant
I	I	keratitis
O	O	,
O	O	and
B	B	familial
I	I	foveal
I	I	dysplasia
O	O	.
O	O	It
O	O	is
O	O	believed
O	O	that
O	O	the
O	O	mutated
O	O	allele
O	O	of
O	O	PAX6
O	O	produces
O	O	an
O	O	inactive
O	O	protein
O	O	and
B	B	aniridia
O	O	is
O	O	caused
O	O	due
O	O	to
B	O	genetic
B	O	haploinsufficiency
O	O	.
O	O	However
O	O	,
O	O	several
O	O	truncation
O	O	mutations
O	O	have
O	O	been
O	O	found
O	O	to
O	O	occur
O	O	in
O	O	the
O	O	C
O	O	-
O	O	terminal
O	O	half
O	O	of
O	O	PAX6
O	O	in
O	O	patients
O	O	with
B	B	Aniridia
O	O	resulting
O	O	in
O	O	mutant
O	O	proteins
O	O	that
O	O	retain
O	O	the
O	O	DNA
O	O	-
O	O	binding
O	O	domains
O	O	but
O	O	have
O	O	lost
O	O	most
O	O	of
O	O	the
O	O	transactivation
O	O	domain
O	O	.
O	O	It
O	O	is
O	O	not
O	O	clear
O	O	whether
O	O	such
O	O	mutants
O	O	really
O	O	behave
O	O	as
O	O	loss
O	O	-
O	O	of
O	O	-
O	O	function
O	O	mutants
O	O	as
O	O	predicted
O	O	by
B	O	haploinsufficiency
O	O	.
O	O	Contrary
O	O	to
O	O	this
O	O	theory
O	O	,
O	O	our
O	O	data
O	O	showed
O	O	that
O	O	these
O	O	mutants
O	O	are
O	O	dominant
O	O	-
O	O	negative
O	O	in
O	O	transient
O	O	transfection
O	O	assays
O	O	when
O	O	they
O	O	are
O	O	coexpressed
O	O	with
O	O	wild
O	O	-
O	O	type
O	O	PAX6
O	O	.
O	O	We
O	O	found
O	O	that
O	O	the
O	O	dominant
O	O	-
O	O	negative
O	O	effects
O	O	result
O	O	from
O	O	the
O	O	enhanced
O	O	DNA
O	O	binding
O	O	ability
O	O	of
O	O	these
O	O	mutants
O	O	.
O	O	Kinetic
O	O	studies
O	O	of
O	O	binding
O	O	and
O	O	dissociation
O	O	revealed
O	O	that
O	O	various
O	O	truncation
O	O	mutants
O	O	have
O	O	3
O	O	-
O	O	5
O	O	-
O	O	fold
O	O	higher
O	O	affinity
O	O	to
O	O	various
O	O	DNA
O	O	-
O	O	binding
O	O	sites
O	O	when
O	O	compared
O	O	with
O	O	the
O	O	wild
O	O	-
O	O	type
O	O	PAX6
O	O	.
O	O	These
O	O	results
O	O	provide
O	O	a
O	O	new
O	O	insight
O	O	into
O	O	the
O	O	role
O	O	of
O	O	mutant
O	O	PAX6
O	O	in
O	O	causing
B	B	aniridia
O	O	.
O	O	.
O	O	Reversal
O	O	of
O	O	severe
B	B	hypertrophic
I	I	cardiomyopathy
O	O	and
O	O	excellent
O	O	neuropsychologic
O	O	outcome
O	O	in
O	B	very
O	I	-
O	I	long
O	I	-
O	I	chain
O	I	acyl
O	I	-
O	I	coenzyme
I	I	A
I	I	dehydrogenase
I	I	deficiency
O	O	.
B	B	Very
I	I	-
I	I	long
I	I	-
I	I	chain
I	I	acyl
I	I	-
I	I	coenzyme
I	I	A
I	I	dehydrogenase
I	I	(
B	I	VLCAD
I	I	)
I	I	deficiency
O	O	is
O	O	a
O	O	disorder
I	O	of
O	O	fatty
O	O	acid
O	O	beta
O	O	oxidation
O	O	that
O	O	reportedly
O	O	has
O	O	high
O	O	rates
O	O	of
B	O	morbidity
O	O	and
O	O	mortality
O	O	.
O	O	We
O	O	describe
O	O	the
O	O	outcome
O	O	of
O	O	a
O	O	5
O	O	-
O	O	year
O	O	-
O	O	old
O	O	girl
O	O	with
B	B	VLCAD
I	I	deficiency
O	O	who
O	O	was
O	O	first
O	O	seen
O	O	at
O	O	5
O	O	months
O	O	of
O	O	age
O	O	with
O	O	severe
B	B	hypertrophic
I	I	cardiomyopathy
O	O	,
B	B	hepatomegaly
O	O	,
B	B	encephalopathy
O	O	,
O	O	and
B	B	hypotonia
O	O	.
O	O	Biochemical
O	O	studies
O	O	indicated
B	B	VLCAD
I	I	deficiency
O	O	caused
O	O	by
O	O	a
O	O	stable
O	O	yet
O	O	inactive
O	O	enzyme
O	O	.
O	O	Molecular
O	O	genetic
O	O	analysis
O	O	of
O	O	her
B	O	VLCAD
O	O	gene
O	O	revealed
O	O	a
O	O	T1372C
O	O	(
O	O	F458L
O	O	)
O	O	missense
O	O	mutation
O	O	and
O	O	a
O	O	1668
O	O	ACAG
O	O	1669
O	O	splice
O	O	site
O	O	mutation
O	O	.
O	O	After
O	O	initial
O	O	treatment
O	O	with
O	O	intravenous
O	O	glucose
O	O	and
O	O	carnitine
O	O	,
O	O	the
O	O	patient
O	O	has
O	O	thrived
O	O	on
O	O	a
O	O	low
O	O	-
O	O	fat
O	O	diet
O	O	supplemented
O	O	with
O	O	medium
O	O	-
O	O	chain
O	O	triglyceride
O	O	oil
O	O	and
O	O	carnitine
O	O	and
O	O	avoidance
O	O	of
O	O	fasting
O	O	.
O	O	Her
B	O	ventricular
I	O	hypertrophy
O	O	resolved
O	O	significantly
O	O	over
O	O	1
O	O	year
O	O	,
O	O	and
O	O	cognitively
O	O	,
O	O	she
O	O	is
O	O	in
O	O	the
O	O	superior
O	O	range
O	O	for
O	O	age
O	O	.
O	O	Clinical
O	O	recognition
O	O	of
B	B	VLCAD
I	I	deficiency
O	O	is
O	O	important
O	O	because
O	O	it
O	O	is
O	O	one
O	O	of
O	O	the
O	O	few
O	O	directly
O	O	treatable
O	O	causes
O	O	of
B	B	cardiomyopathy
O	O	in
O	O	children
O	O	.
O	O	.
O	O	Cloning
O	O	of
O	O	a
O	O	novel
O	O	member
O	O	of
O	O	the
O	O	low
O	O	-
O	O	density
O	O	lipoprotein
O	O	receptor
O	O	family
O	O	.
O	O	A
O	O	gene
O	O	encoding
O	O	a
O	O	novel
O	O	transmembrane
O	O	protein
O	O	was
O	O	identified
O	O	by
O	O	DNA
O	O	sequence
O	O	analysis
O	O	within
O	O	the
O	B	insulin
I	I	-
I	I	dependent
I	I	diabetes
I	I	mellitus
O	O	(
B	B	IDDM
O	O	)
O	O	locus
O	O	IDDM4
O	O	on
O	O	chromosome
O	O	11q13
O	O	.
O	O	Based
O	O	on
O	O	its
O	O	chromosomal
O	O	position
O	O	,
O	O	this
O	O	gene
O	O	is
O	O	a
O	O	candidate
O	O	for
O	O	conferring
O	O	susceptibility
O	O	to
O	B	diabetes
O	O	.
O	O	The
O	O	gene
O	O	,
O	O	termed
O	O	low
O	O	-
O	O	density
O	O	lipoprotein
O	O	receptor
O	O	related
O	O	protein
O	O	5
O	O	(
O	O	LRP5
O	O	)
O	O	,
O	O	encodes
O	O	a
O	O	protein
O	O	of
O	O	1615
O	O	amino
O	O	acids
O	O	that
O	O	contains
O	O	conserved
O	O	modules
O	O	which
O	O	are
O	O	characteristic
O	O	of
O	O	the
O	O	low
O	O	-
O	O	density
O	O	lipoprotein
O	O	(
O	O	LDL
O	O	)
O	O	receptor
O	O	family
O	O	.
O	O	These
O	O	modules
O	O	include
O	O	a
O	O	putative
O	O	signal
O	O	peptide
O	O	for
O	O	protein
O	O	export
O	O	,
O	O	four
O	O	epidermal
O	O	growth
O	O	factor
O	O	(
O	O	EGF
O	O	)
O	O	repeats
O	O	with
O	O	associated
O	O	spacer
O	O	domains
O	O	,
O	O	three
O	O	LDL
O	O	-
O	O	receptor
O	O	(
O	O	LDLR
O	O	)
O	O	repeats
O	O	,
O	O	a
O	O	single
O	O	transmembrane
O	O	spanning
O	O	domain
O	O	,
O	O	and
O	O	a
O	O	cytoplasmic
O	O	domain
O	O	.
O	O	The
O	O	encoded
O	O	protein
O	O	has
O	O	a
O	O	unique
O	O	organization
O	O	of
O	O	EGF
O	O	and
O	O	LDLR
O	O	repeats
O	O	;
O	O	therefore
O	O	,
O	O	LRP5
O	O	likely
O	O	represents
O	O	a
O	O	new
O	O	category
O	O	of
O	O	the
O	O	LDLR
O	O	family
O	O	.
O	O	Both
O	O	human
O	O	and
O	O	mouse
O	O	LRP5
O	O	cDNAs
O	O	have
O	O	been
O	O	isolated
O	O	and
O	O	the
O	O	encoded
O	O	mature
O	O	proteins
O	O	are
O	O	95
O	O	%
O	O	identical
O	O	,
O	O	indicating
O	O	a
O	O	high
O	O	degree
O	O	of
O	O	evolutionary
O	O	conservation
O	O	.
O	O	.
O	O	The
B	B	APC
O	O	variants
O	O	I1307K
O	O	and
O	O	E1317Q
O	O	are
O	O	associated
O	O	with
B	B	colorectal
I	I	tumors
O	O	,
O	O	but
O	O	not
O	O	always
O	O	with
O	O	a
O	O	family
O	O	history
O	O	.
B	O	Classical
B	B	familial
I	I	adenomatous
I	I	polyposis
O	O	(
B	B	FAP
O	O	)
O	O	is
O	O	a
O	O	high
O	O	-
O	O	penetrance
B	B	autosomal
I	I	dominant
I	I	disease
O	O	that
O	O	predisposes
O	O	to
O	O	hundreds
O	O	or
O	O	thousands
O	O	of
B	B	colorectal
I	I	adenomas
O	I	and
B	I	carcinoma
O	O	and
O	O	that
O	O	results
O	O	from
O	O	truncating
O	O	mutations
O	O	in
O	O	the
B	B	APC
O	O	gene
O	O	.
O	O	A
O	O	variant
O	O	of
B	B	FAP
O	O	is
B	B	attenuated
B	I	adenomatous
I	I	polyposis
I	I	coli
O	O	,
O	O	which
O	O	results
O	O	from
O	O	germ
O	O	-
O	O	line
O	O	mutations
O	O	in
O	O	the
O	O	5
O	O	and
O	O	3
O	O	regions
O	O	of
O	O	the
B	B	APC
O	O	gene
O	O	.
B	B	Attenuated
I	I	adenomatous
I	I	polyposis
I	I	coli
O	O	patients
O	O	have
O	O	""""
O	O	multiple
O	O	""""
B	B	colorectal
I	I	adenomas
O	O	(
O	O	typically
O	O	fewer
O	O	than
O	O	100
O	O	)
O	O	without
O	O	the
B	O	florid
O	O	phenotype
O	O	of
O	O	classical
B	B	FAP
O	O	.
O	O	Another
O	O	group
O	O	of
O	O	patients
O	O	with
B	O	multiple
B	B	adenomas
O	O	has
O	O	no
O	O	mutations
O	O	in
O	O	the
B	B	APC
O	O	gene
O	O	,
O	O	and
O	O	their
O	O	phenotype
O	O	probably
O	O	results
O	O	from
O	O	variation
O	O	at
O	O	a
O	O	locus
O	O	,
O	O	or
O	O	loci
O	O	,
O	O	elsewhere
O	O	in
O	O	the
O	O	genome
O	O	.
O	O	Recently
O	O	,
O	O	however
O	O	,
O	O	a
O	O	missense
O	O	variant
O	O	of
B	B	APC
O	O	(
O	O	I1307K
O	O	)
O	O	was
O	O	described
O	O	that
O	O	confers
O	O	an
O	O	increased
O	O	risk
O	O	of
B	B	colorectal
I	I	tumors
O	O	,
O	O	including
B	O	multiple
B	B	adenomas
O	O	,
O	O	in
O	O	Ashkenazim
O	O	.
O	O	We
O	O	have
O	O	studied
O	O	a
O	O	set
O	O	of
O	O	164
O	O	patients
O	O	with
O	O	multiple
B	B	colorectal
I	I	adenomas
O	I	and
O	I	/
O	I	or
B	I	carcinoma
O	O	and
O	O	analyzed
O	O	codons
O	O	1263
O	O	-
O	O	1377
O	O	(
O	O	exon
O	O	15G
O	O	)
O	O	of
O	O	the
B	B	APC
O	O	gene
O	O	for
O	O	germ
O	O	-
O	O	line
O	O	variants
O	O	.
O	O	Three
O	O	patients
O	O	with
O	O	the
O	O	I1307K
O	O	allele
O	O	were
O	O	detected
O	O	,
O	O	each
O	O	of
O	O	Ashkenazi
O	O	descent
O	O	.
O	O	Four
O	O	patients
O	O	had
O	O	a
O	O	germ
O	O	-
O	O	line
O	O	E1317Q
O	O	missense
O	O	variant
O	O	of
B	O	APC
O	O	that
O	O	was
O	O	not
O	O	present
O	O	in
O	O	controls
O	O	;
O	O	one
O	O	of
O	O	these
O	O	individuals
O	O	had
O	O	an
O	O	unusually
O	O	large
O	O	number
O	O	of
B	B	metaplastic
I	I	polyps
I	I	of
I	I	the
I	I	colorectum
O	O	.
O	O	There
O	O	is
O	O	increasing
O	O	evidence
O	O	that
O	O	there
O	O	exist
O	O	germ
O	O	-
O	O	line
O	O	variants
O	O	of
O	O	the
B	B	APC
O	O	gene
O	O	that
O	O	predispose
O	O	to
O	O	the
O	O	development
O	O	of
O	O	multiple
B	B	colorectal
I	I	adenomas
O	I	and
B	I	carcinoma
O	O	,
O	O	but
O	O	without
O	O	the
O	O	florid
O	O	phenotype
O	O	of
O	O	classical
B	B	FAP
O	O	,
O	O	and
O	O	possibly
O	O	with
O	O	importance
O	O	for
B	B	colorectal
I	I	cancer
O	O	risk
O	O	in
O	O	the
O	O	general
O	O	population
O	O	.
O	O	.
O	O	Genomic
O	O	structure
O	O	of
O	O	the
O	O	human
B	B	congenital
I	I	chloride
I	I	diarrhea
O	O	(
B	B	CLD
O	O	)
O	O	gene
O	O	.
B	B	Congenital
I	I	chloride
I	I	diarrhea
O	O	(
B	B	CLD
O	O	)
O	O	is
O	O	caused
O	O	by
O	O	mutations
O	O	in
O	O	a
O	O	gene
O	O	which
O	O	encodes
O	O	an
O	O	intestinal
O	O	anion
O	O	transporter
O	O	.
O	O	We
O	O	report
O	O	here
O	O	the
O	O	complete
O	O	genomic
O	O	organization
O	O	of
O	O	the
O	O	human
B	B	CLD
O	O	gene
O	O	which
O	O	spans
O	O	approximately
O	O	39kb
O	O	,
O	O	and
O	O	comprises
O	O	21
O	O	exons
O	O	.
O	O	All
O	O	exon
O	O	/
O	O	intron
O	O	boundaries
O	O	conform
O	O	to
O	O	the
O	O	GT
O	O	/
O	O	AG
O	O	rule
O	O	.
O	O	An
O	O	analysis
O	O	of
O	O	the
O	O	putative
O	O	promoter
O	O	region
O	O	sequence
O	O	shows
O	O	a
O	O	putative
O	O	TATA
O	O	box
O	O	and
O	O	predicts
O	O	multiple
O	O	transcription
O	O	factor
O	O	binding
O	O	sites
O	O	.
O	O	The
O	O	genomic
O	O	structure
O	O	was
O	O	determined
O	O	using
O	O	DNA
O	O	from
O	O	several
O	O	sources
O	O	including
O	O	multiple
O	O	large
O	O	-
O	O	insert
O	O	libaries
O	O	and
O	O	genomic
O	O	DNA
O	O	from
O	O	Finnish
B	B	CLD
O	O	patients
O	O	and
O	O	controls
O	O	.
O	O	Exon
O	O	-
O	O	specific
O	O	primers
O	O	developed
O	O	in
O	O	this
O	O	study
O	O	will
O	O	facilitate
O	O	mutation
O	O	screening
O	O	studies
O	O	of
O	O	patients
O	O	with
O	O	the
O	O	disease
O	O	.
O	O	Genomic
O	O	sequencing
O	O	of
O	O	a
B	O	BAC
O	O	clone
O	O	H
O	O	_
O	O	RG364P16
O	O	revealed
O	O	the
O	O	presence
O	O	of
O	O	another
O	O	,
O	O	highly
O	O	homologous
O	O	gene
O	O	3
O	O	of
O	O	the
O	B	CLD
O	O	gene
O	O	,
O	O	with
O	O	a
O	O	similar
O	O	genomic
O	O	structure
O	O	,
O	O	recently
O	O	identified
O	O	as
O	O	the
B	B	Pendred
I	I	syndrome
O	O	gene
O	O	(
B	B	PDS
O	O	)
O	O	.
O	O	.
O	O	The
O	O	APCI1307K
O	O	allele
O	O	and
B	B	cancer
O	O	risk
O	O	in
O	O	a
O	O	community
O	O	-
O	O	based
O	O	study
O	O	of
O	O	Ashkenazi
O	O	Jews
O	O	.
O	O	Mutations
O	O	in
B	O	APC
O	O	are
O	O	classically
O	O	associated
O	O	with
B	B	familial
I	I	adenomatous
I	I	polyposis
O	O	(
B	B	FAP
O	O	)
O	O	,
O	O	a
O	O	highly
O	O	penetrant
B	B	autosomal
I	I	dominant
I	I	disorder
O	O	characterized
O	O	by
O	O	multiple
I	O	intestinal
I	B	polyps
O	O	and
O	O	,
O	O	without
O	O	surgical
O	O	intervention
O	O	,
O	O	the
O	O	development
O	O	of
B	B	colorectal
I	I	cancer
O	O	(
B	B	CRC
O	O	)
O	O	.
O	B	APC
O	O	is
O	O	a
B	O	tumour
O	O	-
O	O	suppressor
O	O	gene
O	O	,
O	O	and
O	O	somatic
O	O	loss
O	O	occurs
O	O	in
B	B	tumours
O	O	.
O	O	The
O	O	germline
O	O	T
O	O	-
O	O	to
O	O	-
O	O	A
O	O	transversion
O	O	responsible
O	O	for
O	O	the
B	O	APC
O	O	I1307K
O	O	allele
O	O	converts
O	O	the
O	O	wild
O	O	-
O	O	type
O	O	sequence
O	O	to
O	O	a
O	O	homopolymer
O	O	tract
O	O	(
O	O	A8
O	O	)
O	O	that
O	O	is
O	O	genetically
O	O	unstable
O	O	and
O	O	prone
O	O	to
O	O	somatic
O	O	mutation
O	O	.
O	O	The
O	O	I1307K
O	O	allele
O	O	was
O	O	found
O	O	in
O	O	6
O	O	.
O	O	1
O	O	%
O	O	of
O	O	unselected
O	O	Ashkenazi
O	O	Jews
O	O	and
O	O	higher
O	O	proportions
O	O	of
O	O	Ashkenazim
O	O	with
O	O	family
O	O	or
O	O	personal
O	O	histories
O	O	of
B	B	CRC
O	O	(
O	O	ref
O	O	.
O	O	2
O	O	)
O	O	.
O	O	To
O	O	evaluate
O	O	the
O	O	role
O	O	of
O	O	I1307K
O	O	in
O	B	cancer
O	O	,
O	O	we
O	O	genotyped
O	O	5
O	O	,
O	O	081
O	O	Ashkenazi
O	O	volunteers
O	O	in
O	O	a
O	O	community
O	O	survey
O	O	.
O	O	Risk
O	O	of
O	O	developing
B	B	colorectal
I	I	,
B	I	breast
I	I	and
I	I	other
I	I	cancers
O	O	were
O	O	compared
O	O	between
O	O	genotyped
O	O	I1307K
O	O	carriers
O	O	and
O	O	non
O	O	-
O	O	carriers
O	O	and
O	O	their
O	O	first
O	O	-
O	O	degree
O	O	relatives
O	O	.
O	O	Sperm
O	O	DNA
O	O	analysis
O	O	in
O	O	a
B	B	Friedreich
I	I	ataxia
O	O	premutation
O	O	carrier
O	O	suggests
O	O	both
O	O	meiotic
O	O	and
O	O	mitotic
O	O	expansion
O	O	in
O	O	the
B	B	FRDA
O	O	gene
O	O	.
B	B	Friedreich
I	I	ataxia
O	O	is
O	O	usually
O	O	caused
O	O	by
O	O	an
O	O	expansion
O	O	of
O	O	a
O	O	GAA
O	O	trinucleotide
O	O	repeat
O	O	in
O	O	intron
O	O	1
O	O	of
O	O	the
B	B	FRDA
O	O	gene
O	O	.
O	O	Occasionally
O	O	,
O	O	a
O	O	fully
O	O	expanded
O	O	allele
O	O	has
O	O	been
O	O	found
O	O	to
O	O	arise
O	O	from
O	O	a
O	O	premutation
O	O	of
O	O	100
O	O	or
O	O	less
O	O	triplet
O	O	repeats
O	O	.
O	O	We
O	O	have
O	O	examined
O	O	the
O	O	sperm
O	O	DNA
O	O	of
O	O	a
O	O	premutation
O	O	carrier
O	O	.
O	O	This
O	O	mans
O	O	leucocyte
O	O	DNA
O	O	showed
O	O	one
O	O	normal
O	O	allele
O	O	and
O	O	one
O	O	allele
O	O	of
O	O	approximately
O	O	100
O	O	repeats
O	O	.
O	O	His
O	O	sperm
O	O	showed
O	O	an
O	O	expanded
O	O	allele
O	O	in
O	O	a
O	O	tight
O	O	range
O	O	centering
O	O	on
O	O	a
O	O	size
O	O	of
O	O	approximately
O	O	320
O	O	trinucleotide
O	O	repeats
O	O	.
O	O	His
O	O	affected
O	O	son
O	O	has
O	O	repeat
O	O	sizes
O	O	of
O	O	1040
O	O	and
O	O	540
O	O	.
O	O	These
O	O	data
O	O	suggest
O	O	that
O	O	expansion
O	O	occurs
O	O	in
O	O	two
O	O	stages
O	O	,
O	O	the
O	O	first
O	O	during
O	O	meiosis
O	O	followed
O	O	by
O	O	a
O	O	second
O	O	mitotic
O	O	expansion
O	O	.
O	O	We
O	O	also
O	O	show
O	O	that
O	O	in
O	O	all
O	O	informative
O	O	carrier
O	O	father
O	O	to
O	O	affected
O	O	child
O	O	transmissions
O	O	,
O	O	with
O	O	the
O	O	notable
O	O	exception
O	O	of
O	O	the
O	O	premutation
O	O	carrier
O	O	,
O	O	the
O	O	expansion
O	O	size
O	O	decreases
O	O	.
O	O	.
O	O	The
O	O	R496H
O	O	mutation
O	O	of
O	O	arylsulfatase
O	O	A
O	O	does
O	O	not
O	O	cause
B	B	metachromatic
I	I	leukodystrophy
O	O	.
O	B	Deficiency
O	I	of
O	I	arylsulfatase
O	I	A
O	O	(
O	O	ARSA
O	O	)
O	O	enzyme
O	O	activity
O	O	causes
B	B	metachromatic
I	I	leukodystrophy
O	O	(
B	B	MLD
O	O	)
O	O	.
O	O	A
O	O	number
O	O	of
B	O	ARSA
O	O	gene
O	O	mutations
O	O	responsible
O	O	for
B	B	MLD
O	O	have
O	O	been
O	O	identified
O	O	.
O	O	Recently
O	O	,
O	O	the
O	O	R496H
O	O	mutation
O	O	of
O	O	ARSA
O	O	was
O	O	proposed
O	O	to
O	O	be
O	O	a
O	O	cause
O	O	of
B	B	MLD
O	O	(
O	O	Draghia
O	O	et
O	O	al
O	O	.
O	O	,
O	O	1997
O	O	)
O	O	.
O	O	We
O	O	have
O	O	investigated
O	O	the
O	O	R496H
O	O	mutation
O	O	and
O	O	found
O	O	this
O	O	mutation
O	O	at
O	O	a
O	O	relatively
O	O	high
O	O	frequency
O	O	in
O	O	an
O	O	African
O	O	American
O	O	population
O	O	(
O	O	f
O	O	=
O	O	0
O	O	.
O	O	09
O	O	,
O	O	n
O	O	=
O	O	61
O	O	subjects
O	O	)
O	O	.
O	O	The
O	O	ARSA
O	O	enzyme
O	O	activity
O	O	in
O	O	subjects
O	O	with
O	O	and
O	O	without
O	O	the
O	O	R496H
O	O	mutation
O	O	was
O	O	determined
O	O	and
O	O	found
O	O	to
O	O	be
O	O	normal
O	O	.
O	O	It
O	O	is
O	O	therefore
O	O	concluded
O	O	that
O	O	the
O	O	R496H
O	O	mutation
O	O	of
O	O	ARSA
O	O	does
O	O	not
O	O	negatively
O	O	influence
O	O	the
O	O	activity
O	O	of
O	O	ARSA
O	O	and
O	O	is
O	O	not
O	O	a
O	O	cause
O	O	of
B	B	MLD
O	O	Down
O	O	-
O	O	regulation
O	O	of
O	O	transmembrane
O	O	carbonic
O	O	anhydrases
O	O	in
B	B	renal
I	I	cell
I	I	carcinoma
O	O	cell
O	O	lines
O	O	by
O	O	wild
O	O	-
O	O	type
B	B	von
I	I	Hippel
I	I	-
I	I	Lindau
O	O	transgenes
O	O	.
O	O	To
O	O	discover
O	O	genes
O	O	involved
O	O	in
B	B	von
I	I	Hippel
I	I	-
I	I	Lindau
O	O	(
B	B	VHL
O	O	)
O	O	-
O	O	mediated
O	O	carcinogenesis
O	O	,
O	O	we
O	O	used
B	B	renal
I	I	cell
I	I	carcinoma
O	O	cell
O	O	lines
O	O	stably
O	O	transfected
O	O	with
O	O	wild
O	O	-
O	O	type
B	O	VHL
O	O	-
O	O	expressing
O	O	transgenes
O	O	.
O	O	Large
O	O	-
O	O	scale
O	O	RNA
O	O	differential
O	O	display
O	O	technology
O	O	applied
O	O	to
O	O	these
O	O	cell
O	O	lines
O	O	identified
O	O	several
O	O	differentially
O	O	expressed
O	O	genes
O	O	,
O	O	including
O	O	an
O	O	alpha
O	O	carbonic
O	O	anhydrase
O	O	gene
O	O	,
O	O	termed
O	O	CA12
O	O	.
O	O	The
O	O	deduced
O	O	protein
O	O	sequence
O	O	was
O	O	classified
O	O	as
O	O	a
O	O	one
O	O	-
O	O	pass
O	O	transmembrane
O	O	CA
O	O	possessing
O	O	an
O	O	apparently
O	O	intact
O	O	catalytic
O	O	domain
O	O	in
O	O	the
O	O	extracellular
O	O	CA
O	O	module
O	O	.
O	O	Reintroduced
O	O	wild
O	O	-
O	O	type
B	B	VHL
O	O	strongly
O	O	inhibited
O	O	the
O	O	overexpression
O	O	of
O	O	the
O	O	CA12
O	O	gene
O	O	in
O	O	the
B	O	parental
I	B	renal
I	I	cell
I	I	carcinoma
O	O	cell
O	O	lines
O	O	.
O	O	Similar
O	O	results
O	O	were
O	O	obtained
O	O	with
O	O	CA9
O	O	,
O	O	encoding
O	O	another
O	O	transmembrane
O	O	CA
O	O	with
O	O	an
O	O	intact
O	O	catalytic
O	O	domain
O	O	.
O	O	Although
O	O	both
O	O	domains
O	O	of
O	O	the
B	B	VHL
O	O	protein
O	O	contribute
O	O	to
O	O	regulation
O	O	of
O	O	CA12
O	O	expression
O	O	,
O	O	the
O	O	elongin
O	O	binding
O	O	domain
O	O	alone
O	O	could
O	O	effectively
O	O	regulate
O	O	CA9
O	O	expression
O	O	.
O	O	We
O	O	mapped
O	O	CA12
O	O	and
O	O	CA9
O	O	loci
O	O	to
O	O	chromosome
O	O	bands
O	O	15q22
O	O	and
O	O	17q21
O	O	.
O	O	2
O	O	respectively
O	O	,
O	O	regions
O	O	prone
O	O	to
O	O	amplification
O	O	in
O	O	some
O	O	human
B	B	cancers
O	O	.
O	O	Additional
O	O	experiments
O	O	are
O	O	needed
O	O	to
O	O	define
O	O	the
O	O	role
O	O	of
O	O	CA
O	O	IX
O	O	and
O	O	CA
O	O	XII
O	O	enzymes
O	O	in
O	O	the
O	O	regulation
O	O	of
O	O	pH
O	O	in
O	O	the
O	O	extracellular
O	O	microenvironment
O	O	and
O	O	its
O	O	potential
O	O	impact
O	O	on
B	B	cancer
O	O	cell
O	O	growth
O	O	.
O	O	A
O	O	gene
O	O	encoding
O	O	a
O	O	transmembrane
O	O	protein
O	O	is
O	O	mutated
O	O	in
O	O	patients
O	O	with
B	B	diabetes
I	I	mellitus
O	O	and
B	B	optic
I	I	atrophy
O	O	(
B	B	Wolfram
I	I	syndrome
O	O	)
O	O	.
B	B	Wolfram
I	I	syndrome
O	O	(
B	B	WFS
O	O	;
O	O	OMIM
O	O	222300
O	O	)
O	O	is
O	O	an
B	B	autosomal
I	I	recessive
I	I	neurodegenerative
I	I	disorder
O	O	defined
O	O	by
O	O	young
O	O	-
O	O	onset
B	O	non
I	O	-
B	O	immune
B	B	insulin
I	I	-
I	I	dependent
I	I	diabetes
I	I	mellitus
O	O	and
B	O	progressive
I	B	optic
I	I	atrophy
O	O	.
O	O	Linkage
O	O	to
O	O	markers
O	O	on
O	O	chromosome
O	O	4p
O	O	was
O	O	confirmed
O	O	in
O	O	five
O	O	families
O	O	.
O	O	On
O	O	the
O	O	basis
O	O	of
O	O	meiotic
O	O	recombinants
O	O	and
O	O	disease
O	O	-
O	O	associated
O	O	haplotypes
O	O	,
O	O	the
B	B	WFS
O	O	gene
O	O	was
O	O	localized
O	O	to
O	O	a
O	O	BAC
O	O	/
O	O	P1
O	O	contig
O	O	of
O	O	less
O	O	than
O	O	250
O	O	kb
O	O	.
O	O	Mutations
O	O	in
O	O	a
O	O	novel
O	O	gene
O	O	(
O	O	WFS1
O	O	)
O	O	encoding
O	O	a
O	O	putative
O	O	transmembrane
O	O	protein
O	O	were
O	O	found
O	O	in
O	O	all
O	O	affected
O	O	individuals
O	O	in
O	O	six
B	B	WFS
O	O	families
O	O	,
O	O	and
O	O	these
O	O	mutations
O	O	were
O	O	associated
O	O	with
O	O	the
O	O	disease
O	O	phenotype
O	O	.
O	O	WFS1
O	O	appears
O	O	to
O	O	function
O	O	in
O	O	survival
O	O	of
O	O	islet
O	O	beta
O	O	-
O	O	cells
O	O	and
O	O	neurons
O	O	.
O	O	.
O	O	Stable
O	O	interaction
O	O	between
O	O	the
O	O	products
O	O	of
O	O	the
O	O	BRCA1
O	O	and
O	O	BRCA2
O	B	tumor
O	O	suppressor
O	O	genes
O	O	in
O	O	mitotic
O	O	and
O	O	meiotic
O	O	cells
O	O	.
O	O	BRCA1
O	O	and
O	O	BRCA2
O	O	account
O	O	for
O	O	most
O	O	cases
O	O	of
B	O	familial
O	O	,
O	O	early
O	O	onset
B	B	breast
I	I	and
I	I	/
I	I	or
I	I	ovarian
I	I	cancer
O	O	and
O	O	encode
O	O	products
O	O	that
O	O	each
O	O	interact
O	O	with
O	O	hRAD51
O	O	.
O	O	Results
O	O	presented
O	O	here
O	O	show
O	O	that
O	O	BRCA1
O	O	and
O	O	BRCA2
O	O	coexist
O	O	in
O	O	a
O	O	biochemical
O	O	complex
O	O	and
O	O	colocalize
O	O	in
O	O	subnuclear
O	O	foci
O	O	in
O	O	somatic
O	O	cells
O	O	and
O	O	on
O	O	the
O	O	axial
O	O	elements
O	O	of
O	O	developing
O	O	synaptonemal
O	O	complexes
O	O	.
O	O	Like
O	O	BRCA1
O	O	and
O	O	RAD51
O	O	,
O	O	BRCA2
O	O	relocates
O	O	to
O	O	PCNA
O	O	+
O	O	replication
O	O	sites
O	O	following
O	O	exposure
O	O	of
O	O	S
O	O	phase
O	O	cells
O	O	to
O	O	hydroxyurea
O	O	or
O	O	UV
O	O	irradiation
O	O	.
O	O	Thus
O	O	,
O	O	BRCA1
O	O	and
O	O	BRCA2
O	O	participate
O	O	,
O	O	together
O	O	,
O	O	in
O	O	a
O	O	pathway
O	O	(
O	O	s
O	O	)
O	O	associated
O	O	with
O	O	the
O	O	activation
O	O	of
O	O	double
O	O	-
O	O	strand
O	O	break
O	O	repair
O	O	and
O	O	/
O	O	or
O	O	homologous
O	O	recombination
O	O	.
O	O	Dysfunction
O	O	of
O	O	this
O	O	pathway
O	O	may
O	O	be
O	O	a
O	O	general
O	O	phenomenon
O	O	in
O	O	the
O	O	majority
O	O	of
O	O	cases
O	O	of
B	B	hereditary
I	I	breast
I	I	and
I	I	/
I	I	or
I	I	ovarian
I	I	cancer
O	O	.
O	O	.
O	O	A
O	O	novel
O	O	Arg362Ser
O	O	mutation
O	O	in
O	O	the
O	O	sterol
O	O	27
O	O	-
O	O	hydroxylase
O	O	gene
O	O	(
O	O	CYP27
O	O	)
O	O	:
O	O	its
O	O	effects
O	O	on
O	O	pre
O	O	-
O	O	mRNA
O	O	splicing
O	O	and
O	O	enzyme
O	O	activity
O	O	.
O	O	A
O	O	novel
O	O	C
O	O	to
O	O	A
O	O	mutation
O	O	in
O	O	the
O	O	sterol
O	O	27
O	O	-
O	O	hydroxylase
O	O	gene
O	O	(
O	O	CYP27
O	O	)
O	O	was
O	O	identified
O	O	by
O	O	sequencing
O	O	amplified
O	O	CYP27
O	O	gene
O	O	products
O	O	from
O	O	a
O	O	patient
O	O	with
B	B	cerebrotendinous
I	I	xanthomatosis
O	O	(
B	B	CTX
O	O	)
O	O	.
O	O	The
O	O	mutation
O	O	changed
O	O	the
O	O	adrenodoxin
O	O	cofactor
O	O	binding
O	O	residue
O	O	362Arg
O	O	to
O	O	362Ser
O	O	(
O	O	CGT
O	O	362Arg
O	O	to
O	O	AGT
O	O	362Ser
O	O	)
O	O	,
O	O	and
O	O	was
O	O	responsible
O	O	for
O	O	deficiency
O	O	in
O	O	the
O	O	sterol
O	O	27
O	O	-
O	O	hydroxylase
O	O	activity
O	O	,
O	O	as
O	O	confirmed
O	O	by
O	O	expression
O	O	of
O	O	mutant
O	O	cDNA
O	O	into
O	O	COS
O	O	-
O	O	1
O	O	cells
O	O	.
O	O	Quantitative
O	O	analysis
O	O	showed
O	O	that
O	O	the
O	O	expression
O	O	of
O	O	CYP27
O	O	gene
O	O	mRNA
O	O	in
O	O	the
O	O	patient
O	O	represented
O	O	52
O	O	.
O	O	5
O	O	%
O	O	of
O	O	the
O	O	normal
O	O	level
O	O	.
O	O	As
O	O	the
O	O	mutation
O	O	occurred
O	O	at
O	O	the
O	O	penultimate
O	O	nucleotide
O	O	of
O	O	exon
O	O	6
O	O	(
O	O	-
O	O	2
O	O	position
O	O	of
O	O	exon
O	O	6
O	O	-
O	O	intron
O	O	6
O	O	splice
O	O	site
O	O	)
O	O	of
O	O	the
O	O	gene
O	O	,
O	O	we
O	O	hypothesized
O	O	that
O	O	the
O	O	mutation
O	O	may
O	O	partially
O	O	affect
O	O	the
O	O	normal
O	O	splicing
O	O	efficiency
O	O	in
O	O	exon
O	O	6
O	O	and
O	O	cause
O	O	alternative
O	O	splicing
O	O	elsewhere
O	O	,
O	O	which
O	O	resulted
O	O	in
O	O	decreased
O	O	transcript
O	O	in
O	O	the
O	O	patient
O	O	.
O	O	Transfection
O	O	of
O	O	constructed
O	O	minigenes
O	O	,
O	O	with
O	O	or
O	O	without
O	O	the
O	O	mutation
O	O	,
O	O	into
O	O	COS
O	O	-
O	O	1
O	O	cells
O	O	confirmed
O	O	that
O	O	the
O	O	mutant
O	O	minigene
O	O	was
O	O	responsible
O	O	for
O	O	a
O	O	mRNA
O	O	species
O	O	alternatively
O	O	spliced
O	O	at
O	O	an
O	O	activated
O	O	cryptic
O	O	5
O	O	splice
O	O	site
O	O	88
O	O	bp
O	O	upstream
O	O	from
O	O	the
O	O	3
O	O	end
O	O	of
O	O	exon
O	O	6
O	O	.
O	O	Our
O	O	data
O	O	suggest
O	O	that
O	O	the
O	O	C
O	O	to
O	O	A
O	O	mutation
O	O	at
O	O	the
O	O	penultimate
O	O	nucleotide
O	O	of
O	O	exon
O	O	6
O	O	of
O	O	the
O	O	CYP27
O	O	gene
O	O	not
O	O	only
O	O	causes
O	O	the
O	B	deficiency
O	I	in
O	I	the
O	I	sterol
O	I	27
O	I	-
O	I	hydroxylase
O	I	activity
O	O	,
O	O	but
O	O	also
O	O	partially
O	O	leads
O	O	to
O	O	alternative
O	O	pre
O	O	-
O	O	mRNA
O	O	splicing
O	O	of
O	O	the
O	O	gene
O	O	.
O	O	To
O	O	our
O	O	knowledge
O	O	,
O	O	this
O	O	is
O	O	the
O	O	first
O	O	report
O	O	regarding
O	O	effects
O	O	on
O	O	pre
O	O	-
O	O	mRNA
O	O	splicing
O	O	of
O	O	a
O	O	mutation
O	O	at
O	O	the
O	O	-
O	O	2
O	O	position
O	O	of
O	O	a
O	O	5
O	O	splice
O	O	site
O	O	.
O	O	ATM
O	O	germline
O	O	mutations
O	O	in
O	O	classical
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	patients
O	O	in
O	O	the
O	O	Dutch
O	O	population
O	O	.
O	O	Germline
O	O	mutations
O	O	in
O	O	the
O	O	ATM
O	O	gene
O	O	are
O	O	responsible
O	O	for
O	O	the
B	B	autosomal
I	I	recessive
I	I	disorder
B	B	ataxia
I	I	-
I	I	telangiectasia
O	O	(
B	B	A
I	I	-
I	I	T
O	O	)
O	O	.
O	O	In
O	O	our
O	O	study
O	O	,
O	O	we
O	O	have
O	O	determined
O	O	the
O	O	ATM
O	O	mutation
O	O	spectrum
O	O	in
O	O	19
O	O	classical
B	B	A
I	I	-
I	I	T
O	O	patients
O	O	,
O	O	including
O	O	some
O	O	immigrant
O	O	populations
O	O	,
O	O	as
O	O	well
O	O	as
O	O	12
O	O	of
O	O	Dutch
O	O	ethnic
O	O	origin
O	O	.
O	O	Both
O	O	the
O	O	protein
O	O	truncation
O	O	test
O	O	(
O	O	PTT
O	O	)
O	O	and
O	O	the
O	O	restriction
O	O	endonuclease
O	O	fingerprinting
O	O	(
O	O	REF
O	O	)
O	O	method
O	O	were
O	O	used
O	O	and
O	O	compared
O	O	for
O	O	their
O	O	detection
O	O	efficiency
O	O	,
O	O	identifying
O	O	76
O	O	%
O	O	and
O	O	60
O	O	%
O	O	of
O	O	the
O	O	mutations
O	O	,
O	O	respectively
O	O	.
O	O	Most
O	O	patients
O	O	were
O	O	found
O	O	to
O	O	be
O	O	compound
O	O	heterozygote
O	O	.
O	O	Seventeen
O	O	mutations
O	O	were
O	O	distinct
O	O	,
O	O	of
O	O	which
O	O	10
O	O	were
O	O	not
O	O	reported
O	O	previously
O	O	.
O	O	Mutations
O	O	are
O	O	small
O	O	deletions
O	O	or
O	O	point
O	O	mutations
O	O	frequently
O	O	affecting
O	O	splice
O	O	sites
O	O	.
O	O	Moreover
O	O	,
O	O	a
O	O	16
O	O	.
O	O	7
O	O	-
O	O	kb
O	O	genomic
O	O	deletion
O	O	of
O	O	the
O	O	3
O	O	end
O	O	of
O	O	the
O	O	gene
O	O	,
O	O	most
O	O	likely
O	O	a
O	O	result
O	O	of
O	O	recombination
O	O	between
O	O	two
O	O	LINE
O	O	elements
O	O	,
O	O	was
O	O	identified
O	O	.
O	O	The
O	O	most
O	O	frequently
O	O	found
O	O	mutation
O	O	,
O	O	identified
O	O	in
O	O	three
O	O	unrelated
O	O	Turkish
B	B	A
I	I	-
I	I	T
O	O	individuals
O	O	,
O	O	was
O	O	previously
O	O	described
O	O	to
O	O	be
O	O	a
O	O	Turkish
B	B	A
I	I	-
I	I	T
O	O	founder
O	O	mutation
O	O	.
O	O	The
O	O	presence
O	O	of
O	O	a
O	O	founder
O	O	mutation
O	O	among
O	O	relatively
O	O	small
O	O	ethnic
O	O	population
O	O	groups
O	O	in
O	O	Western
O	O	Europe
O	O	could
O	O	indicate
O	O	a
O	O	high
O	O	carrier
O	O	frequency
O	O	in
O	O	such
O	O	communities
O	O	.
O	O	In
O	O	patients
O	O	of
O	O	Dutch
O	O	ethnic
O	O	origin
O	O	,
O	O	however
O	O	,
O	O	no
O	O	significant
O	O	founder
O	O	effect
O	O	could
O	O	be
O	O	identified
O	O	.
O	O	The
O	O	observed
O	O	genetic
O	O	heterogeneity
O	O	including
O	O	the
O	O	relative
O	O	high
O	O	percentage
O	O	of
O	O	splice
O	O	-
O	O	site
O	O	mutations
O	O	had
O	O	no
O	O	reflection
O	O	on
O	O	the
O	O	phenotype
O	O	.
O	O	All
O	O	patients
O	O	manifested
O	O	classical
B	B	A
I	I	-
I	I	T
O	O	and
O	O	increased
O	O	cellular
O	O	radioresistant
O	O	DNA
O	O	synthesis
O	O	.
O	O	Determination
O	O	of
O	O	the
O	O	genomic
O	O	structure
O	O	of
O	O	the
O	O	COL4A4
O	O	gene
O	O	and
O	O	of
O	O	novel
O	O	mutations
O	O	causing
B	B	autosomal
I	I	recessive
B	I	Alport
I	I	syndrome
O	O	.
B	B	Autosomal
I	I	recessive
I	I	Alport
I	I	syndrome
O	O	is
O	O	a
O	O	progressive
B	B	hematuric
I	I	glomerulonephritis
O	O	characterized
O	O	by
B	B	glomerular
I	I	basement
I	I	membrane
I	I	abnormalities
O	O	and
O	O	associated
O	O	with
O	O	mutations
O	O	in
O	O	either
O	O	the
O	O	COL4A3
O	O	or
O	O	the
O	O	COL4A4
O	O	gene
O	O	,
O	O	which
O	O	encode
O	O	the
O	O	alpha3
O	O	and
O	O	alpha4
O	O	type
O	O	IV
O	O	collagen
O	O	chains
O	O	,
O	O	respectively
O	O	.
O	O	To
O	O	date
O	O	,
O	O	mutation
O	O	screening
O	O	in
O	O	the
O	O	two
O	O	genes
O	O	has
O	O	been
O	O	hampered
O	O	by
O	O	the
O	O	lack
O	O	of
O	O	genomic
O	O	structure
O	O	information
O	O	.
O	O	We
O	O	report
O	O	here
O	O	the
O	O	complete
O	O	characterization
O	O	of
O	O	the
O	O	48
O	O	exons
O	O	of
O	O	the
O	O	COL4A4
O	O	gene
O	O	,
O	O	a
O	O	comprehensive
O	O	gene
O	O	screen
O	O	,
O	O	and
O	O	the
O	O	subsequent
O	O	detection
O	O	of
O	O	10
O	O	novel
O	O	mutations
O	O	in
O	O	eight
O	O	patients
O	O	diagnosed
O	O	with
B	B	autosomal
I	I	recessive
B	I	Alport
I	I	syndrome
O	O	.
O	O	Furthermore
O	O	,
O	O	we
O	O	identified
O	O	a
O	O	glycine
O	O	to
O	O	alanine
O	O	substitution
O	O	in
O	O	the
O	O	collagenous
O	O	domain
O	O	that
O	O	is
O	O	apparently
O	O	silent
O	O	in
O	O	the
O	O	heterozygous
O	O	carriers
O	O	,
O	O	in
O	O	11
O	O	.
O	O	5
O	O	%
O	O	of
O	O	all
O	O	control
O	O	individuals
O	O	,
O	O	and
O	O	in
O	O	one
O	O	control
O	O	individual
O	O	homozygous
O	O	for
O	O	this
O	O	glycine
O	O	substitution
O	O	.
O	O	There
O	O	has
O	O	been
O	O	no
O	O	previous
O	O	finding
O	O	of
O	O	a
O	O	glycine
O	O	substitution
O	O	that
O	O	is
O	O	not
O	O	associated
O	O	with
O	O	any
O	O	obvious
O	O	phenotype
O	O	in
O	O	homozygous
O	O	individuals
O	O	.
O	O	Founder
O	O	BRCA1
O	O	and
O	O	BRCA2
O	O	mutations
O	O	in
O	O	French
O	O	Canadian
B	B	breast
I	I	and
I	I	ovarian
I	I	cancer
O	O	families
O	O	.
O	O	We
O	O	have
O	O	identified
O	O	four
O	O	mutations
O	O	in
O	O	each
O	O	of
O	O	the
B	B	breast
I	I	cancer
O	O	-
O	O	susceptibility
O	O	genes
O	O	,
O	O	BRCA1
O	O	and
O	O	BRCA2
O	O	,
O	O	in
O	O	French
O	O	Canadian
B	B	breast
I	I	cancer
O	O	and
B	B	breast
I	I	/
I	I	ovarian
I	I	cancer
O	O	families
O	O	from
O	O	Quebec
O	O	.
O	O	To
O	O	identify
O	O	founder
O	O	effects
O	O	,
O	O	we
O	O	examined
O	O	independently
O	O	ascertained
O	O	French
O	O	Canadian
O	B	cancer
O	O	families
O	O	for
O	O	the
O	O	distribution
O	O	of
O	O	these
O	O	eight
O	O	mutations
O	O	.
O	O	Mutations
O	O	were
O	O	found
O	O	in
O	O	41
O	O	of
O	O	97
O	O	families
O	O	.
O	O	Six
O	O	of
O	O	eight
O	O	mutations
O	O	were
O	O	observed
O	O	at
O	O	least
O	O	twice
O	O	.
O	O	The
O	O	BRCA1
O	O	C4446T
O	O	mutation
O	O	was
O	O	the
O	O	most
O	O	common
O	O	mutation
O	O	found
O	O	,
O	O	followed
O	O	by
O	O	the
O	O	BRCA2
O	O	8765delAG
O	O	mutation
O	O	.
O	O	Together
O	O	,
O	O	these
O	O	mutations
O	O	were
O	O	found
O	O	in
O	O	28
O	O	of
O	O	41
O	O	families
O	O	identified
O	O	to
O	O	have
O	O	a
O	O	mutation
O	O	.
O	O	The
O	O	odds
O	O	of
O	O	detection
O	O	of
O	O	any
O	O	of
O	O	the
O	O	four
O	O	BRCA1
O	O	mutations
O	O	was
O	O	18
O	O	.
O	O	7x
O	O	greater
O	O	if
O	O	one
O	O	or
O	O	more
O	O	cases
O	O	of
B	B	ovarian
I	I	cancer
O	O	were
O	O	also
O	O	present
O	O	in
O	O	the
O	O	family
O	O	.
O	O	The
O	O	odds
O	O	of
O	O	detection
O	O	of
O	O	any
O	O	of
O	O	the
O	O	four
O	O	BRCA2
O	O	mutations
O	O	was
O	O	5
O	O	.
O	O	3x
O	O	greater
O	O	if
O	O	there
O	O	were
O	O	at
O	O	least
O	O	five
O	O	cases
O	O	of
B	B	breast
I	I	cancer
O	O	in
O	O	the
O	O	family
O	O	.
O	O	Interestingly
O	O	,
O	O	the
O	O	presence
O	O	of
O	O	a
B	B	breast
I	I	cancer
O	O	case
O	O	<
O	O	36
O	O	years
O	O	of
O	O	age
O	O	was
O	O	strongly
O	O	predictive
O	O	of
O	O	the
O	O	presence
O	O	of
O	O	any
O	O	of
O	O	the
O	O	eight
O	O	mutations
O	O	screened
O	O	.
O	O	Carriers
O	O	of
O	O	the
O	O	same
O	O	mutation
O	O	,
O	O	from
O	O	different
O	O	families
O	O	,
O	O	shared
O	O	similar
O	O	haplotypes
O	O	,
O	O	indicating
O	O	that
O	O	the
O	O	mutant
O	O	alleles
O	O	were
O	O	likely
O	O	to
O	O	be
O	O	identical
O	O	by
O	O	descent
O	O	for
O	O	a
O	O	mutation
O	O	in
O	O	the
O	O	founder
O	O	population
O	O	.
O	O	The
O	O	identification
O	O	of
O	O	common
O	O	BRCA1
O	O	and
O	O	BRCA2
O	O	mutations
O	O	will
O	O	facilitate
O	O	carrier
O	O	detection
O	O	in
O	O	French
O	O	Canadian
B	B	breast
I	I	cancer
O	O	and
B	B	breast
I	I	/
I	I	ovarian
I	I	cancer
O	O	families
O	O	.
O	O	Are
O	O	Dp71
O	O	and
O	O	Dp140
O	O	brain
O	O	dystrophin
O	O	isoforms
O	O	related
O	O	to
B	B	cognitive
I	I	impairment
O	O	in
B	B	Duchenne
I	I	muscular
I	I	dystrophy
O	O	?
O	O	Molecular
O	O	study
O	O	and
O	O	neuropsychological
O	O	analysis
O	O	were
O	O	performed
O	O	concurrently
O	O	on
O	O	49
O	O	patients
O	O	with
B	B	Duchenne
I	I	muscular
I	I	dystrophy
O	O	(
B	B	DMD
O	O	)
O	O	in
O	O	order
O	O	to
O	O	find
O	O	a
O	O	molecular
O	O	explanation
O	O	for
O	O	the
B	B	cognitive
I	I	impairment
O	O	observed
O	O	in
O	O	most
B	B	DMD
O	O	patients
O	O	.
O	O	Complete
O	O	analysis
O	O	of
O	O	the
O	O	dystrophin
O	O	gene
O	O	was
O	O	performed
O	O	to
O	O	define
O	O	the
O	O	localization
O	O	of
O	O	deletions
O	O	and
O	O	duplications
O	O	in
O	O	relation
O	O	to
O	O	the
O	O	different
B	B	DMD
O	O	promoters
O	O	.
O	O	Qualitative
O	O	analysis
O	O	of
O	O	the
O	O	Dp71
O	O	transcript
O	O	and
O	O	testing
O	O	for
O	O	the
O	O	specific
O	O	first
O	O	exon
O	O	of
O	O	Dp140
O	O	were
O	O	also
O	O	carried
O	O	out
O	O	.
O	O	Neuropsychological
O	O	analysis
O	O	assessed
O	O	verbal
O	O	and
O	O	visuospatial
O	O	intelligence
O	O	,
O	O	verbal
O	O	memory
O	O	,
O	O	and
O	O	reading
O	O	skills
O	O	.
O	O	Comparison
O	O	of
O	O	molecular
O	O	and
O	O	psychometric
O	O	findings
O	O	demonstrated
O	O	that
O	O	deletions
O	O	and
O	O	duplications
O	O	that
O	O	were
O	O	localized
O	O	in
O	O	the
O	O	distal
O	O	part
O	O	of
O	O	the
O	O	gene
O	O	seemed
O	O	to
O	O	be
O	O	preferentially
O	O	associated
O	O	with
B	B	cognitive
I	I	impairment
O	O	.
O	O	Two
O	O	altered
O	O	Dp71
O	O	transcripts
O	O	and
O	O	two
O	O	deleted
O	O	Dp140
O	O	DNA
O	O	sequences
O	O	were
O	O	found
O	O	in
O	O	four
O	O	patients
O	O	with
O	O	severe
B	B	cerebral
I	I	dysfunction
O	O	.
O	O	These
O	O	findings
O	O	suggest
O	O	that
O	O	some
O	O	sequences
O	O	located
O	O	in
O	O	the
O	O	distal
O	O	part
O	O	of
O	O	the
O	O	gene
O	O	and
O	O	,
O	O	in
O	O	particular
O	O	,
O	O	some
B	B	DMD
O	O	isoforms
O	O	expressed
O	O	in
O	O	the
O	O	brain
O	O	may
O	O	be
O	O	related
O	O	to
O	O	the
B	B	cognitive
I	I	impairment
O	O	associated
O	O	with
B	B	DMD
O	O	.
O	O	.
O	O	I1307K
O	O	APC
O	O	and
O	O	hMLH1
O	O	mutations
O	O	in
O	O	a
O	O	non
O	O	-
O	O	Jewish
O	O	family
O	O	with
B	B	hereditary
I	I	non
I	I	-
I	I	polyposis
I	I	colorectal
I	I	cancer
O	O	.
O	O	We
O	O	describe
O	O	a
O	O	French
O	O	Canadian
B	B	hereditary
I	I	non
I	I	-
I	I	polyposis
I	I	colorectal
I	I	cancer
O	O	(
B	B	HNPCC
O	O	)
O	O	kindred
O	O	which
O	O	carries
O	O	a
O	O	novel
O	O	truncating
O	O	mutation
O	O	in
O	O	hMLH1
O	O	.
O	O	Interestingly
O	O	,
O	O	the
O	O	I1307K
B	O	APC
O	O	polymorphism
O	O	,
O	O	associated
O	O	with
O	O	an
O	O	increased
O	O	risk
O	O	of
B	B	colorectal
I	I	cancer
O	O	,
O	O	is
O	O	also
O	O	present
O	O	in
O	O	this
O	O	family
O	O	.
O	O	The
O	O	I1307K
O	O	polymorphism
O	O	has
O	O	previously
O	O	only
O	O	been
O	O	identified
O	O	in
O	O	individuals
O	O	of
O	O	self
O	O	-
O	O	reported
O	O	Ashkenazi
O	O	Jewish
O	O	origins
O	O	.
O	O	In
O	O	addition
O	O	,
O	O	in
O	O	this
O	O	family
O	O	,
O	O	there
O	O	appears
O	O	to
O	O	be
O	O	no
O	O	relationship
O	O	between
O	O	the
O	O	I1307K
O	O	polymorphism
O	O	and
O	O	the
O	O	presence
O	O	or
O	O	absence
O	O	of
B	B	cancer
O	O	.
O	O	.
O	O	Identification
O	O	of
O	O	a
O	O	novel
O	O	mutation
O	O	of
O	O	the
B	O	CPO
O	O	gene
O	O	in
O	O	a
O	O	Japanese
B	B	hereditary
I	I	coproporphyria
O	O	family
O	O	.
B	B	Hereditary
I	I	coproporphyria
O	O	(
B	B	HCP
O	O	)
O	O	is
O	O	an
B	B	autosomal
I	I	dominant
I	I	disease
O	O	characterized
O	O	by
O	O	a
B	B	deficiency
I	I	of
I	I	coproporphyrinogen
I	I	oxidase
O	O	(
B	O	CPO
O	O	)
O	O	caused
O	O	by
O	O	a
O	O	mutation
O	O	in
O	O	the
O	O	CPO
O	O	gene
O	O	.
O	O	Only
O	O	11
O	O	mutations
O	O	of
O	O	the
O	O	gene
O	O	have
O	O	been
O	O	reported
O	O	in
B	B	HCP
O	O	patients
O	O	.
O	O	We
O	O	report
O	O	another
O	O	mutation
O	O	in
O	O	a
O	O	Japanese
O	O	family
O	O	.
O	O	Polymerase
O	O	chain
O	O	reaction
O	O	-
O	O	single
O	O	strand
O	O	conformational
O	O	polymorphism
O	O	and
O	O	direct
O	O	sequence
O	O	analyses
O	O	demonstrated
O	O	a
O	O	C
O	O	to
O	O	T
O	O	substitution
O	O	in
O	O	exon
O	O	1
O	O	of
O	O	the
O	O	CPO
O	O	gene
O	O	at
O	O	nucleotide
O	O	position
O	O	85
O	O	,
O	O	which
O	O	lies
O	O	in
O	O	the
O	O	putative
O	O	presequence
O	O	for
O	O	targeting
O	O	to
O	O	mitochondria
O	O	.
O	O	This
O	O	mutation
O	O	changes
O	O	the
O	O	codon
O	O	for
O	O	glutamine
O	O	to
O	O	a
O	O	termination
O	O	codon
O	O	at
O	O	amino
O	O	acid
O	O	position
O	O	29
O	O	.
O	O	MaeI
O	O	restriction
O	O	analysis
O	O	showed
O	O	two
O	O	other
O	O	carriers
O	O	in
O	O	the
O	O	family
O	O	.
O	O	The
O	O	C
O	O	-
O	O	T
O	O	mutation
O	O	is
O	O	located
O	O	within
O	O	a
O	O	recently
O	O	proposed
O	O	putative
O	O	alternative
O	O	translation
O	O	initiation
O	O	codon
O	O	(
O	O	TIC
O	O	-
O	O	1
O	O	)
O	O	,
O	O	supporting
O	O	that
O	O	TIC
O	O	-
O	O	1
O	O	is
O	O	the
O	O	real
O	O	TIC
O	O	rather
O	O	than
O	O	TIC
O	O	-
O	O	2
O	O	.
O	O	.
O	B	Human
B	I	complement
I	I	factor
I	I	H
I	I	deficiency
O	O	associated
O	O	with
B	B	hemolytic
I	I	uremic
I	I	syndrome
O	O	.
O	O	This
O	O	study
O	O	reports
O	O	on
O	O	six
O	O	cases
O	O	of
B	B	deficiency
O	I	in
O	I	the
O	I	human
O	I	complement
O	I	regulatory
O	I	protein
O	I	Factor
O	I	H
O	O	(
O	O	FH
O	O	)
O	O	in
O	O	the
O	O	context
O	O	of
O	O	an
B	B	acute
B	I	renal
I	I	disease
O	O	.
O	O	Five
O	O	of
O	O	the
O	O	cases
O	O	were
O	O	observed
O	O	in
O	O	children
O	O	presenting
O	O	with
B	O	idiopathic
I	B	hemolytic
I	I	uremic
I	I	syndrome
O	O	(
B	B	HUS
O	O	)
O	O	.
O	O	Two
O	O	of
O	O	the
O	O	children
O	O	exhibited
O	O	a
O	O	homozygous
O	O	deficiency
O	O	characterized
O	O	by
O	O	the
O	O	absence
O	O	of
O	O	the
O	O	150
O	O	-
O	O	kD
O	O	form
O	O	of
O	O	Factor
O	O	H
O	O	and
O	O	the
O	O	presence
O	O	,
O	O	upon
O	O	immunoblotting
O	O	,
O	O	of
O	O	the
O	O	42
O	O	-
O	O	kD
O	O	Factor
O	O	H
O	O	-
O	O	like
O	O	protein
O	O	1
O	O	(
O	O	FHL
O	O	-
O	O	1
O	O	)
O	O	and
O	O	other
O	O	FH
O	O	-
O	O	related
O	O	protein
O	O	(
O	O	FHR
O	O	)
O	O	bands
O	O	.
O	O	Southern
O	O	blot
O	O	and
O	O	PCR
O	O	analysis
O	O	of
O	O	DNA
O	O	of
O	O	one
O	O	patient
O	O	with
B	O	homozygous
B	O	deficiency
O	O	ruled
O	O	out
O	O	the
O	O	presence
O	O	of
O	O	a
O	O	large
O	O	deletion
O	O	of
O	O	the
B	O	FH
O	O	gene
O	O	as
O	O	the
O	O	underlying
O	O	defect
O	O	for
O	O	the
O	O	deficiency
O	O	.
O	O	The
O	O	other
O	O	four
O	O	children
O	O	presented
O	O	with
O	O	heterozygous
O	O	deficiency
O	O	and
O	O	exhibited
O	O	a
O	O	normal
O	O	immunoblotting
O	O	pattern
O	O	of
O	O	proteins
O	O	of
O	O	the
B	O	FH
O	O	family
O	O	.
B	B	Factor
I	I	H
I	I	deficiency
O	O	is
O	O	the
O	O	only
B	B	complement
I	I	deficiency
O	O	associated
O	O	with
B	B	HUS
O	O	.
O	O	These
O	O	observations
O	O	suggest
O	O	a
O	O	role
O	O	for
O	O	FH
O	O	and
O	O	/
O	O	or
B	O	FH
O	O	receptors
O	O	in
O	O	the
O	O	pathogenesis
O	O	of
B	O	idiopathic
I	B	HUS
O	O	.
O	O	.
O	O	Further
O	O	evidence
O	O	for
O	O	a
O	O	major
O	O	ancient
O	O	mutation
O	O	underlying
B	B	myotonic
I	I	dystrophy
O	O	from
O	O	linkage
O	O	disequilibrium
O	O	studies
O	O	in
O	O	the
O	O	Japanese
O	O	population
O	O	.
O	O	The
B	B	myotonic
I	I	dystrophy
O	O	(
B	B	DM
O	O	)
O	O	mutation
O	O	is
O	O	an
O	O	unstable
O	O	(
O	O	CTG
O	O	)
O	O	n
O	O	repeat
O	O	,
O	O	present
O	O	at
O	O	a
O	O	copy
O	O	number
O	O	of
O	O	5
O	O	-
O	O	37
O	O	repeats
O	O	on
O	O	normal
O	O	chromosomes
O	O	but
O	O	amplified
O	O	to
O	O	50
O	O	-
O	O	3000
O	O	copies
O	O	on
B	B	DM
O	O	chromosomes
O	O	.
O	O	Previous
O	O	findings
O	O	in
O	O	Caucasian
O	O	populations
O	O	of
O	O	a
B	B	DM
O	O	founder
O	O	chromosome
O	O	raise
O	O	a
O	O	question
O	O	about
O	O	the
O	O	molecular
O	O	events
O	O	involved
O	O	in
O	O	the
O	O	expansion
O	O	mutation
O	O	.
O	O	To
O	O	investigate
O	O	whether
O	O	a
O	O	founder
O	O	chromosome
O	O	for
O	O	the
B	B	DM
O	O	mutation
O	O	exists
O	O	in
O	O	the
O	O	Japanese
O	O	population
O	O	,
O	O	we
O	O	genotyped
O	O	families
O	O	using
O	O	polymorphic
O	O	markers
O	O	near
O	O	the
O	O	(
O	O	CTG
O	O	)
O	O	n
O	O	repeat
O	O	region
O	O	and
O	O	constructed
O	O	haplotypes
O	O	.
O	O	Six
O	O	different
O	O	haplotypes
O	O	were
O	O	found
O	O	and
B	B	DM
O	O	alleles
O	O	were
O	O	always
O	O	haplotype
O	O	A
O	O	.
O	O	To
O	O	find
O	O	an
O	O	origin
O	O	of
O	O	the
O	O	(
O	O	CTG
O	O	)
O	O	n
O	O	repeat
O	O	mutation
O	O	and
O	O	to
O	O	investigate
O	O	the
O	O	mechanism
O	O	of
O	O	the
O	O	expansion
O	O	mutation
O	O	in
O	O	the
O	O	Japanese
O	O	population
O	O	we
O	O	have
O	O	studied
O	O	90
O	O	Japanese
B	B	DM
O	O	families
O	O	comprising
O	O	190
O	O	affected
O	O	and
O	O	130
O	O	unaffected
O	O	members
O	O	.
O	O	The
O	O	results
O	O	suggest
O	O	that
O	O	a
O	O	few
O	O	common
O	O	ancestral
O	O	mutations
O	O	in
O	O	both
O	O	Caucasian
O	O	and
O	O	Japanese
O	O	populations
O	O	have
O	O	originated
O	O	by
O	O	expansion
O	O	of
O	O	an
O	O	ancestral
O	O	n
O	O	=
O	O	5
O	O	repeat
O	O	to
O	O	n
O	O	=
O	O	19
O	O	-
O	O	37
O	O	copies
O	O	.
O	O	These
O	O	data
O	O	support
O	O	multistep
O	O	models
O	O	of
O	O	triplet
O	O	repeat
O	O	expansion
O	O	that
O	O	have
O	O	been
O	O	proposed
O	O	for
O	O	both
B	B	DM
O	O	and
B	B	Friedreichs
I	I	ataxia
O	O	.
O	O	.
O	O	The
O	O	molecular
O	O	basis
O	O	of
B	B	C6
I	I	deficiency
O	O	in
O	O	the
O	O	western
O	O	Cape
O	O	,
O	O	South
O	O	Africa
O	O	.
B	B	Deficiency
I	I	of
I	I	the
I	I	sixth
I	I	component
I	I	of
I	I	human
I	I	complement
O	O	(
B	O	C6
O	O	)
O	O	has
O	O	been
O	O	reported
O	O	in
O	O	a
O	O	number
O	O	of
O	O	families
O	O	from
O	O	the
O	O	western
O	O	Cape
O	O	,
O	O	South
O	O	Africa
O	O	.
B	B	Meningococcal
I	I	disease
O	O	is
O	O	endemic
O	O	in
O	O	the
O	O	Cape
O	O	and
O	O	almost
O	O	all
O	O	pedigrees
O	O	of
B	O	total
B	B	C6
I	I	deficiency
O	O	(
B	O	C6Q0
O	O	)
O	O	have
O	O	been
O	O	ascertained
O	O	because
O	O	of
O	O	recurrent
O	O	disease
O	O	.
O	O	We
O	O	have
O	O	sequenced
O	O	the
O	O	expressed
O	O	exons
O	O	of
O	O	the
O	O	C6
O	O	gene
O	O	from
O	O	selected
O	O	cases
O	O	and
O	O	have
O	O	found
O	O	three
O	O	molecular
O	O	defects
O	O	leading
O	O	to
O	O	total
O	O	deficiency
O	O	879delG
O	O	,
O	O	which
O	O	is
O	O	the
O	O	common
O	O	defect
O	O	in
O	O	the
O	O	Cape
O	O	and
O	O	hitherto
O	O	unreported
O	O	,
O	O	and
O	O	1195delC
O	O	and
O	O	1936delG
O	O	,
O	O	which
O	O	have
O	O	been
O	O	previously
O	O	reported
O	O	in
O	O	African
O	O	-
O	O	Americans
O	O	.
O	O	We
O	O	also
O	O	show
O	O	that
O	O	the
O	O	879delG
O	O	and
O	O	1195delC
O	O	defects
O	O	are
O	O	associated
O	O	with
O	O	characteristic
O	O	C6
O	O	/
O	O	C7
O	O	region
O	O	DNA
O	O	marker
O	O	haplotypes
O	O	,
O	O	although
O	O	small
O	O	variations
O	O	were
O	O	observed
O	O	.
O	O	The
O	O	1936delG
O	O	defect
O	O	was
O	O	observed
O	O	only
O	O	once
O	O	in
O	O	the
O	O	Cape
O	O	,
O	O	but
O	O	its
O	O	associated
O	O	haplotype
O	O	could
O	O	be
O	O	deduced
O	O	.
O	O	The
O	O	data
O	O	from
O	O	the
O	O	haplotypes
O	O	indicate
O	O	that
O	O	these
O	O	three
O	O	molecular
O	O	defects
O	O	account
O	O	for
O	O	the
O	O	defects
O	O	in
O	O	all
O	O	the
O	O	38
O	O	unrelated
O	O	C6Q0
O	O	individuals
O	O	we
O	O	have
O	O	studied
O	O	from
O	O	the
O	O	Cape
O	O	.
O	O	We
O	O	have
O	O	also
O	O	observed
O	O	the
O	O	879delG
O	O	defect
O	O	in
O	O	two
O	O	Dutch
B	B	C6
I	I	-
I	I	deficient
O	O	kindreds
O	O	,
O	O	but
O	O	the
O	O	879delG
O	O	defect
O	O	in
O	O	the
O	O	Cape
O	O	probably
O	O	did
O	O	not
O	O	come
O	O	from
O	O	The
O	O	Netherlands
O	O	.
O	O	.
B	B	Complement
I	I	C7
I	I	deficiency
O	O	:
O	O	seven
O	O	further
B	O	molecular
I	O	defects
O	O	and
O	O	their
O	O	associated
O	O	marker
O	O	haplotypes
O	O	.
O	O	Seven
O	O	further
O	O	molecular
O	O	bases
O	O	of
B	B	C7
I	I	deficiency
O	O	are
O	O	described
O	O	.
O	O	All
O	O	these
O	O	new
O	O	molecular
O	O	defects
O	O	involve
O	O	single
O	O	-
O	O	nucleotide
O	O	events
O	O	,
O	O	deletions
O	O	and
O	O	substitutions
O	O	,
O	O	some
O	O	of
O	O	which
O	O	alter
O	O	splice
O	O	sites
O	O	,
O	O	and
O	O	others
O	O	codons
O	O	.
O	O	They
O	O	are
O	O	distributed
O	O	along
O	O	the
O	O	C7
O	O	gene
O	O	,
O	O	but
O	O	predominantly
O	O	towards
O	O	the
O	O	3
O	O	end
O	O	.
O	O	All
O	O	were
O	O	found
O	O	in
O	O	compound
O	O	heterozygous
O	O	individuals
O	O	.
O	O	The
O	O	C6
O	O	/
O	O	C7
O	O	marker
O	O	haplotypes
O	O	associated
O	O	with
O	O	most
B	B	C7
O	I	defects
O	O	are
O	O	tabulated
O	O	.
O	O	.
O	O	A
O	O	genome
O	O	-
O	O	wide
O	O	search
O	O	for
O	O	chromosomal
O	O	loci
O	O	linked
O	O	to
B	O	mental
O	O	health
O	O	wellness
O	O	in
O	O	relatives
O	O	at
O	O	high
O	O	risk
O	O	for
B	B	bipolar
I	I	affective
I	I	disorder
O	O	among
O	O	the
O	O	Old
O	O	Order
O	O	Amish
O	O	.
B	B	Bipolar
I	I	affective
I	I	disorder
O	O	(
B	B	BPAD
O	O	;
B	B	manic
I	I	-
I	I	depressive
I	I	illness
O	O	)
O	O	is
O	O	characterized
O	O	by
O	O	episodes
O	O	of
B	B	mania
O	O	and
O	O	/
O	O	or
B	B	hypomania
O	O	interspersed
O	O	with
O	O	periods
O	O	of
B	B	depression
B	O	.
O	O	Compelling
O	O	evidence
O	O	supports
O	O	a
O	O	significant
O	O	genetic
O	O	component
O	O	in
O	O	the
O	O	susceptibility
O	O	to
O	O	develop
B	B	BPAD
O	O	.
O	O	To
O	O	date
O	O	,
O	O	however
O	O	,
O	O	linkage
O	O	studies
O	O	have
O	O	attempted
O	O	only
O	O	to
O	O	identify
O	O	chromosomal
O	O	loci
O	O	that
O	O	cause
O	O	or
O	O	increase
O	O	the
O	O	risk
O	O	of
O	O	developing
B	B	BPAD
O	O	.
O	O	To
O	O	determine
O	O	whether
O	O	there
O	O	could
O	O	be
O	O	protective
O	O	alleles
O	O	that
O	O	prevent
O	O	or
O	O	reduce
O	O	the
O	O	risk
O	O	of
O	O	developing
B	B	BPAD
O	O	,
O	O	similar
O	O	to
O	O	what
O	O	is
O	O	observed
O	O	in
O	O	other
B	B	genetic
O	I	disorders
O	O	,
O	O	we
O	O	used
B	O	mental
O	O	health
O	O	wellness
O	O	(
O	O	absence
O	O	of
O	O	any
B	B	psychiatric
I	I	disorder
O	O	)
O	O	as
O	O	the
O	O	phenotype
O	O	in
O	O	our
O	O	genome
O	O	-
O	O	wide
O	O	linkage
O	O	scan
O	O	of
O	O	several
O	O	large
O	O	multigeneration
O	O	Old
O	O	Order
O	O	Amish
O	O	pedigrees
O	O	exhibiting
O	O	an
O	O	extremely
O	O	high
O	O	incidence
O	O	of
B	B	BPAD
O	O	.
O	O	We
O	O	have
O	O	found
O	O	strong
O	O	evidence
O	O	for
O	O	a
O	O	locus
O	O	on
O	O	chromosome
O	O	4p
O	O	at
O	O	D4S2949
O	O	(
O	O	maximum
O	O	GENEHUNTER
O	O	-
O	O	PLUS
O	O	nonparametric
O	O	linkage
O	O	score
O	O	=
O	O	4
O	O	.
O	O	05
O	O	,
O	O	P
O	O	=
O	O	5
O	O	.
O	O	22
O	O	x
O	O	10
O	O	(
O	O	-
O	O	4
O	O	)
O	O	;
O	O	SIBPAL
O	O	Pempirical
O	O	value
O	O	<
O	O	3
O	O	x
O	O	10
O	O	(
O	O	-
O	O	5
O	O	)
O	O	)
O	O	and
O	O	suggestive
O	O	evidence
O	O	for
O	O	a
O	O	locus
O	O	on
O	O	chromosome
O	O	4q
O	O	at
O	O	D4S397
O	O	(
O	O	maximum
O	O	GENEHUNTER
O	O	-
O	O	PLUS
O	O	nonparametric
O	O	linkage
O	O	score
O	O	=
O	O	3
O	O	.
O	O	29
O	O	,
O	O	P
O	O	=
O	O	2
O	O	.
O	O	57
O	O	x
O	O	10
O	O	(
O	O	-
O	O	3
O	O	)
O	O	;
O	O	SIBPAL
O	O	Pempirical
O	O	value
O	O	<
O	O	1
O	O	x
O	O	10
O	O	(
O	O	-
O	O	3
O	O	)
O	O	)
O	O	that
O	O	are
O	O	linked
O	O	to
B	O	mental
O	O	health
O	O	wellness
O	O	.
O	O	These
O	O	findings
O	O	are
O	O	consistent
O	O	with
O	O	the
O	O	hypothesis
O	O	that
O	O	certain
O	O	alleles
O	O	could
O	O	prevent
O	O	or
O	O	modify
O	O	the
O	O	clinical
O	O	manifestations
O	O	of
B	B	BPAD
O	O	and
O	O	perhaps
O	O	other
O	O	related
B	B	affective
O	I	disorders
O	O	.
O	O	Segregation
O	O	distortion
O	O	in
B	B	myotonic
I	I	dystrophy
O	O	.
B	B	Myotonic
I	I	dystrophy
O	O	(
B	B	DM
O	O	)
O	O	is
O	O	an
B	B	autosomal
O	I	dominant
I	I	disease
O	O	which
O	O	,
O	O	in
O	O	the
O	O	typical
O	O	pedigree
O	O	,
O	O	shows
O	O	a
O	O	three
O	O	generation
O	O	anticipation
O	O	cascade
O	O	.
O	O	This
O	O	results
O	O	in
B	B	infertility
O	O	and
B	B	congenital
I	I	myotonic
I	I	dystrophy
O	O	(
B	B	CDM
O	O	)
O	O	with
O	O	the
O	O	disappearance
O	O	of
B	B	DM
O	O	in
O	O	that
O	O	pedigree
O	O	.
O	O	The
O	O	concept
O	O	of
O	O	segregation
O	O	distortion
O	O	,
O	O	where
O	O	there
O	O	is
O	O	preferential
O	O	transmission
O	O	of
O	O	the
O	O	larger
O	O	allele
O	O	at
O	O	the
B	B	DM
O	O	locus
O	O	,
O	O	has
O	O	been
O	O	put
O	O	forward
O	O	to
O	O	explain
O	O	partially
O	O	the
O	O	maintenance
O	O	of
B	B	DM
O	O	in
O	O	the
O	O	population
O	O	.
O	O	In
O	O	a
O	O	survey
O	O	of
B	B	DM
O	O	in
O	O	Northern
O	O	Ireland
O	O	,
O	O	59
O	O	pedigrees
O	O	were
O	O	ascertained
O	O	.
O	O	Sibships
O	O	where
O	O	the
O	O	status
O	O	of
O	O	all
O	O	the
O	O	members
O	O	had
O	O	been
O	O	identified
O	O	were
O	O	examined
O	O	to
O	O	determine
O	O	the
O	O	transmission
O	O	of
O	O	the
B	B	DM
O	O	expansion
O	O	from
O	O	affected
O	O	parents
O	O	to
O	O	their
O	O	offspring
O	O	.
O	O	Where
O	O	the
O	O	transmitting
O	O	parent
O	O	was
O	O	male
O	O	,
O	O	58
O	O	.
O	O	3
O	O	%
O	O	of
O	O	the
O	O	offspring
O	O	were
O	O	affected
O	O	,
O	O	and
O	O	in
O	O	the
O	O	case
O	O	of
O	O	a
O	O	female
O	O	transmitting
O	O	parent
O	O	,
O	O	68
O	O	.
O	O	7
O	O	%
O	O	were
O	O	affected
O	O	.
O	O	Studies
O	O	on
O	O	meiotic
O	O	drive
O	O	in
B	B	DM
O	O	have
O	O	shown
O	O	increased
O	O	transmission
O	O	of
O	O	the
O	O	larger
O	O	allele
O	O	at
O	O	the
B	B	DM
O	O	locus
O	O	in
O	O	non
O	O	-
B	O	DM
O	O	heterozygotes
O	O	for
O	O	CTGn
O	O	.
O	O	This
O	O	study
O	O	provides
O	O	further
O	O	evidence
O	O	that
O	O	the
B	B	DM
O	O	expansion
O	O	tends
O	O	to
O	O	be
O	O	transmitted
O	O	preferentially
O	O	.
O	O	Diagnosis
O	O	of
B	B	hemochromatosis
O	O	.
O	O	If
O	O	untreated
O	O	,
B	B	hemochromatosis
O	O	can
O	O	cause
O	O	serious
O	O	illness
O	O	and
O	B	early
O	I	death
O	O	,
O	O	but
O	O	the
O	O	disease
O	O	is
O	O	still
O	O	substantially
O	O	under
O	O	-
O	O	diagnosed
O	O	.
O	O	The
O	O	cornerstone
O	O	of
O	O	screening
O	O	and
O	O	case
O	O	detection
O	O	is
O	O	the
O	O	measurement
O	O	of
O	O	serum
O	O	transferrin
O	O	saturation
O	O	and
O	O	the
O	O	serum
O	O	ferritin
O	O	level
O	O	.
O	O	Once
O	O	the
O	O	diagnosis
O	O	is
O	O	suspected
O	O	,
O	O	physicians
O	O	must
O	O	use
O	O	serum
O	O	ferritin
O	O	levels
O	O	and
O	O	hepatic
O	O	iron
O	O	stores
O	O	on
O	O	liver
O	O	biopsy
O	O	specimens
O	O	to
O	O	assess
O	O	patients
O	O	for
O	O	the
O	O	presence
O	O	of
O	B	iron
O	I	overload
O	O	.
O	O	Liver
O	O	biopsy
O	O	is
O	O	also
O	O	used
O	O	to
O	O	establish
O	O	the
O	O	presence
O	O	or
O	O	absence
O	O	of
B	B	cirrhosis
O	O	,
O	O	which
O	O	can
O	O	affect
O	O	prognosis
O	O	and
O	O	management
O	O	.
O	O	A
O	O	DNA
O	O	-
O	O	based
O	O	test
O	O	for
O	O	the
O	O	HFE
O	O	gene
O	O	is
O	O	commercially
O	O	available
O	O	,
O	O	but
O	O	its
O	O	place
O	O	in
O	O	the
O	O	diagnosis
O	O	of
B	B	hemochromatosis
O	O	is
O	O	still
O	O	being
O	O	evaluated
O	O	.
O	O	Currently
O	O	,
O	O	the
O	O	most
O	O	useful
O	O	role
O	O	for
O	O	this
O	O	test
O	O	is
O	O	in
O	O	the
O	O	detection
O	O	of
B	B	hemochromatosis
O	O	in
O	O	the
O	O	family
O	O	members
O	O	of
O	O	patients
O	O	with
O	O	a
O	O	proven
O	O	case
O	O	of
O	O	the
O	O	disease
O	O	.
O	O	It
O	O	is
O	O	crucial
O	O	to
O	O	diagnose
B	B	hemochromatosis
O	O	before
B	B	hepatic
I	I	cirrhosis
O	O	develops
O	O	because
B	O	phlebotomy
O	O	therapy
O	O	can
O	O	avert
O	O	serious
B	O	chronic
I	O	disease
O	O	and
O	O	can
O	O	even
O	O	lead
O	O	to
O	O	normal
O	O	life
O	O	expectancy
O	O	.
O	O	.
O	O	Prevalence
O	O	of
O	O	the
O	O	I1307K
B	B	APC
O	O	gene
O	O	variant
O	O	in
O	O	Israeli
O	O	Jews
O	O	of
O	O	differing
O	O	ethnic
O	O	origin
O	O	and
O	O	risk
O	O	for
B	B	colorectal
I	I	cancer
O	O	.
O	O	BACKGROUND
O	O	&
O	O	AIMS
O	O	Israeli
O	O	Jews
O	O	of
O	O	European
O	O	birth
O	O	,
O	O	i
O	O	.
O	O	e
O	O	.
O	O	,
O	O	Ashkenazim
O	O	,
O	O	have
O	O	the
O	O	highest
B	B	colorectal
I	I	cancer
O	O	incidence
O	O	of
O	O	any
O	O	Israeli
O	O	ethnic
O	O	group
O	O	.
O	O	The
O	O	I1307K
B	B	APC
O	O	gene
O	O	variant
O	O	was
O	O	found
O	O	in
O	O	6
O	O	.
O	O	1
O	O	%
O	O	of
O	O	American
O	O	Jews
O	O	,
O	O	28
O	O	%
O	O	of
O	O	their
B	O	familial
I	B	colorectal
I	I	cancer
O	O	cases
O	O	,
O	O	but
O	O	not
O	O	in
O	O	non
O	O	-
O	O	Jews
O	O	.
O	O	We
O	O	assessed
O	O	the
O	O	I1307K
O	O	prevalence
O	O	in
O	O	Israeli
O	O	Jews
O	O	of
O	O	differing
O	O	ethnic
O	O	origin
O	O	and
O	O	risk
O	O	for
B	B	colorectal
I	I	cancer
O	O	.
O	O	METHODS
O	O	DNA
O	O	samples
O	O	from
O	O	500
O	O	unrelated
O	O	Jews
O	O	of
O	O	European
O	O	or
O	O	non
O	O	-
O	O	European
O	O	origin
O	O	,
O	O	with
O	O	or
O	O	without
O	O	a
O	O	personal
O	O	and
O	O	/
O	O	or
O	O	family
O	O	history
O	O	of
B	B	neoplasia
O	O	,
O	O	were
O	O	examined
O	O	for
O	O	the
O	O	I1307K
O	O	variant
O	O	by
O	O	the
O	O	allele
O	O	-
O	O	specific
O	O	oligonucleotide
O	O	(
O	O	ASO
O	O	)
O	O	method
O	O	.
O	O	RESULTS
O	O	In
O	O	persons
O	O	at
O	O	average
O	O	risk
O	O	for
B	B	colorectal
I	I	cancer
O	O	,
O	O	I1307K
O	O	was
O	O	found
O	O	in
O	O	5
O	O	.
O	O	0
O	O	%
O	O	of
O	O	120
O	O	European
O	O	and
O	O	1
O	O	.
O	O	6
O	O	%
O	O	of
O	O	188
O	O	non
O	O	-
O	O	European
O	O	Jews
O	O	(
O	O	P
O	O	=
O	O	0
O	O	.
O	O	08
O	O	)
O	O	.
O	O	It
O	O	occurred
O	O	in
O	O	15
O	O	.
O	O	4
O	O	%
O	O	of
O	O	52
O	O	Ashkenazi
O	O	Israelis
O	O	with
B	O	familial
I	B	cancer
O	O	(
O	O	P
O	O	=
O	O	0
O	O	.
O	O	02
O	O	)
O	O	and
O	O	was
O	O	not
O	O	detected
O	O	in
O	O	51
O	O	non
O	O	-
O	O	European
O	O	Jews
O	O	at
O	O	increased
B	B	cancer
O	O	risk
O	O	.
B	B	Colorectal
I	I	neoplasia
O	O	occurred
O	O	personally
O	O	or
O	O	in
O	O	the
O	O	families
O	O	of
O	O	13
O	O	of
O	O	20
O	O	Ashkenazi
O	O	I1307K
O	O	carriers
O	O	,
O	O	8
O	O	of
O	O	whom
O	O	also
O	O	had
O	O	a
O	O	personal
O	O	or
O	O	family
O	O	history
O	O	of
B	O	noncolonic
I	B	neoplasia
O	O	.
O	O	CONCLUSIONS
O	O	The
O	O	I1307K
B	O	APC
O	O	variant
O	O	may
O	O	represent
O	O	a
O	O	susceptibility
O	O	gene
O	O	for
B	B	colorectal
I	I	,
O	I	or
I	I	other
O	I	,
I	I	cancers
O	O	in
O	O	Ashkenazi
O	O	Jews
O	O	,
O	O	and
O	O	partially
O	O	explains
O	O	the
O	O	higher
O	O	incidence
O	O	of
B	B	colorectal
I	I	cancer
O	O	in
O	O	European
O	O	Israelis
O	O	.
O	O	Systematic
O	O	analysis
O	O	of
O	O	coproporphyrinogen
O	O	oxidase
O	O	gene
O	O	defects
O	O	in
B	B	hereditary
I	I	coproporphyria
O	O	and
O	O	mutation
O	O	update
O	O	.
B	B	Hereditary
I	I	coproporphyria
O	O	(
B	B	HC
O	O	)
O	O	is
O	O	an
O	O	acute
B	B	hepatic
I	I	porphyria
O	O	with
O	O	autosomal
O	O	dominant
O	O	inheritance
O	O	caused
O	O	by
O	B	deficient
O	I	activity
O	I	of
O	I	coproporphyrinogen
O	I	III
O	I	oxidase
O	O	(
O	O	CPO
O	O	)
O	O	.
O	O	Clinical
O	O	manifestations
O	O	of
O	O	the
O	O	disease
O	O	are
O	O	characterized
O	O	by
O	O	acute
O	O	attacks
O	O	of
B	B	neurological
I	I	dysfunction
O	O	often
O	O	precipitated
O	O	by
O	O	drugs
O	O	,
O	O	fasting
O	O	,
O	O	cyclical
O	O	hormonal
O	O	changes
O	O	,
O	O	or
B	B	infectious
O	I	diseases
O	O	.
O	O	Skin
O	O	photosensitivity
O	O	may
O	O	also
O	O	be
O	O	present
O	O	.
O	O	The
O	O	seven
O	O	exons
O	O	,
O	O	the
O	O	exon
O	O	/
O	O	intron
O	O	boundaries
O	O	and
O	O	part
O	O	of
O	O	3
O	O	noncoding
O	O	sequence
O	O	of
O	O	the
O	O	CPO
O	O	gene
O	O	were
O	O	systematically
O	O	analyzed
O	O	by
O	O	an
O	O	exon
O	O	-
O	O	by
O	O	-
O	O	exon
O	O	denaturing
O	O	gradient
O	O	gel
O	O	electrophoresis
O	O	(
O	O	DGGE
O	O	)
O	O	strategy
O	O	followed
O	O	by
O	O	direct
O	O	sequencing
O	O	in
O	O	seven
O	O	unrelated
O	O	heterozygous
B	B	HC
O	O	patients
O	O	from
O	O	France
O	O	,
O	O	Holland
O	O	,
O	O	and
O	O	Czech
O	O	Republic
O	O	.
O	O	Seven
O	O	novel
O	O	mutations
O	O	and
O	O	two
O	O	new
O	O	polymorphisms
O	O	were
O	O	detected
O	O	.
O	O	Among
O	O	these
O	O	mutations
O	O	two
O	O	are
O	O	missense
O	O	(
O	O	G197W
O	O	,
O	O	W427R
O	O	)
O	O	,
O	O	two
O	O	are
O	O	nonsense
O	O	(
O	O	Q306X
O	O	,
O	O	Q385X
O	O	)
O	O	,
O	O	two
O	O	are
O	O	small
O	O	deletions
O	O	(
O	O	662de14bp
O	O	;
O	O	1168del3bp
O	O	removing
O	O	a
O	O	glycine
O	O	at
O	O	position
O	O	390
O	O	)
O	O	,
O	O	and
O	O	one
O	O	is
O	O	a
O	O	splicing
O	O	mutation
O	O	(
O	O	IVS1
O	O	-
O	O	15c
O	O	-
O	O	-
O	O	>
O	O	g
O	O	)
O	O	which
O	O	creates
O	O	a
O	O	new
O	O	acceptor
O	O	splice
O	O	site
O	O	.
O	O	The
O	O	pathological
O	O	significance
O	O	of
O	O	the
O	O	point
O	O	mutations
O	O	G197W
O	O	,
O	O	W427R
O	O	,
O	O	and
O	O	the
O	O	in
O	O	-
O	O	frame
O	O	deletion
O	O	390delGly
O	O	were
O	O	assessed
O	O	by
O	O	their
O	O	respective
O	O	expression
O	O	in
O	O	a
O	O	prokaryotic
O	O	system
O	O	using
O	O	site
O	O	-
O	O	directed
O	O	mutagenesis
O	O	.
O	O	These
O	O	mutations
O	O	resulted
O	O	in
O	O	the
O	O	absence
O	O	or
O	O	a
O	O	dramatic
O	O	decrease
O	O	of
B	O	CPO
O	O	activity
O	O	.
O	O	The
O	O	two
O	O	polymorphisms
O	O	were
O	O	localized
O	O	in
O	O	noncoding
O	O	part
O	O	of
O	O	the
O	O	gene
O	O	1
O	O	)
O	O	a
O	O	C
O	O	/
O	O	G
O	O	polymorphism
O	O	in
O	O	the
O	O	promotor
O	O	region
O	O	,
O	O	142
O	O	bp
O	O	upstream
O	O	from
O	O	the
O	O	transcriptional
O	O	initiation
O	O	site
O	O	(
O	O	-
O	O	142C
O	O	/
O	O	G
O	O	)
O	O	,
O	O	and
O	O	2
O	O	)
O	O	a
O	O	6
O	O	bp
O	O	deletion
O	O	polymorphism
O	O	in
O	O	the
O	O	3
O	O	noncoding
O	O	part
O	O	of
O	O	the
O	O	CPO
O	O	gene
O	O	,
O	O	574
O	O	bp
O	O	downstream
O	O	of
O	O	the
O	O	last
O	O	base
O	O	of
O	O	the
O	O	normal
O	O	termination
O	O	codon
O	O	(
O	O	+
O	O	574
O	O	delATTCTT
O	O	)
O	O	.
O	O	Five
O	O	intragenic
O	O	dimorphisms
O	O	are
O	O	now
O	O	well
O	O	characterized
O	O	and
O	O	the
O	O	high
O	O	degree
O	O	of
O	O	allelic
O	O	heterogeneity
O	O	in
O	B	HC
O	O	is
O	O	demonstrated
O	O	with
O	O	seven
O	O	new
O	O	different
O	O	mutations
O	O	making
O	O	a
O	O	total
O	O	of
O	O	nineteen
B	O	CPO
O	B	gene
O	I	defects
O	O	reported
O	O	so
O	O	far
O	O	.
O	O	.
O	O	Coincidence
O	O	of
O	O	two
O	O	novel
O	O	arylsulfatase
O	O	A
O	O	alleles
O	O	and
O	O	mutation
O	O	459
O	O	+
O	O	1G
O	O	>
O	O	A
O	O	within
O	O	a
O	O	family
O	O	with
B	B	metachromatic
I	I	leukodystrophy
O	O	:
O	O	molecular
O	O	basis
O	O	of
O	O	phenotypic
O	O	heterogeneity
O	O	.
O	O	In
O	O	a
O	O	family
O	O	with
O	O	three
O	O	siblings
O	O	,
O	O	one
O	O	developed
O	O	classical
B	O	late
B	O	infantile
I	B	metachromatic
I	I	leukodystrophy
O	O	(
B	B	MLD
O	O	)
O	O	,
O	O	fatal
O	O	at
O	O	age
O	O	5
O	O	years
O	O	,
O	O	with
O	O	deficient
O	O	arylsulfatase
O	O	A
O	O	(
O	O	ARSA
O	O	)
O	O	activity
O	O	and
O	O	increased
O	O	galactosylsulfatide
O	O	(
O	O	GS
O	O	)
O	O	excretion
O	O	.
O	O	The
O	O	two
O	O	other
O	O	siblings
O	O	,
O	O	apparently
O	O	healthy
O	O	at
O	O	12
O	O	(
O	O	1
O	O	/
O	O	2
O	O	)
O	O	and
O	O	15
O	O	years
O	O	,
O	O	respectively
O	O	,
O	O	and
O	O	their
O	O	father
O	O	,
O	O	apparently
O	O	healthy
O	O	as
O	O	well
O	O	,
O	O	presented
B	O	ARSA
O	O	and
B	O	GS
O	O	values
O	O	within
O	O	the
O	O	range
O	O	of
B	B	MLD
O	O	patients
O	O	.
O	O	Mutation
O	O	screening
O	O	and
O	O	sequence
O	O	analysis
O	O	disclosed
O	O	the
O	O	involvement
O	O	of
O	O	three
O	O	different
O	O	ARSA
O	O	mutations
O	O	being
O	O	the
O	O	molecular
O	O	basis
O	O	of
O	O	intrafamilial
O	O	phenotypic
O	O	heterogeneity
O	O	.
O	O	The
O	O	late
O	O	infantile
O	O	patient
O	O	inherited
O	O	from
O	O	his
O	O	mother
O	O	the
O	O	frequent
O	O	0
O	O	-
O	O	type
O	O	mutation
O	O	459
O	O	+
O	O	1G
O	O	>
O	O	A
O	O	,
O	O	and
O	O	from
O	O	his
O	O	father
O	O	a
O	O	novel
O	O	,
O	O	single
O	O	basepair
O	O	microdeletion
O	O	of
O	O	guanine
O	O	at
O	O	nucleotide
O	O	7
O	O	in
O	O	exon
O	O	1
O	O	(
O	O	7delG
O	O	)
O	O	.
O	O	The
O	O	two
O	O	clinically
O	O	unaffected
O	O	siblings
O	O	carried
O	O	the
O	O	maternal
O	O	mutation
O	O	459
O	O	+
O	O	1G
O	O	>
O	O	A
O	O	and
O	O	,
O	O	on
O	O	their
O	O	paternal
O	O	allele
O	O	,
O	O	a
O	O	novel
O	O	cytosine
O	O	to
O	O	thymidine
O	O	transition
O	O	at
O	O	nucleotide
O	O	2435
O	O	in
O	O	exon
O	O	8
O	O	,
O	O	resulting
O	O	in
O	O	substitution
O	O	of
O	O	alanine
O	O	464
O	O	by
O	O	valine
O	O	(
O	O	A464V
O	O	)
O	O	.
O	O	The
O	O	fathers
O	O	genotype
O	O	thus
O	O	was
O	O	7delG
O	O	/
O	O	A464V
O	O	.
O	O	Mutation
O	O	A464V
O	O	was
O	O	not
O	O	found
O	O	in
O	O	18
O	O	unrelated
B	B	MLD
O	O	patients
O	O	and
O	O	50
O	O	controls
O	O	.
O	O	A464V
O	O	,
O	O	although
O	O	clearly
O	O	modifying
O	O	ARSA
O	O	and
B	O	GS
O	O	levels
O	O	,
O	O	apparently
O	O	bears
O	O	little
O	O	significance
O	O	for
O	O	clinical
O	O	manifestation
O	O	of
B	B	MLD
O	O	,
O	O	mimicking
O	O	the
O	O	frequent
B	O	ARSA
O	O	pseudodeficiency
O	O	allele
O	O	.
O	O	Our
O	O	results
O	O	demonstrate
O	O	that
O	O	in
O	O	certain
O	O	genetic
O	O	conditions
B	B	MLD
O	O	-
O	O	like
O	O	ARSA
O	O	and
B	O	GS
O	O	values
O	O	need
O	O	not
O	O	be
O	O	paralleled
O	O	by
O	O	clinical
O	O	disease
O	O	,
O	O	a
O	O	finding
O	O	with
O	O	serious
O	O	diagnostic
O	O	and
O	O	prognostic
O	O	implications
O	O	.
O	O	Moreover
O	O	,
O	O	further
B	O	ARSA
O	O	alleles
O	O	functionally
O	O	similar
O	O	to
O	O	A464V
O	O	might
O	O	exist
O	O	which
O	O	,
O	O	together
O	O	with
O	O	0
O	O	-
O	O	type
O	O	mutations
O	O	,
O	O	may
O	O	cause
O	O	pathological
B	O	ARSA
O	O	and
B	O	GS
O	O	levels
O	O	,
O	O	but
O	O	not
O	O	clinical
O	O	outbreak
O	O	of
O	O	the
O	O	disease
O	O	.
O	O	.
O	O	Human
B	O	MLH1
I	O	deficiency
O	O	predisposes
O	O	to
B	B	hematological
I	I	malignancy
O	O	and
B	B	neurofibromatosis
I	I	type
I	I	1
O	O	.
O	O	Heterozygous
O	O	germ
O	O	-
O	O	line
O	O	mutations
O	O	in
O	O	the
O	O	DNA
O	O	mismatch
O	O	repair
O	O	genes
O	O	lead
O	O	to
B	B	hereditary
I	I	nonpolyposis
I	I	colorectal
I	I	cancer
O	O	.
O	O	The
O	O	disease
O	O	susceptibility
O	O	of
O	O	individuals
O	O	who
O	O	constitutionally
O	O	lack
O	O	both
O	O	wild
O	O	-
O	O	type
O	O	alleles
O	O	is
O	O	unknown
O	O	.
O	O	We
O	O	have
O	O	identified
O	O	three
O	O	offspring
O	O	in
O	O	a
B	B	hereditary
I	I	nonpolyposis
I	I	colorectal
I	I	cancer
O	O	family
O	O	who
O	O	developed
B	B	hematological
I	I	malignancy
O	O	at
O	O	a
O	O	very
O	O	early
O	O	age
O	O	,
O	O	and
O	O	at
O	O	least
O	O	two
O	O	of
O	O	them
O	O	displayed
O	O	signs
O	O	of
B	B	neurofibromatosis
I	I	type
O	I	1
O	O	(
B	B	NF1
O	O	)
O	O	.
O	O	DNA
O	O	sequence
O	O	analysis
O	O	and
O	O	allele
O	O	-
O	O	specific
O	O	amplification
O	O	in
O	O	two
O	O	siblings
O	O	revealed
O	O	a
O	O	homozygous
O	O	MLH1
O	O	mutation
O	O	(
O	O	C676T
O	O	-
O	O	-
O	O	>
O	O	Arg226Stop
O	O	)
O	O	.
O	O	Thus
O	O	,
O	O	a
O	O	homozygous
O	O	germ
O	O	-
O	O	line
O	O	MLH1
O	O	mutation
O	O	and
O	O	consequent
B	O	mismatch
O	O	repair
O	O	deficiency
O	O	results
O	O	in
O	O	a
O	O	mutator
O	O	phenotype
O	O	characterized
O	O	by
B	B	leukemia
O	O	and
O	O	/
O	O	or
B	B	lymphoma
O	O	associated
O	O	with
B	B	neurofibromatosis
I	I	type
I	I	1
O	O	.
O	O	.
O	O	Missense
O	O	mutations
O	O	in
O	O	the
O	O	most
O	O	ancient
O	O	residues
O	O	of
O	O	the
O	O	PAX6
O	O	paired
O	O	domain
O	O	underlie
O	O	a
O	O	spectrum
O	O	of
O	O	human
B	B	congenital
I	I	eye
I	I	malformations
O	O	.
O	O	Mutations
O	O	of
O	O	the
O	O	human
O	O	PAX6
O	O	gene
O	O	underlie
B	B	aniridia
O	O	(
B	B	congenital
I	I	absence
I	I	of
I	I	the
I	I	iris
O	O	)
O	O	,
O	O	a
O	O	rare
O	O	dominant
I	B	malformation
I	I	of
I	I	the
I	I	eye
O	O	.
O	O	The
O	O	spectrum
O	O	of
O	O	PAX6
O	O	mutations
O	O	in
B	B	aniridia
O	O	patients
O	O	is
O	O	highly
O	O	biased
O	O	,
O	O	with
O	O	92
O	O	%
O	O	of
O	O	all
O	O	reported
O	O	mutations
O	O	leading
O	O	to
O	O	premature
O	O	truncation
O	O	of
O	O	the
O	O	protein
O	O	(
O	O	nonsense
O	O	,
O	O	splicing
O	O	,
O	O	insertions
O	O	and
O	O	deletions
O	O	)
O	O	and
O	O	just
O	O	2
O	O	%
O	O	leading
O	O	to
O	O	substitution
O	O	of
O	O	one
O	O	amino
O	O	acid
O	O	by
O	O	another
O	O	(
O	O	missense
O	O	)
O	O	.
O	O	The
O	O	extraordinary
O	O	conservation
O	O	of
O	O	the
O	O	PAX6
O	O	protein
O	O	at
O	O	the
O	O	amino
O	O	acid
O	O	level
O	O	amongst
O	O	vertebrates
O	O	predicts
O	O	that
O	O	pathological
O	O	missense
O	O	mutations
O	O	should
O	O	in
O	O	fact
O	O	be
O	O	common
O	O	even
O	O	though
O	O	they
O	O	are
O	O	hardly
O	O	ever
O	O	seen
O	O	in
B	B	aniridia
O	O	patients
O	O	.
O	O	This
O	O	indicates
O	O	that
O	O	there
O	O	is
O	O	a
O	O	heavy
O	O	ascertainment
O	O	bias
O	O	in
O	O	the
O	O	selection
O	O	of
O	O	patients
O	O	for
O	O	PAX6
O	O	mutation
O	O	analysis
O	O	and
O	O	that
O	O	the
O	O	missing
O	O	PAX6
O	O	missense
O	O	mutations
O	O	frequently
O	O	may
O	O	underlie
O	O	phenotypes
O	O	distinct
O	O	from
O	O	textbook
B	B	aniridia
O	O	.
O	O	Here
O	O	we
O	O	present
O	O	four
O	O	novel
O	O	PAX6
O	O	missense
O	O	mutations
O	O	,
O	O	two
O	O	in
O	O	association
O	O	with
B	O	atypical
O	O	phenotypes
B	B	ectopia
O	I	pupillae
O	O	(
O	B	displaced
O	I	pupils
O	O	)
O	O	and
B	B	congenital
I	I	nystagmus
O	O	(
O	B	searching
O	I	gaze
O	O	)
O	O	,
O	O	and
O	O	two
O	O	in
O	O	association
O	O	with
O	O	more
O	O	recognizable
B	B	aniridia
O	O	phenotypes
O	O	.
O	O	Strikingly
O	O	,
O	O	all
O	O	four
O	O	mutations
O	O	are
O	O	located
O	O	within
O	O	the
O	O	PAX6
O	O	paired
O	O	domain
O	O	and
O	O	affect
O	O	amino
O	O	acids
O	O	which
O	O	are
O	O	highly
O	O	conserved
O	O	in
O	O	all
O	O	known
O	O	paired
O	O	domain
O	O	proteins
O	O	.
O	O	Our
O	O	results
O	O	support
O	O	the
O	O	hypothesis
O	O	that
O	O	the
O	O	under
O	O	-
O	O	representation
O	O	of
O	O	missense
O	O	mutations
O	O	is
O	O	caused
O	O	by
O	O	ascertainment
O	O	bias
O	O	and
O	O	suggest
O	O	that
O	O	a
O	O	substantial
O	O	burden
O	O	of
B	B	PAX6
O	I	-
O	I	related
I	I	disease
O	O	remains
O	O	to
O	O	be
O	O	uncovered
O	O	.
O	O	.
O	O	The
O	O	chromosomal
O	O	order
O	O	of
O	O	genes
O	O	controlling
O	O	the
O	O	major
O	O	histocompatibility
O	O	complex
O	O	,
O	O	properdin
O	O	factor
O	O	B
O	O	,
O	O	and
B	B	deficiency
I	I	of
I	I	the
I	I	second
I	I	component
I	I	of
I	I	complement
O	O	.
O	O	The
O	O	relationship
O	O	of
O	O	the
O	O	genes
O	O	coding
O	O	for
O	O	HLA
O	O	to
O	O	those
O	O	coding
O	O	for
O	O	properdin
O	O	Factor
O	O	B
O	O	allotypes
O	O	and
O	O	for
B	B	deficiency
I	I	of
I	I	the
I	I	second
I	I	component
I	I	of
I	I	complement
O	O	(
O	O	C2
O	O	)
O	O	was
O	O	studied
O	O	in
O	O	families
O	O	of
O	O	patients
O	O	with
B	O	connective
I	O	tissue
I	O	disorders
O	O	.
O	O	Patients
O	O	were
O	O	selected
O	O	because
O	O	they
O	O	were
O	O	heterozygous
O	O	or
O	O	homozygous
O	O	for
B	B	C2
I	I	deficiency
O	O	.
O	O	12
O	O	families
O	O	with
O	O	15
O	O	matings
O	O	informative
O	O	for
B	B	C2
I	I	deficiency
O	O	were
O	O	found
O	O	.
O	O	Of
O	O	57
O	O	informative
O	O	meioses
O	O	,
O	O	two
O	O	crossovers
O	O	were
O	O	noted
O	O	between
O	O	the
B	B	C2
I	I	deficiency
O	O	gene
O	O	and
O	O	the
O	O	HLA
O	O	-
O	O	B
O	O	gene
O	O	,
O	O	with
O	O	a
O	O	recombinant
O	O	fraction
O	O	of
O	O	0
O	O	.
O	O	035
O	O	.
O	O	A
O	O	lod
O	O	score
O	O	of
O	O	13
O	O	was
O	O	calculated
O	O	for
O	O	linkage
O	O	between
B	B	C2
I	I	deficiency
O	O	and
B	O	HLA
O	O	-
O	O	B
O	O	at
O	O	a
O	O	maximum
O	O	likelihood
O	O	value
O	O	of
O	O	the
O	O	recombinant
O	O	fraction
O	O	of
O	O	0
O	O	.
O	O	04
O	O	.
O	O	18
O	O	families
O	O	with
O	O	21
O	O	informative
O	O	matings
O	O	for
O	O	both
O	O	properdin
O	O	Factor
O	O	B
O	O	allotype
O	O	and
O	O	HLA
O	O	-
O	O	B
O	O	were
O	O	found
O	O	.
O	O	Of
O	O	72
O	O	informative
O	O	meioses
O	O	,
O	O	three
O	O	recombinants
O	O	were
O	O	found
O	O	,
O	O	giving
O	O	a
O	O	recombinant
O	O	fraction
O	O	of
O	O	0
O	O	.
O	O	042
O	O	.
O	O	A
O	O	lod
O	O	score
O	O	of
O	O	16
O	O	between
O	O	HLA
O	O	-
O	O	B
O	O	and
O	O	Factor
O	O	B
O	O	allotypes
O	O	was
O	O	calculated
O	O	at
O	O	a
O	O	maximum
O	O	likelihood
O	O	value
O	O	of
O	O	the
O	O	recombinant
O	O	fraction
O	O	of
O	O	0
O	O	.
O	O	04
O	O	.
O	O	A
O	O	crossover
O	O	was
O	O	shown
O	O	to
O	O	have
O	O	occurred
O	O	between
O	O	genes
O	O	for
O	O	Factor
O	O	B
O	O	and
O	O	HLA
O	O	-
O	O	D
O	O	,
O	O	in
O	O	which
O	O	HLA
O	O	-
O	O	D
O	O	segregared
O	O	with
O	O	HLA
O	O	-
O	O	A
O	O	and
O	O	B
O	O	.
O	O	These
O	O	studies
O	O	suggest
O	O	that
O	O	the
O	O	genes
O	O	for
O	O	Factor
O	O	B
O	O	and
B	B	C2
I	I	deficiency
O	O	are
O	O	located
O	O	outside
O	O	those
O	O	for
B	O	HLA
O	O	,
O	O	that
O	O	the
O	O	order
O	O	of
O	O	genese
O	O	is
O	O	HLA
O	O	-
O	O	A
O	O	,
O	O	-
O	O	B
O	O	,
O	O	-
O	O	D
O	O	,
O	O	Factor
O	O	B
O	O	allotype
O	O	,
B	B	C2
I	I	deficiency
O	O	,
O	O	that
O	O	the
O	O	genes
O	O	coding
O	O	for
B	B	C2
I	I	deficiency
O	O	and
B	O	Factor
I	O	B
O	O	allotypes
O	O	are
O	O	approximately
O	O	3
O	O	-
O	O	-
O	O	5
O	O	centimorgans
O	O	from
O	O	the
O	O	HLA
O	O	-
O	O	A
O	O	and
O	O	HLA
O	O	-
O	O	B
O	O	loci
O	O	,
O	O	and
O	O	that
O	O	the
O	O	apparent
O	O	lack
O	O	of
O	O	recombinants
O	O	between
O	O	the
O	O	Factor
O	O	B
O	O	gene
O	O	and
B	B	C2
I	I	deficiency
O	O	gene
O	O	suggests
O	O	that
O	O	these
O	O	two
O	O	genes
O	O	lie
O	O	in
O	O	close
O	O	proximity
O	O	to
O	O	one
O	O	another
O	O	.
O	O	Distribution
O	O	of
O	O	emerin
O	O	and
O	O	lamins
O	O	in
O	O	the
O	O	heart
O	O	and
O	O	implications
O	O	for
B	B	Emery
I	I	-
I	I	Dreifuss
I	I	muscular
I	I	dystrophy
O	O	.
O	O	Emerin
O	O	is
O	O	a
O	O	nuclear
O	O	membrane
O	O	protein
O	O	which
O	O	is
O	O	missing
O	O	or
O	O	defective
O	O	in
B	B	Emery
I	I	-
I	I	Dreifuss
I	I	muscular
I	I	dystrophy
O	O	(
B	B	EDMD
O	O	)
O	O	.
O	O	It
O	O	is
O	O	one
O	O	member
O	O	of
O	O	a
O	O	family
O	O	of
O	O	lamina
O	O	-
O	O	associated
O	O	proteins
O	O	which
O	O	includes
O	O	LAP1
O	O	,
O	O	LAP2
O	O	and
O	O	lamin
O	O	B
O	O	receptor
O	O	(
O	O	LBR
O	O	)
O	O	.
O	O	A
O	O	panel
O	O	of
O	O	16
O	O	monoclonal
O	O	antibodies
O	O	(
O	O	mAbs
O	O	)
O	O	has
O	O	been
O	O	mapped
O	O	to
O	O	six
O	O	specific
O	O	sites
O	O	throughout
O	O	the
O	O	emerin
O	O	molecule
O	O	using
O	O	phage
O	O	-
O	O	displayed
O	O	peptide
O	O	libraries
O	O	and
O	O	has
O	O	been
O	O	used
O	O	to
O	O	localize
O	O	emerin
O	O	in
O	O	human
O	O	and
O	O	rabbit
O	O	heart
O	O	.
O	O	Several
O	O	mAbs
O	O	against
O	O	different
O	O	emerin
O	O	epitopes
O	O	did
O	O	not
O	O	recognize
O	O	intercalated
O	O	discs
O	O	in
O	O	the
O	O	heart
O	O	,
O	O	though
O	O	they
O	O	recognized
O	O	cardiomyocyte
O	O	nuclei
O	O	strongly
O	O	,
O	O	both
O	O	at
O	O	the
O	O	rim
O	O	and
O	O	in
O	O	intranuclear
O	O	spots
O	O	or
O	O	channels
O	O	.
O	O	A
O	O	polyclonal
O	O	rabbit
O	O	antiserum
O	O	against
O	O	emerin
O	O	did
O	O	recognize
O	O	both
O	O	nuclear
O	O	membrane
O	O	and
O	O	intercalated
O	O	discs
O	O	but
O	O	,
O	O	after
O	O	affinity
O	O	purification
O	O	against
O	O	a
O	O	pure
O	O	-
O	O	emerin
O	O	band
O	O	on
O	O	a
O	O	western
O	O	blot
O	O	,
O	O	it
O	O	stained
O	O	only
O	O	the
O	O	nuclear
O	O	membrane
O	O	.
O	O	These
O	O	results
O	O	would
O	O	not
O	O	be
O	O	expected
O	O	if
O	O	immunostaining
O	O	at
O	O	intercalated
O	O	discs
O	O	were
O	O	due
O	O	to
O	O	a
O	O	product
O	O	of
O	O	the
O	O	emerin
O	O	gene
O	O	and
O	O	,
O	O	therefore
O	O	,
O	O	cast
O	O	some
O	O	doubt
O	O	upon
O	O	the
O	O	hypothesis
O	O	that
B	B	cardiac
I	I	defects
O	O	in
B	B	EDMD
O	O	are
O	O	caused
O	O	by
O	O	absence
O	O	of
O	O	emerin
O	O	from
O	O	intercalated
O	O	discs
O	O	.
O	O	Although
O	O	emerin
O	O	was
O	O	abundant
O	O	in
O	O	the
O	O	membranes
O	O	of
O	O	cardiomyocyte
O	O	nuclei
O	O	,
O	O	it
O	O	was
O	O	absent
O	O	from
O	O	many
O	O	non
O	O	-
O	O	myocyte
O	O	cells
O	O	in
O	O	the
O	O	heart
O	O	.
O	O	This
O	O	distribution
O	O	of
O	O	emerin
O	O	was
O	O	similar
O	O	to
O	O	that
O	O	of
O	O	lamin
O	O	A
O	O	,
O	O	a
O	O	candidate
O	O	gene
O	O	for
O	O	an
O	O	autosomal
O	O	form
O	O	of
B	B	EDMD
O	O	.
O	O	In
O	O	contrast
O	O	,
O	O	lamin
O	O	B1
O	O	was
O	O	absent
O	O	from
O	O	cardiomyocyte
O	O	nuclei
O	O	,
O	O	showing
O	O	that
O	O	lamin
O	O	B1
O	O	is
O	O	not
O	O	essential
O	O	for
O	O	localization
O	O	of
O	O	emerin
O	O	to
O	O	the
O	O	nuclear
O	O	lamina
O	O	.
O	O	Lamin
O	O	B1
O	O	is
O	O	also
O	O	almost
O	O	completely
O	O	absent
O	O	from
O	O	skeletal
O	O	muscle
O	O	nuclei
O	O	.
O	O	In
B	B	EDMD
O	O	,
O	O	the
O	O	additional
O	O	absence
O	O	of
O	O	lamin
O	O	B1
O	O	from
O	O	heart
O	O	and
O	O	skeletal
O	O	muscle
O	O	nuclei
O	O	which
O	O	already
O	O	lack
O	O	emerin
O	O	may
O	O	offer
O	O	an
O	O	alternative
O	O	explanation
O	O	of
O	O	why
O	O	these
O	O	tissues
O	O	are
O	O	particularly
O	O	affected
O	O	.
O	O	.
O	O	Genetic
O	O	mapping
O	O	of
O	O	the
B	B	copper
O	I	toxicosis
O	O	locus
O	O	in
B	O	Bedlington
O	O	terriers
O	O	to
O	O	dog
O	O	chromosome
O	O	10
O	O	,
O	O	in
O	O	a
O	O	region
O	O	syntenic
O	O	to
O	O	human
O	O	chromosome
O	O	region
O	O	2p13
O	O	-
O	O	p16
O	O	.
O	O	Abnormal
I	B	hepatic
O	I	copper
I	I	accumulation
O	O	is
O	O	recognized
O	O	as
O	O	an
O	B	inherited
O	I	disorder
O	O	in
O	O	man
O	O	,
O	O	mouse
O	O	,
O	O	rat
O	O	and
O	O	dog
O	O	.
O	O	The
O	O	major
O	O	cause
O	O	of
B	B	hepatic
O	I	copper
O	I	accumulation
O	O	in
O	O	man
O	O	is
O	O	a
O	O	dysfunctional
O	O	ATP7B
O	O	gene
O	O	,
O	O	causing
B	B	Wilson
I	I	disease
O	O	(
B	B	WD
O	O	)
O	O	.
O	O	Mutations
O	O	in
O	O	the
O	O	ATP7B
O	O	genes
O	O	have
O	O	also
O	O	been
O	O	demonstrated
O	O	in
O	O	mouse
O	O	and
O	O	rat
O	O	.
O	O	The
O	O	ATP7B
O	O	gene
O	O	has
O	O	been
O	O	excluded
O	O	in
O	O	the
O	O	much
O	O	rarer
O	O	human
O	B	copper
I	I	overload
O	O	disease
O	B	non
O	I	-
O	I	Indian
I	I	childhood
I	I	cirrhosis
O	O	,
O	O	indicating
O	O	genetic
O	O	heterogeneity
O	O	.
O	O	By
O	O	investigating
O	O	the
O	O	common
B	O	autosomal
I	O	recessive
I	B	copper
I	I	toxicosis
O	O	(
B	B	CT
O	O	)
O	O	in
B	O	Bedlington
O	O	terriers
O	O	,
O	O	we
O	O	have
O	O	identified
O	O	a
O	O	new
O	O	locus
O	O	involved
O	O	in
B	O	progressive
B	B	liver
I	I	disease
O	O	.
O	O	We
O	O	examined
O	O	whether
O	O	the
B	B	WD
O	O	gene
O	O	ATP7B
O	O	was
O	O	also
O	O	causative
O	O	for
O	B	CT
O	O	by
O	O	investigating
O	O	the
O	O	chromosomal
O	O	co
O	O	-
O	O	localization
O	O	of
O	O	ATP7B
O	O	and
O	O	C04107
O	O	,
O	O	using
O	O	fluorescence
O	O	in
O	O	situ
O	O	hybridization
O	O	(
O	O	FISH
O	O	)
O	O	.
O	O	C04107
O	O	is
O	O	an
O	O	anonymous
O	O	microsatellite
O	O	marker
O	O	closely
O	O	linked
O	O	to
O	B	CT
O	O	.
O	O	However
O	O	,
B	O	BAC
O	O	clones
O	O	containing
O	O	ATP7B
O	O	and
O	O	C04107
O	O	mapped
O	O	to
O	O	the
O	O	canine
O	O	chromosome
O	O	regions
O	O	CFA22q11
O	O	and
O	O	CFA10q26
O	O	,
O	O	respectively
O	O	,
O	O	demonstrating
O	O	that
B	B	WD
O	O	cannot
O	O	be
O	O	homologous
O	O	to
O	B	CT
O	O	.
O	O	The
O	O	copper
O	O	transport
O	O	genes
O	O	CTR1
O	O	and
O	O	CTR2
O	O	were
O	O	also
O	O	excluded
O	O	as
O	O	candidate
O	O	genes
O	O	for
O	B	CT
O	O	since
O	O	they
O	O	both
O	O	mapped
O	O	to
O	O	canine
O	O	chromosome
O	O	region
O	O	CFA11q22
O	O	.
O	O	2
O	O	-
O	O	22
O	O	.
O	O	5
O	O	.
O	O	A
O	O	transcribed
O	O	sequence
O	O	identified
O	O	from
O	O	the
O	O	C04107
O	O	-
O	O	containing
O	O	BAC
O	O	was
O	O	found
O	O	to
O	O	be
O	O	homologous
O	O	to
O	O	a
O	O	gene
O	O	expressed
O	O	from
O	O	human
O	O	chromosome
O	O	2p13
O	O	-
O	O	p16
O	O	,
O	O	a
O	O	region
O	O	devoid
O	O	of
O	O	any
O	O	positional
O	O	candidate
O	O	genes
O	O	.
O	O	Molecular
O	O	analysis
O	O	of
O	O	the
B	B	APC
O	O	gene
O	O	in
O	O	205
O	O	families
O	O	:
O	O	extended
O	O	genotype
O	O	-
O	O	phenotype
O	O	correlations
O	O	in
B	B	FAP
O	O	and
O	O	evidence
O	O	for
O	O	the
O	O	role
O	O	of
B	B	APC
O	O	amino
O	O	acid
O	O	changes
O	O	in
B	B	colorectal
I	I	cancer
O	O	predisposition
O	O	.
B	O	BACKGROUND
O	O	/
B	O	AIMS
O	O	The
O	O	development
O	O	of
B	B	colorectal
I	I	cancer
O	O	and
O	O	a
O	O	variable
O	O	range
O	O	of
O	O	extracolonic
O	O	manifestations
O	O	in
B	B	familial
I	I	adenomatous
I	I	polyposis
O	O	(
B	B	FAP
O	O	)
O	O	is
O	O	the
O	O	result
O	O	of
O	O	the
O	O	dominant
O	O	inheritance
O	O	of
B	B	adenomatous
I	I	polyposis
I	I	coli
O	O	(
B	B	APC
O	O	)
O	O	gene
O	O	mutations
O	O	.
O	O	In
O	O	this
O	O	study
O	O	,
O	O	direct
O	O	mutation
O	O	analysis
O	O	of
O	O	the
B	B	APC
O	O	gene
O	O	was
O	O	performed
O	O	to
O	O	determine
O	O	genotype
O	O	-
O	O	phenotype
O	O	correlations
O	O	for
O	O	nine
O	O	extracolonic
O	O	manifestations
O	O	and
O	O	to
O	O	investigate
O	O	the
O	O	incidence
O	O	of
B	B	APC
O	O	mutations
O	O	in
B	O	non
I	O	-
B	O	FAP
B	B	colorectal
I	I	cancer
O	O	.
O	O	METHODS
O	O	The
B	B	APC
O	O	gene
O	O	was
O	O	analysed
O	O	in
O	O	190
O	O	unrelated
B	B	FAP
O	O	and
O	O	15
O	O	non
O	O	-
B	O	FAP
B	B	colorectal
I	I	cancer
O	O	patients
O	O	using
O	O	denaturing
O	O	gradient
O	O	gel
O	O	electrophoresis
O	O	,
O	O	the
O	O	protein
O	O	truncation
O	O	test
O	O	,
O	O	and
O	O	direct
O	O	sequencing
O	O	.
O	O	RESULTS
O	O	Chain
O	O	terminating
O	O	signals
O	O	were
O	O	only
O	O	identified
O	O	in
O	O	patients
O	O	belonging
O	O	to
O	O	the
B	B	FAP
O	O	group
O	O	(
O	O	105
O	O	patients
O	O	)
O	O	.
O	O	Amino
O	O	acid
O	O	changes
O	O	were
O	O	identified
O	O	in
O	O	four
O	O	patients
O	O	,
O	O	three
O	O	of
O	O	whom
O	O	belonged
O	O	to
O	O	the
O	O	non
O	O	-
O	O	FAP
O	O	group
O	O	of
B	B	colorectal
I	I	cancer
O	O	patients
O	O	.
O	O	Genotype
O	O	-
O	O	phenotype
O	O	correlations
O	O	identified
O	O	significant
O	O	differences
O	O	in
O	O	the
O	O	nature
O	O	of
O	O	certain
O	O	extracolonic
O	O	manifestations
O	O	in
B	B	FAP
O	O	patients
O	O	belonging
O	O	to
O	O	three
O	O	mutation
O	O	subgroups
O	O	.
O	O	CONCLUSIONS
O	O	Extended
O	O	genotype
O	O	-
O	O	phenotype
O	O	correlations
O	O	made
O	O	in
O	O	this
O	O	study
O	O	may
O	O	have
O	O	the
O	O	potential
O	O	to
O	O	determine
O	O	the
O	O	most
O	O	appropriate
O	O	surveillance
O	O	and
O	O	prophylactic
O	O	treatment
O	O	regimens
O	O	for
O	O	those
O	O	patients
O	O	with
O	O	mutations
O	O	associated
O	O	with
O	O	life
O	O	threatening
O	O	conditions
O	O	.
O	O	This
O	O	study
O	O	also
O	O	provided
O	O	evidence
O	O	for
O	O	the
O	O	pathological
O	O	nature
O	O	of
O	O	amino
O	O	acid
O	O	changes
O	O	in
B	O	APC
O	O	associated
O	O	with
O	O	both
B	B	FAP
O	O	and
B	O	non
I	O	-
B	O	FAP
I	B	colorectal
I	I	cancer
O	O	patients
O	O	.
O	O	.
O	B	Inherited
B	I	colorectal
I	I	polyposis
O	O	and
B	B	cancer
O	O	risk
O	O	of
O	O	the
B	O	APC
O	O	I1307K
O	O	polymorphism
O	O	.
O	O	Germ
O	O	-
O	O	line
O	O	and
O	O	somatic
O	O	truncating
O	O	mutations
O	O	of
O	O	the
B	B	APC
O	O	gene
O	O	are
O	O	thought
O	O	to
O	O	initiate
B	B	colorectal
I	I	tumor
O	O	formation
O	O	in
B	B	familial
I	I	adenomatous
I	I	polyposis
I	I	syndrome
O	O	and
O	O	sporadic
B	O	colorectal
I	O	carcinogenesis
O	O	,
O	O	respectively
O	O	.
O	O	Recently
O	O	,
O	O	an
O	O	isoleucine
O	O	-
O	O	-
O	O	>
O	O	lysine
O	O	polymorphism
O	O	at
O	O	codon
O	O	1307
O	O	(
O	O	I1307K
O	O	)
O	O	of
O	O	the
B	B	APC
O	O	gene
O	O	has
O	O	been
O	O	identified
O	O	in
O	O	6
O	O	%
O	O	-
O	O	7
O	O	%
O	O	of
O	O	the
O	O	Ashkenazi
O	O	Jewish
O	O	population
O	O	.
O	O	To
O	O	assess
O	O	the
O	O	risk
O	O	of
O	O	this
O	O	common
B	B	APC
O	O	allelic
O	O	variant
O	O	in
B	O	colorectal
O	O	carcinogenesis
O	O	,
O	O	we
O	O	have
O	O	analyzed
O	O	a
O	O	large
O	O	cohort
O	O	of
O	O	unselected
O	O	Ashkenazi
O	O	Jewish
O	O	subjects
O	O	with
B	B	adenomatous
I	I	polyps
O	O	and
O	O	.
O	O	or
B	B	colorectal
I	I	cancer
O	I	,
O	O	for
O	O	the
B	O	APC
O	O	I1307K
O	O	polymorphism
O	O	.
O	O	The
B	O	APC
O	O	I1307K
O	O	allele
O	O	was
O	O	identified
O	O	in
O	O	48
O	O	(
O	O	10
O	O	.
O	O	1
O	O	%
O	O	)
O	O	of
O	O	476
O	O	patients
O	O	.
O	O	Compared
O	O	with
O	O	the
O	O	frequency
O	O	in
O	O	two
O	O	separate
O	O	population
O	O	control
O	O	groups
O	O	,
O	O	the
B	O	APC
O	O	I1307K
O	O	allele
O	O	is
O	O	associated
O	O	with
O	O	an
O	O	estimated
O	O	relative
O	O	risk
O	O	of
O	O	1
O	O	.
O	O	5
O	O	-
O	O	1
O	O	.
O	O	7
O	O	for
B	B	colorectal
I	I	neoplasia
O	O	(
O	O	both
O	O	P
O	O	=
O	O	.
O	O	01
O	O	)
O	O	.
O	O	Furthermore
O	O	,
O	O	compared
O	O	with
O	O	noncarriers
O	O	,
B	O	APC
O	O	I1307K
O	O	carriers
O	O	had
O	O	increased
O	O	numbers
O	O	of
B	B	adenomas
O	O	and
B	B	colorectal
I	I	cancers
O	O	per
O	O	patient
O	O	(
O	O	P
O	O	=
O	O	.
O	O	03
O	O	)
O	O	,
O	O	as
O	O	well
O	O	as
O	O	a
O	O	younger
O	O	age
O	O	at
O	O	diagnosis
O	O	.
O	O	We
O	O	conclude
O	O	that
O	O	the
B	O	APC
O	O	I1307K
O	O	variant
O	O	leads
O	O	to
O	O	increased
B	B	adenoma
O	O	formation
O	O	and
O	O	directly
O	O	contributes
O	O	to
O	O	3
O	O	%
O	O	-
O	O	4
O	O	%
O	O	of
O	O	all
B	O	Ashkenazi
O	O	Jewish
B	B	colorectal
I	I	cancer
O	O	.
O	O	The
O	O	estimated
O	O	relative
O	O	risk
O	O	for
O	O	carriers
O	O	may
O	O	justify
O	O	specific
O	O	clinical
O	O	screening
O	O	for
O	O	the
O	O	360
O	O	,
O	O	000
O	O	Americans
O	O	expected
O	O	to
O	O	harbor
O	O	this
O	O	allele
O	O	,
O	O	and
O	O	genetic
O	O	testing
O	O	in
O	O	the
O	O	setting
O	O	of
O	O	long
O	O	-
O	O	term
O	O	-
O	O	outcome
O	O	studies
O	O	may
O	O	impact
O	O	significantly
O	O	on
B	B	colorectal
I	I	cancer
O	O	prevention
O	O	in
O	O	this
O	O	population
O	O	.
O	O	Localization
O	O	of
O	O	human
O	O	BRCA1
O	O	and
O	O	its
O	O	loss
O	O	in
O	O	high
O	O	-
O	O	grade
O	O	,
O	B	non
I	I	-
O	I	inherited
B	I	breast
I	I	carcinomas
O	O	.
O	O	Although
O	O	the
O	O	link
O	O	between
O	O	the
O	O	BRCA1
I	B	tumour
O	O	-
O	O	suppressor
O	O	gene
O	O	and
B	B	hereditary
I	I	breast
I	I	and
I	I	ovarian
I	I	cancer
O	O	is
O	O	established
O	O	,
O	O	the
O	O	role
O	O	,
O	O	if
O	O	any
O	O	,
O	O	of
O	O	BRCA1
O	O	in
B	B	non
I	I	-
B	I	familial
I	I	cancers
O	O	is
O	O	unclear
O	O	.
O	O	BRCA1
O	O	mutations
O	O	are
O	O	rare
O	O	in
B	B	sporadic
I	I	cancers
O	O	,
O	O	but
O	O	loss
O	O	of
O	O	BRCA1
O	O	resulting
O	O	from
O	O	reduced
O	O	expression
O	O	or
O	O	incorrect
O	O	subcellular
O	O	localization
O	O	is
O	O	postulated
O	O	to
O	O	be
O	O	important
O	O	in
B	B	non
I	I	-
B	I	familial
I	I	breast
I	I	and
I	I	ovarian
I	I	cancers
O	O	.
O	O	Epigenetic
O	O	loss
O	O	,
O	O	however
O	O	,
O	O	has
O	O	not
O	O	received
O	O	general
O	O	acceptance
O	O	due
O	O	to
O	O	controversy
O	O	regarding
O	O	the
O	O	subcellular
O	O	localization
O	O	of
O	O	BRCA1
O	O	proteins
O	O	,
O	O	reports
O	O	of
O	O	which
O	O	have
O	O	ranged
O	O	from
O	O	exclusively
O	O	nuclear
O	O	,
O	O	to
O	O	conditionally
O	O	nuclear
O	O	,
O	O	to
O	O	the
O	O	ER
O	O	/
O	O	golgi
O	O	,
O	O	to
O	O	cytoplasmic
O	O	invaginations
O	O	into
O	O	the
O	O	nucleus
O	O	.
O	O	In
O	O	an
O	O	attempt
O	O	to
O	O	resolve
O	O	this
O	O	issue
O	O	,
O	O	we
O	O	have
O	O	comprehensively
O	O	characterized
O	O	19
O	O	anti
O	O	-
O	O	BRCA1
O	O	antibodies
O	O	.
O	O	These
O	O	reagents
O	O	detect
O	O	a
O	O	220
O	O	-
O	O	kD
O	O	protein
O	O	localized
O	O	in
O	O	discrete
O	O	nuclear
O	O	foci
O	O	in
O	O	all
O	O	epithelial
O	O	cell
O	O	lines
O	O	,
O	O	including
O	O	those
O	O	derived
O	O	from
B	B	breast
I	I	malignancies
O	O	.
O	O	Immunohistochemical
O	O	staining
O	O	of
O	O	human
O	O	breast
O	O	specimens
O	O	also
O	O	revealed
O	O	BRCA1
O	O	nuclear
O	O	foci
O	O	in
B	O	benign
O	O	breast
O	O	,
B	B	invasive
I	I	lobular
I	I	cancers
O	O	and
B	B	low
I	I	-
I	I	grade
B	I	ductal
I	I	carcinomas
O	O	.
O	O	Conversely
O	O	,
O	O	BRCA1
O	O	expression
O	O	was
O	O	reduced
O	O	or
O	O	undetectable
O	O	in
O	O	the
O	O	majority
O	O	of
B	O	high
O	O	-
O	O	grade
O	O	,
B	B	ductal
I	I	carcinomas
O	O	,
O	O	suggesting
O	O	that
O	O	absence
O	O	of
O	O	BRCA1
O	O	may
O	O	contribute
O	O	to
O	O	the
O	O	pathogenesis
O	O	of
O	O	a
O	O	significant
O	O	percentage
O	O	of
B	B	sporadic
B	I	breast
I	I	cancers
O	O	.
O	O	.
